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Abstract 
The human gut microbiota’s (HGM’s) interplay with the host and diet exerts a profound 
impact on our health. Dietary fibers, which are fermented to short chain fatty acids 
(SCFAs), are key in shaping the composition and the metabolic output of the HGM. 
The SCFA butyrate, produced mainly by Clostridium XIVa Firmicutes modulates host 
immune homeostasis and confers protection from inflammatory disorders and colorectal 
cancer. Despite this vital role on human health, the mechanisms underpinning the uti-
lization of dietary fibers by butyrate producers are largely unexplored. This thesis aims 
at bringing insight into this facet using the abundant and prevalent butyrogenic bacte-
rium Roseburia intestinalis as a model system.  
The major dietary fiber xylan is shown to be an excellent substrate for R. intestinalis 
in this work. Transcriptomic analysis identified the molecular apparatus that confers 
growth on xylan, including a key cell-attached modular xylanase of glycoside hydrolase 
family 10 (GH10). This enzyme harbor a new low affinity xylan binding module, which 
showed an atypical architecture, featuring an open and shallow binding site with a few 
polar contacts to a single xylosyl unit. Investigation of transport and intracellular hy-
drolysis outlined a model for xylan breakdown to monosaccharides. An ATP-binding 
cassette (ABC) transporter with preference for 4-5 xylosyl units creates a competitive 
window that enables R. intestinalis to co-grow with key primary xylan degraders from 
the Bacteroides genus, which possess an uptake preference for larger ligands.     
R. intestinalis uses a similar approach, as described above, to capture, degrade and 
transport complex dietary β-mannans. Capture and depolymerisation of mannan is ini-
tiated by a modular GH26 mannanase and the mannan-oligosaccharides are subse-
quently imported into the cell for further hydrolysis using an ABC uptake system. An 
in vivo experiment in mice colonized by a mock community of human commensals 
showed that β-mannan boosts commensal mannan degraders, including R. intestinalis.  
Altogether, this project highlights the differentiation of capture and transport prefer-
ences of primary glycan degraders using xylan as a model. It provides a potential strat-
egy for promotion of key members of a healthy HGM, by designing prebiotics that 
selectively target specific health promoting taxonomic groups. 
 
  
V 
Dansk resumé 
Den menneskelige tarmmikrobiotas (HGMs) samspil med deres vært og kosten har stor 
indflydelse på vores helbred. Kostfibre, der bliver fermenteret til kortkædede fedtsyre 
(SCFA), er vigtige i forhold til kompositionen af denne population og dets metabolisti-
ske produkter. Den kortkædede fedtsyre butyrat, som primært bliver produceret af Clo-
stridium XIVa Firmicutes, modulerer menneskets immunhomøostase og giver beskyt-
telse mod inflammatoriske sygdomme og tarmkræft. På trods af den væsentlige rolle 
butyratproducenter har på vores helbred, er mekanismerne der understøtter nedbryd-
ningen og optagelsen af kostfibre af denne gruppe af bakterier ikke særligt godt forstået. 
Denne afhandlings formål er at give indsigt i dette aspekt ved at bruge den udbredte 
butyratproducerende bakterie Roseburia intestinalis som et model system.    
En transkriptionsanalyse identificerede det molekylære apparat, der er ansvarlig for 
vækst på xylan, herunder en stor celleforankret modulær xylanase fra glykosid hydrolase 
familie 10 (GH10). Dette enzym indeholder et nyt bindningsmodul med lav affinitet for 
xylan. Det viste sig at have en atypisk arkitektur med et åbent og fladt bindings site 
med få polære interaktioner til en enkel xylosylenhed. En undersøgelse af transportsy-
stemet og intracellular hydrolyse enzymer skitserede en model for nedbrydningen af 
xylan til monosakkarider. En ATP-bindende kassette (ABC) transporter med præfe-
rence for 4-5 xylosyl enheder kreere et vindue for at R. intestinalis kan gro sammen med 
den xylan nedbrydende Bacteroides ovatus, som har præference for større ligander.     
R. intestinalis benytter sig af en lignende strategi til at fange, nedbryde og transportere 
kompleks β-mannans fra vores kost. Den indledende binding og depolymerisering af 
mannan er udført af en modulær mannanase, og herefter importres mannan-oligosakka-
riderne ind i cellen for videre nedbrydning via et ABC optagelsessystem. Et in vivo 
eksperiment, hvor mus blev koloniseret med et defineret samfund af gavnlige bakterier, 
viste at β-mannan kunne booste gavnlige mannannedbrydende bakterier, som R. in-
testinalis. 
Ved at bruge xylan som model fremhæver dette studie differentiering af binding- og 
transportpræferencer hos glykannedbrydende bakterier. Dette giver en potentiel strategi 
for fremme væksten af vigtige medlemmer af en sund HGM ved at designe selektive 
prebiotika til specifikke taxa.  
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1 
Aim of the present study 
The work presented in this thesis focus on bringing molecular insight into the glycan 
capture, uptake and degradation machinery of the human gut symbiont R. intestinalis. 
This was done by identification and characterization of enzymes and transport proteins 
mediating glycan catabolism, with a focus on the hemicelluloses xylan and mannan as 
model substrates. 
The scientific aims are: 
• Establish growth profiles of R. intestinalis on the dietary fibers xylan and man-
nan.
• Identify potential gene loci encoding enzymes and transport proteins involved in
xylan and mannan utilization using a transcriptomic based approach.
• Biochemical and structural characterization of key xylan utilization enzymes and
transporters.
• Investigate the interplay between R. intestinalis and other primary xylan de-
graders from the human gut microbiota.
1
2 
Chapter 1 Introduction 
1.1 The human gut microbiota 
The human gastrointestinal tract harbors a complex and dynamic community of micro-
organisms (collectively known as the human gut microbiota(HGM)), which plays an 
important role for its human host’s health[1]. The HGM includes all three genetic 
branches of life; Bacteria, Archaea, Eukarya, with the former being the most abundant 
and diversely represented[2]. In a recent study, the number of bacteria in the HGM is 
estimated to be 3.8·1013 bacteria - in a 70 kg ”reference man”, which equals a total 
mass of about 0.2 kg[3]. The study also updates the widely-cited 10:1 ratio, showing 
that the number of bacteria in the body is within the same order of human cells[3]. The 
adult HGM is dominated by members of two phyla; the Gram positive Firmicutes and 
the Gram negative Bacteroidetes. These phyla, together with the Actinobacteria, Pro-
teobacteria, and Verrucomicobia, contain almost all of the bacterial species found in the 
human gastrointestinal tract[4]. Despite harboring bacterial genera from just a few phyla, 
the HGM shows a tremendous diversity at lower taxonomic levels. There are as such 
several hundred different species in the human gut, with at least 57 species detected in 
≥90% of all individuals[5].  
The composition of the HGM along the gastrointestinal tract is not homogenous. Phys-
ical variations including chemical and nutrient gradients have led to the development 
of specific microbial niches (Figure 1). In the gut, the small intestine has the lowest 
amount of bacteria and is dominated by a few species that tolerate the combined effects 
of bile acids and antimicrobials[2]. By contrast, the colon has the highest density of 
bacteria and a more diverse community, which makes it one of the most densely popu-
lated natural ecosystems. The intestinal epithelium is covered by a mucus layer of var-
iable thickness and composition. In the colon, the mucosa is divided into an inner and 
an outer layer, with the latter providing a site of adhesion and a nutrient-rich habitat 
for adherent members of the HGM [1]. The wall of the colon contains folds, creating 
compartments between the folds (inter-fold region) that has higher amounts of mucus 
and are distinct from the central luminal (digesta) (Figure 1). In a mice study, the inter-
fold regions were highly enriched in the phylum Firmicutes and more specifically, the 
families Lachnospiraceae and Ruminococcaceae[6]. Other families such as Prevotellaceae, 
Bacteroidaceae and Rikenellaceae were all enriched in the digesta region[6]. 
2
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Figure 1 Microbial habitats in the human gut. In the small intestine, the families Lactobacillaceae and Entero-
bacteriaceae dominate, whereas the colon is characterized by the presence of species from the families Bacteroidaceae, 
Prevotellaceae, Rikenellaceae, Lachnospiraceae and Ruminococcaceae. Physiological differences exist along the length 
of the gut. For example, a gradient of oxygen, antimicrobial peptides (including bile acids, secreted by the bile duct) 
and pH limits the bacterial density in the small intestinal community, whereas the colon carries high bacterial loads. 
A cross-section of the colon shows the digesta, which is dominated by Bacteroidaceae, Prevotellaceae and Rikenel-
laceae, and the inter-fold regions of the lumen, which are dominated by Lachnospiraceae and Ruminococcaceae. Cfu, 
colony-forming units. Figure adapted from[2]  
The neonatal gastrointestinal tract is believed to be sterile or contain a very few mi-
crobes[7]. The HGM is established shortly after birth and develops with the host through 
life. During the first year of life, the composition of the HGM is rather simple and varies 
to a larger degree among individuals[7]. The first colonizers of the gastrointestinal tract 
are facultative anaerobes that create a new environment, which further promotes the 
colonization of strict anaerobes such as Bacteroides, Clostridia and Bifidobacterium 
species[8]. The composition and diversity change to resemble that of an adult HGM by 
the end of the first 2 years of life with the dominance of Firmicutes and Bacteriodetes[8], 
[9]. Different factors can influence the composition of the adult HGM including the 
mother’s HGM, mode of delivery (vaginal or caesarean), environmental exposition, an-
timicrobials, and diet[10]. The diet seems to be the major factor with the HGM respond-
ing rapidly to large changes in the diet. Clear differences have been observed in popu-
lations with a plant-based diet compared to a Western diet that is relatively low in 
3
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dietary fibers[11], [12]. A recent study showed that host genetics has a minor role in 
determining the composition of HGM and confirms the statement that environment and 
diet have the larger impact than host genetics[13]. 
 
The metagenome of the HGM is estimated to be approximately 150 times larger than 
the human genome[5] endowing the host with a substantial expansion of metabolic ca-
pabilities. The HGM can metabolize host indigestible carbohydrates, supply the host 
with essential nutrients and vitamins, and make minerals more accessible[14]. It also 
offers additional benefits to the host such as protection against pathogens[15], regulation 
of host immunity[16] and metabolic homeostasis[17]. Given this close symbiotic rela-
tionship it is not surprising that the HGM exerts a major impact on human health and 
physiology. Abnormalities in the composition of bacteria (dysbiosis) are therefore also 
associated with immune, metabolic and neurological disorders at both local intestinal 
and systemic levels. For example, inflammatory bowel disease is correlated with dysbio-
sis, characterized by decreased abundance of Clostridia and an overall reduction in bac-
terial diversity[18]. Childhood asthma is associated with low bacterial diversity during 
the first years of life[19]. The HGM associated with obesity is characterized by an in-
crease in the Firmicutes to Bacteriodetes ratio and reduced diversity[20]–[22]. These 
examples indicate that the extent of bacterial diversity in the human gut might be an 
important factor for maintaining immune and metabolic homeostasis. This is consistent 
with studies showing decreased bacterial diversity in Western populations compared 
with those of hunter-gather populations, whom are not known to develop many of these 
diseases[23], [24]. The decline in diversity and loss of specific phylogenetic groups in the 
Western population might be a consequence of modern lifestyles, medical practices and 
processed food[11]. The disease examples also raise the question of whether dysbiosis is 
a cause or a consequence of diseases. Transplantation experiments, where the HGM 
from a diseased animal is grafted to germ-free healthy recipient, have shown that disease 
phenotypes can be transferred by the HGM. The experiments include colitis[25] and 
metabolic syndrome[26], both being diseases that are also known to be affected by host 
genetics and environmental factors[27]. A better understanding of the cause of dysbiosis 
is necessary to develop strategies to restore or boost a healthy bacterial community and 
homeostasis.       
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1.2 Short chain fatty acids and health effects of butyrate 
 
The HGM produces a wide range of metabolites, including short chain fatty acids 
(SCFAs) that are utilized by the host and exert a range of health-promoting func-
tions[28]. These SCFAs are the major products of anaerobic fermentation of carbohy-
drates and are necessary waste products, required to balance redox equivalent produc-
tion in the anaerobic environment of the gut[29]. One health effect attributed to SCFAs 
is the reduction of the luminal pH that inhibits growth of pathogenic microorganisms 
and increases the absorption of nutrients[30]. The concentration of SCFAs varies longi-
tudinally across the gut, with the highest levels in the cecum and proximal colon[31]. 
The most abundant SCFAs are acetate, propionate, and butyrate representing 90–95% 
of the SCFAs present in the colon, typically occurring in a ratio of 3:1:1[29], [30]. Other 
fermentation products such as lactate, succinate and 1,2-propanol are also produced, 
but do usually not accumulate in high concentrations, as they serve as substrates for 
other bacteria, including propionate and butyrate producers[28]. Acetate, propionate, 
and butyrate are rapidly absorbed from the gut lumen, but their subsequent distribution, 
fate and effects on host cell metabolism differ[32]. Acetate achieves high systemic con-
centrations in the blood and is produced by acetogentic bacteria and by most gut an-
aerobes, with the latter producing other reducing equivalents in addition to acetate[28]. 
Propionate and butyrate are produced by a distinct subset of bacteria, with propionate 
contributing to glycogenesis in the liver and butyrate being the preferred energy source 
for colonocytes. There are furthermore differences in how acetate, propionate, and bu-
tyrate interact with host proteins and receptors. The rest of the section below will focus 
on butyrate, as it is most often considered to have highest impact on human health[33], 
[34]. 
 
The ability to produce butyrate is widely distributed among Gram-positive bacteria in 
the colon[35]. The two main butyrate producing groups are the Faecalibacterium 
prausnitzii, belonging to the Clostridium cluster IV, and Eubacterium rectale/Roseburia 
spp., belonging to the Clostridium cluster XIVa[35]. It is produced from carbohydrates 
via glycolysis from the combination of two moles of acetyl-CoA to form acetoacetyl-
CoA, followed by reduction to butyryl-CoA, which can form butyrate by two different 
pathways (Figure 2). One way is by butyryl-CoA:acetate CoA-transferase and the sec-
ond is by phosphotransbutyrylase and butyrate kinase[36]. Only few butyrate producers 
5
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are known to use the butyrate kinase pathway, such as Clostridiumbutyricum, Copro-
coccuseutactus, and Coprococcuscomes. The butyryl-CoA:acetate CoA-transferase 
pathway requires consumption of external acetate, which can come from cross feeding 
on an acetate producing bacteria[37].     
Butyrate’s health effects are partly associated with its ability to inhibit the activity of 
histone deacetylase (HDAC) in colonocytes and immune cells. The inhibition promotes 
hyper acetylation of the histones, which has consequences for gene expression and cel-
lular differentiation, including increase in total colonic regulatory T cells, downregula-
tion of pro-inflammatory cytokines, such as interleukin-6 (IL-6) and interleukin-12 (IL-
12) in colonic macrophages[32]. HDAC inhibition is also thought to promote apoptosis
of colorectal cancer cells[32]. Butyrate appears to have a dual role, sometimes referred
to as the “butyrate paradox” whereby it induces proliferation in healthy colonocytes
but terminal differentiation and apoptosis in transformed cells. This can be explained
by the fact that butyrate is the preferred energy source for colonocytes, while cancerous
colonocytes prefer glucose. Compared to normal colonocytes that oxidize butyrate, bu-
tyrate is accumulated 3-fold in nuclear extracts from cancer cells, where it can act as
an efficient HDAC inhibitor[38], [39].
Figure 2 Pathway for microbial biosynthesis of butyrate from carbohydrates. Redox reactions which involve 
electron carriers are indicated by [H]. CoA, coenzyme A; P, bound phosphate; Pi, inorganic phosphate; PEP, phos-
phoenolpyruvate. Dotted line indicates that several intermediate steps are involved. Enzymes: 1, pyruvate-ferredoxin 
oxidoreductase; 2, acetyl-CoA-acetyltransferase; 3, β-hydroxybutyryl-CoA dehydrogenase; 4, 4-hydroxybutyryl-CoA 
dehydratase; 5, butyryl-CoA dehydrogenase; 6, phosphotransbutyrylase; 7, butyrate kinase; 8, butyryl-CoA:acetate-
CoA transferase. Figure based on [28].  
Several studies have shown that the number of butyrate producers are reduced in in-
flammatory diseases, irritable bowel syndrome[40], colitis ulcerosa[41], colon cancer[42], 
and Crohn’s disease[43]. An explanation for the decrease of butyrate producers is not 
6
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yet clear, but the immune response might play a role in shaping the microbial commu-
nity. Changes in the gut environment and transit time are in addition likely to have 
influence[35]. It is, however, becoming increasingly accepted that prominent butyrate 
producers are an indicator of a healthy HGM and seem to be actively involved in main-
taining a stable and healthy community in the human gut[32]. 
1.3 Roseburia intestinalis 
The genus Roseburia is one of the most abundant bacterial genera in the human gut 
and constitutes on average 5% of the total amount of the gut bacteria [35], [44]. In 
infants, the microbial abundance of Roseburia species is among the top 10 to increase 
within three month after birth[45]. Roseburia belongs to the Firmicutes phylum (Table 
1), which is phylogenetically diverse. Analysis of this phylum, based on 16S rRNA gene 
sequences and multiple shared genotypic and phenotypic traits, has shown that the 
Roseburia genus cluster together with Eubacterium rectale forms a coherent group of 
butyrate-producing Firmicutes[35], [46]. The genus resides in the colon[37], [47] and has 
been shown to adhere to mucin, where it contributes to the mucosal butyrate produc-
tion[48]. It is hypothesized that these bacteria play a critical role for human gut home-
ostasis and host epithelial health via the butyrate production in close proximity to the 
epithelium[48]. In recent years, an increasing body of evidence has shown a decrease in 
abundancy of Roseburia species in connection to chronic diseases such as type 2 diabe-
tes[49], Chron’s disease[50]–[52], and colorectal cancer[53]. This has led to the suggestion 
of using the abundance of Roseburia species as a health marker[54]. Colonization with 
R. intestinalis has in addition shown to decrease levels of inflammatory markers in
atherosclerosis, as R. intestinalis produced butyrate, mediating these effects in a murine
model[55].
Table 1 Classification of R.intestinalis 
Domain Bacteria 
Phylum Firmicutes 
Class Clostridia 
Order Clostridiales 
Family Lachnospiraceae 
Genus Roseburia 
Species Roseburia intestinalis 
Strains L1-82,  
M50/1,  
XB6B4 
Figure 3. Scanning electron micrograph of 
R. intestinalis L1-82. Bar, 1 µm. Figure 
adapted from [57].   
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Five species of Roseburia have so far been described: R. faecis, R. inulinivorans, R. 
hominis, and R. intestinalis[56], [57]. This thesis focuses on the latter, which is one of 
the core 57 species that are present in ≥90% of all individuals[49]. R. intestinalis is a 
low-G+C-content Gram-positive to Gram-variable bacterium isolated from human fe-
ces[57]. It has a curved rod shaped morphology and measures approximately 0.5x1.5-5.0 
µm with multiple subterminal flagella contributing to cell motility (Figure 3)[57]. R. 
intestinalis tolerance against oxygen has been tested, with exposure times above 2 
minutes inhibiting growth, making it an obligate anaerobe bacterium[56]. Analysis of 
the fermentation products of R. intestinalis cells, grown on a rich media containing 
starch, glucose and cellobiose, showed that butyrate and lactate were the main SCFAs 
produced, with a concentration of 18.5 mM and 10.2 mM, respectively[57]. Formate was 
also detected but as a minor product in addition to hydrogen and carbon dioxide [57]. 
R. intestinalis can utilize acetate, however, the presence of this SCFA is not essential 
for growth. Interspecies transfer of acetate and hydrogen between microorganisms dur-
ing xylan utilization has been demonstrated for R. intestinalis[58]. In this experiment, 
R. intestinalis was co-cultured together with an acetogen and a hydrogen-consuming 
bacteria (Ruminococcus hydrogenotrophicus and Ruminococcus hydrogenotrophicus) 
This led to a decrease in acetate and hydrogen and an increase of butyrate, indicating 
that R. intestinalis can utilize the acetate produced by the acetogen and that the hy-
drogen consumer can utilize the hydrogen from R. intestinalis[58]. The elimination of 
hydrogen is important, since it constitutes one of the main gases responsible for digestive 
discomfort for the host. However, hydrogen does not seem to affect the growth of R. 
intestinalis[59].    
 
R. intestinalis ability to grow on a range of carbohydrate substrates has been tested 
(Table 2), In general, R. intestinalis is able to utilize a limited number of polysaccharides 
and monosaccharides compared to its counterparts from the Bacteroides genus[15]. A 
substrate that the strain grows particularly well on is xylan[56]. R. intestinalis has been 
described as a key xylan degrader in the human gut[60]. Xylanolytic bacteria were iso-
lated from freshly voided feces obtained from 21 healthy individuals. The predominant 
xylanolytic bacteria (20 strains) were assigned to R. intestinalis and Bacteriodes spe-
cies[60]. Compared to Bacteriodes species, R. intestinalis colonize insoluble xylan more 
efficiently. This was investigated by scanning electron microscopy, which showed that 
R. intestinalis colonize dietary fibers with a high density, forming a thick biofilm, while 
Bacteriodes cells are rather scattered on the dietary fibers[61]. The ability of R. intesti-
nalis to attach to dietary fibers has been confirmed in another study with wheat bran 
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particles. The particles were incubated with fecal HGM from four individuals and 
washed to remove loosely attached bacteria. The results showed that the wheat bran 
particles were dominated by Lachnospiraceae, including R. intestinalis[62]. Recently, we 
have reported the molecular machinery of xylan utilization including enzymatic degra-
dation and uptake preferences of R. intestinalis[63].  
 
Table 2 Carbohydrates tested for utilization by R. intestinalis  
Substrate Growth  Substrate Growth  
Arabinose + [57], [63], [64] Amylopectin starch  + [64]+ [65] 
Fructose + [57] Arabinan - [64] 
Fucose - [64] Arabinoxylan + [63], [64] 
Galactose + [64], [66]  Cellobiose + [64] 
Glucoronic acid - [63] Fructooligosaccharides + [65] 
Glucose + [63], [64] Galactomannan + [63], [64] 
N-acetylglucoamine + [64] β-Glucan - [64] 
N-acetyl-galactoamine - [64] Glucomannan + [63], [64] 
   Glucuronoxylan + [63] 
   Glycogen + [64] 
   Inulin - [57] 
   Pectic galactan - [64] 
   Pullulan - [64] 
   Xyloglucan - [64] 
   Xylo-oligosaccharides (DP 2-6) + [63], [65] 
   
1.4 Fiber degradation by the microbiota 
The human diet constitutes of large quantities of dietary carbohydrates and most of 
them cannot be exploited by the enzymes encoded by the human genome. The human 
digestive system can digest the diet-derived disaccharides sucrose and lactose, which are 
found in fruits and milk, respectively. The only dietary polysaccharide humans can 
digest is starch (mainly the α-1,4 bonds)[67]. Thus, most dietary carbohydrates reach 
the intestine intact and are termed dietary fibers[68](see next section for definition of 
dietary fibers). To access the energy from the otherwise indigestible dietary fibers, hu-
mans rely completely on the symbiotic HGM. The main products from this fermentation 
of dietary fibers by our HGM are SCFAs, which provide approximately 5-10% of the 
human energy requirements[69]. While the human genome only encodes 17 digestive 
enzymes, distinct gut bacteria produce hundreds of digestive enzymes targeting a vari-
ety of polysaccharides[68] (Figure 4).  
The HGM composition and metabolic output are shaped by the influx of dietary fibers 
in the gut[70]. In a study, where humans over a short-term period of 4 days consumed 
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fiber rich or fiber poor diet compared to reference diet, it was shown that microbial 
community abruptly shift with a change in diet[71].  
 
Figure 4: Diversity of dietary fiber active enzymes. Difference in the number of carbohydrate hydrolases (GHs) 
and polysaccharide lyases (PLs) between different taxonomic groups in a mini-microbiome and in a human is repre-
sented by the size of circle. The Bacteroidetes genomes in the mini-microbiome contain more GH and PL genes 
than genomes from the other phyla present, suggesting that members of this phylum are capable of using a larger 
range of carbohydrate substrates compared to the Firmicutes and the Actinobacteria. Figure modified from[68].   
 
From an ecological perspective, the HGM can be divided into glycan utilization gener-
alist or specialist; where generalist can utilize a broad range of dietary fibers by switch-
ing metabolism, whereas the specialist utilize only a few glycans[72]. Early studies on 
the two dominant phyla have shown that Bacteriodetes tend to be generalists and the 
Firmicutes specialists[73], [74], which also correlates with the number of carbohydrate 
active enzymes encoded in the representative genomes (Figure 4). Other factors that 
influence glycan fermentation by the HGM are transit time and the solubility of the 
dietary fibers[70] (Figure 5). In the ileum the transit time is fast and the bacteria target 
rapidly digestible dietary fibers, such as inulin and oligosaccharide side chains of pectin. 
In contrast, the transit time is slow in the distal colon and the dietary fibers are less 
soluble and therefore require longer time to digest. The density of bacteria is in addition 
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higher in the distal colon, which correlates with the slower transit time, where they 
have more time to proliferate.  
 
Figure 5: Dietary fiber utilization along the human gut. The schematic representation of the intestine is color 
coded to reflect the potential digestion gradients. Figure modified from[70]. 
 
1.5 Dietary fibers 
The term dietary fiber has been defined by the 2009 Codex Alimentaroius as carbohy-
drate polymers with 10 or more monomeric units1, which are neither digested nor ab-
sorbed in the small intestine[75]. Additionally, the definition states that added fibers 
must have been shown to have a physiological benefit to health[75]. Dietary fibers are 
primarily from plants, but can also originate from animals, fungal cell walls and milk-
oligosaccharides. This section will focus on dietary fibers from plants, because cereals, 
fruits and vegetables are major components of human diet. Dietary fibers from plants 
include the fractions of starch that are inaccessible to human α-amylases (resistant 
starch) together with non-starch polysaccharides; gums, mucilages, inulin, and compo-
nents of the plant cell wall[76]. The plant cell wall consists of cellulose microfibrils and 
pectins that are embedded in a matrix of hemicellulose (Figure 6). The structural fea-
tures of these dietary fibers are diverse with respect to monosaccharide composition, 
anomeric configuration, glycosidic linkage-type, linear chain length, branched chain 
composition, reducing terminal attachments and modifications such as acetylations[77]. 
Even though, dietary fibers in general are composed of a relatively small number of 
monosaccharides (mainly glucose, xylose, arabinose, mannose, galactose, fructose, rham-
nose, fucose, and the uronic form of some of the monosaccharides), the possible linkages 
                                      
1 Decision on whether to include carbohydrates with a degree of polymerization from DP 3 to 9 are left to na-
tional authorities. European Union has decided to include DP 3-9. 
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between these units are numerous, making dietary fibers some of the most chemically 
diverse polymers in nature. Thus, degradation of these will require several linkage-spe-
cific enzymes. Moreover, the polymers can be assembled in a way where one type is not 
accessible without prior degradation of another[67].      
 
Figure 6: Plant cell wall structure. Diagrammatic representation of the major structural components; cellulose, 
hemicellulose, pectin, lignin and soluble proteins, of a “typical” plant cell wall. Figure modified from[78].    
 
1.6 Hemicellulose 
 
Hemicellulose are plant cell wall derived dietary fibers that reach the intestine intact. 
However, the digestibility of hemicellulose by the HGM is high. In a study with seven 
women on a standardized diet, it was estimated that 72% of the digested hemicellulose 
was degraded by the HGM[79].   
 
In the plant cell wall hemicellulose constitute approximately one-third of the dry mass 
and contribute to mechanical strength by interactions with cellulose and, in some walls, 
with lignin[80], [81]. Hemicellulose are a heterogeneous group of polysaccharides that 
can be divided into the major groups; xylans, mannans, xyloglucans, and β-glucans[81]. 
These polysaccharides are characterized by having β-(1,4)-linked backbones of glucose, 
xylose, or mannose in an equatorial configuration, with the exception of β-glucan that 
contains both β-(1,4) and β-(1,3) linkages. The backbone is often decorated with sugars, 
which can be simple (a single monosaccharide, few linkage-types) or very complex (many 
monosaccharides, many linkage-types, and varying length of branches). Hemicellulosic 
polysaccharides are in addition acetylated, explaining why some of these polymers are 
not crystalline[82]. The fine structure of these polysaccharides depends on the decoration 
and varies in different plant tissues and species. Table 3 provides an overview of the 
backbone and decorations found in the different hemicellulose polysaccharides. The de-
tailed structures of xylans and mannans will be discussed in the following section.       
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Table 3: Chemical structure of polysaccharides from hemicellulose 
Polysaccharide Backbone Decoration 
Xylan  β-(1,4)-linked D-xylose Linear or branched with L-arabinose and/or D-
glucuronic acid. D-xylose, D/L-galactose and feru-
lic acid or p-coumaric acid can also occur as es-
terification of arabinosyl residues. 
Mannan β-(1,4)-linked D-mannose Linear or branched with D-galactose 
Glucomannan β-(1,4)-linked D-mannose 
and D-glucose 
Linear or branched with D-galactose. Esterifica-
tion of glycosyl residues can also occur. 
Xyloglucan β-(1,4)-linked D-glucose Branched with D-xylose. D-galactose and L-fucose 
can also occur.  
β-glucans β-(1,4)- and β-(1,3)-linked 
D-glucose 
Linear 
1.7 Xylan 
Xylan is the major component of hemicellulose and second most abundant polysaccha-
ride in plant cells. It is found in high amount in hardwoods, where xylans can comprise 
25-35% of the biomass, as well as in cereals grains which contain 30-50%[83]. It is typ-
ically found in the secondary cell wall of plants, but is also present the primary cell 
wall−particular in monocots[84]. Xylan shows large heterogeneity and it varies greatly 
in structure depending on plant origin. A common feature in xylans are a backbone of 
β-1,4-linked D-xylosyl residues with different side chain substitutions, such as D-glucu-
ronic acid, 4-O-methyl-D-glucuronic acid, L-arabinose, D/L-galactose, D-xylose [81], [85]. 
Xylans can be grouped according to their side chains (Table 4) and its degree of 
polymerization is variable, such as in hardwood and softwood, with 150-200 and 70-130 
β-1,4-linked D-xylosyl residues, respectively[84].   
Glucuronoxylan (GX) is found in the secondary cell wall of dicots[81] and is character-
ized by having side chains of D-glucuronic acid and/or 4-O-methyl-D-glucuronic acid 
attached at position 2 of the D-xylosyl polymer. In hardwood and herbs the molar ratio 
of D-xylose and 4-O-methyl-D-glucuronic acid is on average 1:10. D-glucuronic acid sub-
stitutions are less common but has been reported isolated from husk of red gram[86]. 
The backbone of GX is usually acetylated at C2 and/or C3, with the latter being more 
frequent. The degree of acetylation varies considerably, e.g. birchwood GX is heavily 
acetylated with more than 1 mol of acetic acid per 2 mol of D-xylose[87]. The presence 
of acetyl groups is responsible for the partial solubility of xylan in water. GX has a 
unique sequence at the reducing end, which includes D-rhamnose and D-galacturonic 
acid (Figure 7) and it has been shown to be required for normal GX synthesis in the 
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secondary wall of dicots[88]. It is to this date unknown if other types of xylans have a 
similar sequence at their reducing ends. 
Table 4: Structure and occurrence of xylan in plants. Modified from[89]  
Polysaccharide Backbone substitutions Occurrence 
Arabinoxylan        (AX) L-arabinose. Ferulic acid or p-coumaric 
acid can be O-esterified to L-arabinose 
residues.  
Seeds of grasses and cereal 
grains 
Glucuronoxylan     
(GX) 
D-glucuronic acid that can be 4-O-methyl-
ated 
Secondary walls of dicots; hard-
woods, wood plants and herbs 
(methylated form). Various di-
cot seeds and fibers (methylated 
form). 
Glucuronoarabinoxylan 
(GAX) 
L-arabinose and D-glucuronic acid that 
can be 4-O-methylated. Ferulic acid or p-
coumaric acid can be O-esterified to L-
arabinose residues. Complex GAX is 
more heavily substituted and also in-
cludes D-xylose and D/L-galactose. 
Minor component of dicot pri-
mary cell wall, hemicellulose in 
grasses, softwood. 
Complex GAX is mainly found 
in seeds, corn bran, gum exu-
dates, and mucilages 
    
Arabinoxylan (AX) is a dominant hemicellulose component of cereal grains and seeds 
from other monocots, such as rye grass, bamboo shoots, and pangola grass[90]. The AX 
D-xylose backbone contains L-arabinosyl side chains substituted to C2 and/or C3. This 
di-substitution allows high rates of L-arabinosyl substitutions, which in rye grain can 
reach up to 1.3 L-arabinosyl per D-xylosyl[91]. The backbone of AX can be acetylated 
at C2 and/or C3[92]. Another structural feature, is the presence of ferulic acid and p-
coumaric acid, esterified on the C5 position of L-arabinosyl residues, which is found to 
crosslink AXs. This crosslinking is hypothesized to contribute to resistance to enzymatic 
degradation of plant cell walls[93].   
Xylans can also possess both L-arabinosyl and 4-O-methyl-D-glucuronic acid substitu-
tion and are referred to as glucuronoarabinoxylan (GAX), which is found in lignified 
tissues of grasses and in softwoods[83]. In softwood the GAX is not acetylated and the 
4-O-methyl-D-glucuronic acid content is higher compared to GX from hardwoods[87]. 
The structurally most diverse xylan is complex GAX that is present in seeds and corn 
bran. The backbone is highly substituted with mono-, di-, and trisaccharide side chains 
of D-xylosyl, 4-O-methyl-D-glucuronic acid, L-arabinosyl, and D/L-galactosyl [83], [89]. 
The backbone of complex GAX can be acetylated at C2 and/or C3. The distinction 
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between AX, GAX, and complex GAX is in the literature not clear and complex GAX 
is often called AX, GAX, or complex heteroxylan[85], [89], [94]. 
Most xylans occur as heteropolysaccharides with different substituent groups on the 
backbone−as with the tree major classes of xylan described above. Homoxylans, on the 
other hand, are linear and consist exclusively of D-xylosyls linked by 1,3- and/or 1,4- 
linkages and are common in algae and seaweed, but are rarely found in higher plants[83].   
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Figure 7: Structures of xylans and mannans. The monosaccharides and linkages in the main classes of xylan and 
mannan are represented. 
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1.8 Mannan  
 
Mannan is the main hemicellulose in the primary cell wall of softwoods and in specialized 
structures in seeds and fruits[95]. The physiological roles of mannans are either struc-
tural as a component of the hemicellulose-cellulose network or as a storage polysaccha-
ride in seeds[89]. The mannan backbone consist of β-1,4-linked D-mannosyl residues 
that can be interrupted by D-glucosyl and/or branched with D-galactosyl. Based on the 
backbone composition and the side chain substitution mannans can be grouped into 
four categories (Table 5). 
 
Table 5 Structure and occurrence of mannans in plants.  
Polysaccharide Backbone and sidechain substitutions Occurrence 
Linear mannan         
(M) 
Backbone of D-mannose. No sidechain 
substitutions  
Marine algae, seed of e.g. ivory 
nut and coffee bean 
Galactomannan    
(GaM) 
Backbone of D-mannose branched with 
single D-galactose  
Cell wall of e.g. legume seed (guar, 
carob, cassia) 
Glucomannan      
(GM) 
Backbone of D-mannose and D-glucose. 
No sidechain substitutions 
Softwoods, hardwoods, grasses, 
herbal plants 
Galactoglucomannan 
(GaGM) 
Backbone of D-mannose and D-glucose 
branched with single or double D-galac-
tose 
Softwoods, hardwoods, grasses, 
herbal plants 
 
Linear mannan (LM) is an important structural component of some marine algae and 
in seeds of many plants such as ivory nut and coffee bean[96]. It is a homopolysaccharide 
composed of β-1,4-linked D-mannosyl with no sidechains making it water insoluble. 
Galactomannan (GaM) is main storage carbohydrate in the cell wall of seeds[90]. As in 
LM the backbone is composed of β-1,4-linked D-mannosyl, but is branched to various 
degree at C6 with single D-galactosyl residues. True GaM are mannans with more than 
5% D-galactosyl and some branched types can have as high a mannosyl:galactosyl ratio 
as to 1.1:1[96], [97]. An increased D-galactosyl substitution makes GaM water-soluble 
and the most heavily substituted GaM are commercially used as gums (guar, tara gum, 
and carob).   
Glucomannan (GM) is the main component of hemicellulose in the secondary cell wall 
of softwood and a minor component of hemicellulose of hardwood, grasses and herbal 
plants (3-5% of the wood dry weight)[95]. The backbone of GM contains randomly 
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arranged β-1,4-linked D-mannosyl and D-glucosyl and the ratio of the two sugars in the 
backbone varies depending on plant origin. GM can be acetylated at position C2 and/or 
C3, but acetylation at position C6 have also been reported[97]      
GM branched with single D-galactosyl residues is termed galactoglucomannan (GaGM). 
The D-galactosyl residues can be attached to both D-mannosyl and D-glucosyl. There 
are two types of GaGM; galactosyl rich and galactosyl poor, where the molecular ratio 
of galactosyl:glucosyl:mannosyl is approximately 1:1:3 and 0.1:1:3, respectively[97]. Like 
GM, GaGM is water-soluble due to its relatively large content of D-galactosyl. 
 
1.9 Carbohydrate active enzymes  
 
Glycans and glycoconjugates are widely distributed in nature, where they mediate a 
variety of biological functions, from carbon reserves, to structural molecules, decorations 
on lipids and as a variety of specialized metabolites that mediate cellular recognition, 
communication and bioactivities. These functions are facilitated by a diverse chemical 
composition based on a large number of combinations of monosaccharides structures 
and different intersugar linkages, making them some of the most structurally diverse 
substrates on earth. This diversity is a product of multiple enzymes involved in the 
assembly, breakdown and/or modification of glycans. Collectively these enzymes are 
designated Carbohydrate-Active enZymes (CAZymes), which are classified into families 
in the CAZy database (www.cazy.org)[98]. The classification is based on sequence sim-
ilarities and members of the same family display a common fold with a conserved cata-
lytic apparatus and mechanism[82], [99]. To date, the CAZy database is divided into 
five enzymatic classes (glycoside hydrolases (GHs), polysaccharide lyases, carbohydrate 
esterases (CEs), and auxiliary activities) and one non-catalytic family (carbohydrate 
binding modules (CBMs). CAZymes are frequently modular enzymes with a catalytic 
module harboring a variable number of other modules, which can be either catalytic or 
not[98]. Thus, a modular CAZyme can be assigned to several families if its constitutive 
modules belong to separate families. In the following sections the CAZymes families 
involved in this thesis will be thoroughly described. 
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1.10 Glycoside hydrolases 
 
Glycoside hydrolases (GHs) are widespread in nature and catalyze the cleavage of gly-
cosidic bonds between two or more carbohydrates or between a carbohydrate and a non-
carbohydrate moiety[100]. They are important for biotechnological and biomedical ap-
plications and are so far the best characterized CAZymes. This is reflected by GHs 
constituting the largest category in the CAZy database with 154 families (January 2019). 
A number of the enzyme families are further categorized based on conservation of their 
tertiary structure, catalytic residues, and catalytic mechanism forming clans within the 
family, into groups that are named from A-N[101]. GHs are also frequently classified as 
“exo” or “endo” acting, which refers to the enzymes ability to cleave a polysaccharide 
from the end (often the non-reducing end) or within the polymer chain (Figure 8)[100]. 
 
 
Figure 8 Schematic representation of exo- and endo-acting enzymatic cleavages of a polysaccharide. Figure 
adapted from https://www.cazypedia.org/index.php/Glycoside_hydrolases 
 
GHs typically catalyze the hydrolysis of a glycosidic bonds via two general mechanisms 
resulting in either in overall inversion or retention of the anomeric configuration at the 
hydrolysis site (Figure 9)[102].  
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Figure 9: The two major mechanisms of enzymatic glycosidic bond hydrolysis. A) Inverting mechanism of  
α-glycosidase. B) Retaining mechanism of α-glycosidase. Figure modified from https://www.cazypedia.org/in-
dex.php/Glycoside_hydrolases 
 
1.11 Carbohydrate binding modules 
 
Many CAZymes are modular proteins composed of a catalytic module joint to one or 
more ancillary modules often by means of a flexible linker. The most common of ancil-
lary modules are carbohydrate binding modules (CBMs). CBMs are defined as a con-
tiguous, independently folding domains that are appended to catalytic CAZymes to 
confer binding to carbohydrate substrates[103]. The most recognized functions of CBMs 
is to mediate increased substrate binding, thereby bringing the appended catalytic mod-
ule into close proximity and providing prolonged interaction with the target sub-
strate[99], [104]. CBMs may contribute to catalysis by introducing conformational 
changes to carbohydrates[105]. An early report ascribed a disruptive function of crys-
talline cellulose to certain CBMs[106], however, evidence for this hypothesis is lim-
ited[107]. There are currently 84 CBM families in the CAZy database (January 2019), 
A) Inverting 
 
 
 
 
 
 
 
 
B) Retaining 
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with the majority targeting components of the plant cell wall. Structures for 63 of the 
CBM families have been determined, with most of CBM’s assuming one of the seven 
“fold families” - with the β-sandwich being the most common fold[104]. To provide 
additional functional relevance to the CBM classification the modules have been 
grouped into three types; A, B, and C (Figure 10), which where updated in 2013[107]. 
Type A binds crystalline surfaces, type B binds internally onto single glycan chains 
(endo-type) and type C binds the terminal part of glycans (exo-type) (Figure 7).  
 
 
Figure 10: CBM types. A) CBM63 (PDB 4FER), B) CBM58 (PDB 3K8L), C) CBM71 (PDB 4CUB). The back-
bone is displayed as a cyan cartoon with a transparent solvent‐accessible surface. Aromatic amino acids establish-
ing CH– interactions are shown in blue color, amino acids forming hydrogen bonds are shown in purple (with the 
side chains displayed in sticks), and the substrate is shown in green. Figure adapted from [105]. 
 
Substrate binding are primarily facilitated by both the aromatic amino acids side chains 
residues and loop structures that shape the binding site to mirror the conformation of 
the ligand[104]. The aromatic residues are frequently tryptophan, tyrosine and less com-
monly, phenylalanine. These aromatic residues mediate binding to the substrate through 
hydrophobic and CH–π interactions, and the hydrophobic platforms at the binding site 
can be planar, have an angle that reflects the symmetry of the substrate (e.g. helical 3-
fold symmetry for xylan) or form a sandwich[104], [105]. Because the binding site mir-
rors the substrate, the main feature of type A CBMs is planar with a hydrophobic 
surface capable of binding insoluble substrate, such as crystalline cellulose and chi-
tin[108]. Type A CBMs have only been reported to have little or no affinity for oligo-
saccharides[59], [109] and the substrate binding is driven by a favorable entropy change 
consistent with a lower density of hydrogen bonds per sugar ring. Type B CBMs (endo-
type), in contrast, possess a binding site in shape of a cleft that accommodates the 
substrate[105], [107]. The binding site can be located in either the variable loop site, 
positioned towards the end of the β-sandwich, or in the concave face site, with the β-
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strands perpendicular to the ligand chain. The latter region facilitates binding in most 
cases, however, there are families with two binding sites that involve both regions. In 
general, type B CBMs binds a variety of glycans, such as xylans, mannans, starch and 
galactans[108], [110], [111] and the binding is dominated by a favorable enthalpy change. 
Type C CBMs (exo-type) display a binding site with pocket topology consistent with 
the recognition of the non-reducing end of glycans[108]. Most frequently type C CBMs 
recognize exposed or short glycans, such as monosaccharides, disaccharides and disac-
charides[105].   
 
The substrate specificity for a given CBM family can be towards a single type of glycan 
(CBM17, CBM27) or it can be diverse (CBM6, CBM35, CBM4). The diversity in sub-
strate recognition contributes to targeting efficiencies of an enzyme in environments 
with a range of glycans present, such as the cell wall[82]. Often, but not invariably, 
CBMs display a binding specificity that reflects the activity of the catalytic module. In 
general, CBM-glycan interactions are quite weak (KD affinities in µM-1 to mM-1 range) 
indicating that very tight binding is not necessarily an advantageous for enzymatic 
activity. However, these weak interactions are frequently compensated by the presence 
of several and/or multiple copies of CBM associated to a given enzyme, which can be a 
way of fine tuning the specificity to the substrate or the dynamics of enzyme binding 
(affinity/turnover ratio). Thus, diversity in substrate specificity, tandem or multiple 
CBMs are together with binding site topology important factors in understanding the 
mechanisms of substrate recognition of a CBM containing enzyme. 
 
1.12 Carbohydrate esterases  
 
A large group of enzymes are CEs that catalyze the O- or N-deacylation of ester based 
modifications present in mono-, oligo- and polysaccharides[99]. The CAZy database has 
presently classified CEs into 16 families (CE1-CE16), however, there are currently no 
members of family CE10. The substrate specificity of CEs is very diverse (Table 6) and 
as the barrier between carbohydrate esterases and other esterase activities is low, it is 
likely that the sequence-based classification incorporates some enzymes that may act on 
non-carbohydrate esters[99]. 
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Table 6 Overview of carbohydrate esterase families. Modified from[112] 
CE 
family 
Catalytic 
residues 
Known activities Structural fold 
CE1 S,H,D Acetylxylan esterase, feruloyl esterase, car-
boxylesterase, S-formylglutathione hydro-
lase, diacylglycerol O-acyltransferase, and 
thehalose 6-O-mycolyltransferase  
α/β hydrolase fold 
CE2 S,H Acetylxylan esterases Repeated α/β/α motifs; C-
terminal SGNH domain and 
an N-terminal jellyroll domain 
CE3 S,H,D Acetylxylan esterases Repeated α/β/α motifs; N-
terminal SGNH domain and 
linker module on C-terminal  
CE4 D,H,H,Co2+/ 
Zn2+ 
Acetylxylan esterases, chitin deacetylase, 
chitooligosaccharide deacetylase, pepti-
doglycan N-acetylglucosamine deacetylase, 
and peptidoglycan N-acetylmuramic acid 
deacetylase 
Distorted (α/β)7 barrel fold; 
NodB domain 
CE5 S,H,D Acetylxylan esterases and cutinases α/β hydrolase fold 
CE6 S,H,E Acetylxylan esterases Repeated α/β/α motifs; 
SGNH domain  
CE7 S,H,D Acetylxylan esterase and cephalosporin-C 
deacetylase 
α/β hydrolase fold; hexameric 
CE8 D,DR Pectin methylesterase Right-handed -helix fold 
CE9 D, Fe2+/ 
Zn2+/ 
Co2+/Cu2+ 
N-acetylglucosamine-6-phosphate deacety-
lase 
(α/β)8 barrel 
CE11 E, Zn2+, 
Zn2+ 
UDP-3-O-acyl-N-acetylglucosamine 
deacetylase  
Two-layer-sandwich 
CE12 S,H,D Pectin acetylesterase, rhamnogalacturonan 
acetylesterase and acetylxylan esterase 
Repeated α/β/α motifs; 
SGNH domain  
CE13 S,H,D Pectin acetylesterase Unknown 
CE14 H,D, Zn2+ N-acetyl-1-D-myo-inosityl-2-amino-2- de-
oxy-D-glucopyranoside deacetylase (MshB, 
mycothiol S-conjugate amidase and N,N’-
diacetylchitobiose deacetylases 
α/β fold; Rossmann fold 
CE15 S,H,E Glucuronoyl esterase α/β fold; Rossmann fold 
CE16 - Acetylesterase Unknown 
 
1.13 Enzymatic degradation of xylan 
 
The structure of xylan is heterogeneous and complex (section 1.7). Thus, the complete 
breakdown of xylan requires several enzymes with diverse specificity and mode of action. 
Xylanolytic enzymes can be classified into two main groups: those acting on the xylose 
backbone, i.e. endo-β-1,4-xylanases and β-D-1,4-xylosidases, and those cleaving the side 
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chains, i.e. α-L-arabinofuranosidases, α-1,2-glucuronidases, acetylxylan esterases, feru-
loyl esterases, p-coumaroyl esterase, β-D-1,2-xylosidases, and α-D/L-galactosidases (Fig-
ure 12 and Table 7). All of these enzymes act cooperatively to degrade xylan into its 
constituent sugars[87].  
   
 
Figure 12. Xylanolytic and mannolytic degrading enzymes. The site of enzymatic attack on xylan and mannan 
is indicted by an arrow.  
 
An important enzymatic activity for depolymerization of xylan is endo-β-1,4-xylanase 
activity. These enzymes cleave the β-1,4 glycosidic linkage between xylosyl residues in 
the backbone of xylan[113] and are primarily archived by xylanases classified into GH 
families 10, 11, and 30[82], [114]. The cleavage mode of these families are different and 
differs mainly in the way the recognition site forms the enzyme-substrate complexes. 
GH10 requires two unsubstituted xylosyl residues at subsites2 -1 and -2 to attack the 
                                      
2 Subsites are the sites at which enzyme interacts with the substrate (sugar) in the active site. The cleavage of 
the glucoside bond takes place between subsite -1 and +1. Subsites are numbered with increasingly negative num-
bers (-1, -2, -3, etc.) away from the cleavage point towards the non-reducing terminus, and with increasingly posi-
tive numbers (+1, +2, +3, etc.). 
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xylan backbone and can cleave xylosidic linkage to a decorated xylosyl residue at subsite 
+1[114]. Enzymes of GH11 require three unsubstituted xylosyl residues at subsite -1, -
2 and -3 and can cleave the backbone xylosidic linkage with a decorated xylosyl at 
subsite +2[114]. Thus, the product profiles from hydrolysis with these two GHs will be 
different - GH10 hydrolysis yields xylo-oligosaccharides (XOS) with terminal non-re-
ducing end decorations, while GH11 yields XOS with decoration at the penultimate 
xylosyl from the non-reducing end[113]. GH30 xylanases are specialized for GX and 
their mode of action is determined by the presence of glucuronic acid or 4-O-methylglu-
curonic-acid. In general GH30 attack the GX backbone xylosidic linkage with a deco-
rated 4-O-methylglucuronic acid xylosyl residue at subsite -2, which results in hydrolysis 
products that are XOS with 4-O-methylglucuronic acid decoration at the penultimate 
xylosyl residue to the reducing end[114], [115]. 
 
Other xylan backbone acting enzymes are exo-β-1,4-xylosidases that release xylose mon-
omers from the non-reducing end of XOS. The affinity of exo-β-1,4-xylosidases for XOS 
decreases with increasing DP[116]. Exo-β-1,4-xylosidases are classified into five families; 
GH3, 30, 39, 43 52 and 120, which are retaining expect for GH43 (inverting family). 
Another type of xylosidases are reducing-end-β-1,4-xylosidases classified as GH8 that 
release xylose from the reducing end of XOS and are active on linear and decorated 
XOS [117], [118]. Besides the accommodation of decoration in GH8, another difference 
between these families of xylosidases is that the reducing-end-β-1,4-xylosidase cannot 
hydrolyze XOS< xylotriose[63]. 
 
The α-1,2 linkage of glucuronic acid and 4-O-methylglucuronic acid residues to the 
backbone is one of the most acid stable glycosidic linkages in the plant cell and persist 
in an acid hydrolysate of GX[114]. However, the residues are recognized and can be 
liberated from the backbone by α-1,2-glucuronidases. There is two classes of α-1,2-glu-
curonidases; GH67 and GH115. Members of GH67 can only release 4-O-methylglucu-
ronic acid from the XOS that have the residue on non-reducing xylosyl residue[119]. 
Thus, XOS generated from GX by a GH11 need to have the non-reducing xylosyl residue 
removed by a exo-β-1,4-xylosidase prior to debranching by GH67. In contrast, GH115 
has the ability to hydrolyze 4-O-methylglucuronic acid residues placed either internal 
or at the terminal non-reducing end[120].  
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The function of α-L-arabinofuranosidases in xylan degradation is to remove arabinosyl 
residues from the xylosyl backbone. These enzymes are grouped into four families; GH43, 
51, 54, and 62 and hydrolyze the glycosidic linkage through inversion (GH43) or reten-
tion (GH51, and 54). As described in section 1.7 the arabinosyl may be linked to C2, 
C3 or both OH groups of xylosyl residues. α-L-arabinofuranosidases have been divided 
into two groups[114]. The major group of these two consists of enzymes active on mono-
substituted xylosyl residues on position C2 or C3. This group is disseminated in all of 
the α-L-arabinofuranosidase families[121]. The minor group includes enzymes active on 
non-reducing terminal double-substituted xylosyl residues, from which they selectively 
remove arabinosyl on position C3 leaving the arabinosyl on C2[122]. This group primar-
ily have members from family GH43[122], [123]. Arabinosyl decorations in xylan can be 
further esterified with ferulic acid or coumaric acid and the CE family catalyzing the 
de-esterfication belongs to CE1. 
 
The presence of α-D-galactosyl and α-L-galactosyl is more rare and only present in GAX 
where it contributes to recalcitrance of the xylan[114]. There has not been much research 
on α-galactosidases that would release the galactosyl residues, but in a study by 
Rogowski et al they characterize a GH97 and a GH95, which are active on the glycosidic 
linkage for α-D-galactosyl and α-L-galactosyl, respectively[94].       
 
Acetylxylan esterases are enzymes that hydrolyze the deacetylation of xylan and are 
present in family CE1-7, 12, and 16. The xylosyl residues in the xylan backbone can be 
2-O or 3-O mono- or double-acetylated. The positional specificity for five of the families 
has been investigated. CE4 can deacetylate both 2-O or 3-O acetylations but only if the 
xylosyl residue is mono-acetylated[124], while CE1, 5, 6, an 16 are capable of deacety-
lating double-acetylated xylosyl residues[125]. None of the acetylxylan esterases can 
deacetylate the 3-O acetylations on a 4-O-methylglucuronic acid substituted xylosyl 
residue, indicating that 4-O-methylglucuronic acid is a steric barrier for esterases[125]. 
1.14 Enzymatic degradation of mannan 
 
The structure of mannan is heterogeneous (section 1.8) and as with xylan the complete 
breakdown of mannan requires several enzymes with diverse specificity and mode of 
action. Mannolytic enzymes are composed of endo-β-1,4-mannanases, exo-β-1,4-manno-
sidases and β-1,4-glucosidases that hydrolyze the backbone, while α-D-galactosidases 
and acetylmannan esterases remove the side chain decorations(Figure 12 and Table 7). 
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For complete degradation of mannan to its constituent sugars these enzymes work to-
gether in a concerted manner. Two types of synergies have been identified in relation 
to mannan degradation; homosynergy and heterosynergy. Homosynergy is defined as 
cooperativity between two backbone cleaving enzymes (i.e. endo-β-1,4-mannanases and 
exo-β-1,4-mannosidases) or two side chain cleaving enzymes (α-D-galactosidases and 
acetylmannan esterases), whereas heterosynergy is the synergistic interaction between 
a side chain cleaving enzyme and a backbone cleaving enzyme (i.e. α-D-galactosidases 
and endo-β-1,4-mannanases)[97], [126].  
 
After xylanases, mannanases are the most important enzymes for the hydrolysis of hem-
icellulose[95]. Endo-β-1,4-mannanases cleave the β-1,4 glycosidic linkage in the mannan 
backbone liberating short manno-oligosaccharides (MOS) and have been classified into 
family GH5, 26, 113 and 134. GH5 and 26 are the largest and best characterized families, 
while the two other families only have a single or two characterized members respec-
tively. The ability to cleave at the backbone relies for all endo-β-1,4-mannanases on a 
mannosyl residue at subsite -1, but is also depended on the number and distributions 
of the side chain decorations[91]. There is significant variation in the specificity of the 
enzymes, which point out the divergence between GH5 and GH26. GH5 mannanases 
are able to accommodate mannosyl and glucosyl residues at the -2 and +1 subsites and 
are thus able to hydrolyze mannosidic linkages flanked by mannosyl and glucosyl resi-
dues. In contrast, characterized GH26 mannanases display tight specificity for mannose 
at both -2 and +1 subsites[127].  
 
Exo-β-1,4-mannosidases are exo-acting enzymes that catalysis the hydrolysis of the β-
1,4 glycosidic linkage in mannan and MOS, releasing mannosyl from the non-reducing 
end. These enzymes have been classified into family GH1, 2, 5, and 113. The presence 
of a D-galactosyl decorated mannosyl residue adjacent to the terminal mannosyl has 
been shown to significantly reduce the mannosidase activity compared to a linear sub-
strate[128].   
 
β-1,4-glucosidases are required for the complete degradation of GM, and GaGM. These 
are exo-acting enzyme that hydrolyze glucosyl residues from the non-reducing end of 
MOS derived from the degradation of GM, and GaGM by mannanases[97]. The enzymes 
are classified into family GH1, 3, 9, and 30. 
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The backbone of GaM and GaGM are decorated with D-galactosyl residues (section 1.8). 
The α-1,6 galactosidic bonds between D-galactosyl and mannosyl residues are cleaved 
by α-D-galactosidases. The enzymes fall into family GH4, 27, 31, 36, 97 and 110 and 
can be further divided into those that can hydrolyze D-galactosyl residues attached to 
internal mannose residues of oligos or polymers and those that primarily hydrolyze 
terminal D-galactosyl residues[129].  
Acetylmannan esterases hydrolyze deacetylation of O-acetyl groups from mannan. Op-
posed to acetylxylan esterases these enzymes have been long known, however no struc-
tures yet exist[129], [130]. In addition, none of the defined families of CE in the CAZy 
database are ascribed to possess solely acetylmannan activity. This can be due to the 
fact that some acetylmannan esterases also act as acetylxylan esterases[91].  
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Table 7 Xylanolytic and mannolytic enzymes 
Enzyme Sub-
strate 
Reaction Family Clan Mech-
anism 
Catalytic 
residues 
Endo-β-1,4-xy-
lanase 
AX, 
GX, 
GAX 
Endohydrolysis of 1,4-β-D-xy-
losidic linkages in xylans 
GH5.4 A R E,E 
GH5.21 A R E,E 
GH8 M I D,E 
GH10 A R E,E 
GH11 C R E,E 
 GH30 A R E,E 
 GH43 F I D,E 
Exo-β-1,4-D-xy-
losidase 
AX, 
GX, 
GAX 
Hydrolysis of terminal, non-
reducing D-xylose residues in 
1,4-β-D-xylooligomers  
GH3 -  R D,E 
GH30 A R E,E 
GH39 A R E,E 
GH43 F I D,E 
  GH52 O R D,E 
   GH120 - R D,E 
Reducing-end-β-
1,4-D-xylosidase 
AX, 
GX, 
GAX 
Hydrolysis of terminal, reduc-
ing D-xylose residues in 1,4-β-
D-xylooligomers  
GH8 M I D,E 
α-L-arabino-
furanosidase 
AX, 
GAX 
Hydrolysis of terminal non-re-
ducing α-L-arabinofuranoside 
residues 
GH43 F I D,E 
GH51 A R E,E 
GH54 - R -,- 
  GH62 F -  -,- 
α-1,2-D-glucu-
ronidase 
GX, 
GAX 
Hydrolysis of terminal α-D-(4-
O-methyl)glucuronosyl resi-
dues 
GH67 - I -,E 
GH115 - I -,- 
Acetylxylan es-
terase 
AX, 
GX, 
GAX 
Deacetylation of xylan CE1, 3, 
5, 7, 
12, 
- - S,H,D 
   CE2 - - S,H 
   CE4 - - D,H,H,Co2+/ 
Zn2+ 
   CE16 - - - 
Feruloyl esterase AX, 
GAX 
Deferuloylation of xylan CE1 - - S,H,D 
p-coumaroyl es-
terase 
AX, 
GAX 
De-p-coumaroylation of xylan CE1 - - S,H,D 
Endo-β-1,4-D-
mannanase 
M, 
GaM, 
GM, 
GaGM 
Endohydrolysis of 1,4-β-D-
mannosidic linkages in xylans 
GH5 A R E,E 
GH26 A R E,E 
GH113 A R E,E 
GH134 - I -,- 
Exo-β-1,4-D-
mannosidase 
M, 
GaM, 
GM, 
GaGM 
Hydrolysis of terminal, non-
reducing β-D-mannose resi-
dues in 1,4-β-D-mannooligos 
GH1 A R E,E 
GH2 A R E,E 
GH5 A R E,E 
GH130 - I -,- 
β-D-glucosidase GM, 
GaGM 
Hydrolysis of terminal, non-
reducing β-D-glucosyl residues 
with release of β-D-glucose 
GH1 A R E,E 
 GH3 -  R D,E 
 GH9 - I D,E 
 GH30 A R E,E 
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α-D-galacto-
sidase 
GaM, 
GaGM, 
GAX 
Hydrolysis α-D-galactose resi-
dues  
GH4 - R -,- 
 GH27 D R D,D 
 GH31 D R D,D 
 GH36 D R D,D 
 GH57 - R E,- 
 GH97 - I  E,E 
 GH97 - R D,E 
 GH110 - I -,- 
α-L-galacto-
sidase 
GAX Hydrolysis of terminal, non-
reducing α-L-galactose resi-
dues 
GH95 - I N,E 
Acetylmannan 
esterase 
GaM, 
GM, 
GaGM 
Deacetylation of mannan - - - -,- 
R: Retaining, I: Inverting 
 
1.15 Oligosaccharide transporters 
 
Firmicutes utilize a diverse array of transporters to import oligosaccharides for intra-
cellular processing. These transporters fall into three main classes: ATP-binding cassette 
(ABC) transporters, phosphoenolpyruvate-phosphotransferase system (PTS) transport-
ers, and major facilitator superfamily (MFS) transporters[67]. The first part of this 
section will focus on ABC importers, which are frequently encoded in glycan utilization 
loci’s together with intracellular GHs in Firmicutes, suggesting that their expression 
and function is co-regulated[72]. Similar genomic organization of ABC transporters and 
GHs has also been characterized in other phyla such as Actinobacteria[131]. The second 
part of this section will introduce how Bacteriodes species import oligosaccharides facil-
itated by analogues to the starch utilization system (Sus).  
 
ABC transporters comprise one of the largest superfamily of membrane proteins[132]. 
They couple hydrolysis of ATP to translocate substrates across membranes, ranging 
from ions to macromolecules. Transporters of the ABC type are divided into three func-
tional categories[133]. (I) Importers that mediate the uptake of nutrients including 
mono- and oligosaccharides (mainly found in prokaryotes). (II) Exporters that are in-
volved in the secretion of various molecules, such as peptides and lipids. (III) The third 
category of systems is not involved in transport, with some members being involved in 
translation of mRNA and in DNA repair. All ABC transporters share a characteristic 
architecture comprising at least two intracellular nucleotide-binding domains (NBDs) 
and two transmembrane domains (TMDs) that constitute a heterodimeric translocation 
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pore (Figure 13). The primary structure of TMDs are markedly variable compared to 
NBDs, which contain highly conserved motifs[132]. The TMDs span the membrane 
forming a translocation pore that contains a substrate binding site, while the NBDs are 
molecular motors that transform the chemical potential energy of ATP into protein 
conformational changes between an outward facing (open to the exterior) and an inward 
facing (open to cytoplasm) structure of the pore[134]. A “typical” ABC transporter is 
described to possess 12 transmembrane helices (6 per TMD), however, as stated above, 
TMDs are heterogeneous and four distinct folds are currently recognized: type I ABC 
importer, type II ABC importer, type III energy coupling factor importer and ABC 
exporter[135], [136]. Prokaryotic importers from type I and II, also termed permeases, 
require an additional high affinity component−the solute binding protein (SBP). These 
are soluble proteins located in the periplasm of Gram negative bacteria or lipid anchored 
or fused to the TMD in Gram-positive bacteria and archaea[137]. The role of SBPs is 
to capture ligands and deliver them to the TMDs, for translocation across the membrane. 
Based on features from three-dimensional structures Berntsson et al. classified SBPs 
into six clusters (A-F)[137]. An interesting observation from this classification is that 
SBPs with similar architecture do not necessarily bind the same ligand. The overall 
structure of SBPs is composed of two α/β domains connected by a hinge-region and the 
substrate binding takes place between the two domains[137]. In the absence of ligand 
the SBP is flexible and exist mainly in an open conformation. Upon substrate binding 
a closed conformation is stabilized and the ligand trapped. This mechanism is called the 
Venus Fly-trap model[138]. Based on structural work, a model for the ABC import 
system has been proposed[139]. In a resting state, the NBD dimer interface is in its 
inward facing conformation with the two coupling helices farther apart. When SBP 
interact with the substrate, it undergoes a conformational change from the open to the 
stabile closed conformation and docks onto the TMDs. This brings the NBD dimer 
closer such that ATP promotes the outward facing conformation. The substrate will be 
transferred to the TMD binding site and at the same time position ATP at the catalytic 
site for hydrolysis. Once ATP is hydrolyzed the TMD will reorient to the inward facing 
conformation and the substrate diffuse into the cytoplasm. 
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Figure 13 Schematic representation of two bacterial transporter systems. A) Representative structure of an 
ATP-binding cassette (ABC) transporter composed of a solute binding protein (SBP), two transmembrane do-
mains (TMDs) and two nucleotide-binding domains (NBDs). In Gram positive bacteria and archaea the SBP is 
lipid anchored or fused to TMD. Translocation of substrates across the membrane is coupled to ATP hydrolysis by 
NBDs. A glycoside hydrolase (GH) is depicted next the ABC-transporter because long polymers often need to be 
hydrolyzed to oligosaccharides prior to import. B) Representative structure of a starch utilization system (Sus) in 
Bacteroides species composed of surface glycan-binding proteins (SGBPs), GH(s) and a TonB-dependent trans-
porter (TBDT) in the outer membrane. TBDT interacts with the inner membrane TonB-ExbBD complex consist-
ing of TonB, ExbB and ExbD proteins. Regulation of Sus and the respective GHs is commonly mediated by a hy-
brid two-component systems (HTCS). 
Bacteriodetes have few classical glycan-transporters[140]. Instead their genomes have 
gene clusters termed polysaccharide utilization loci (PUL) that encode GHs, glycan-
binding proteins (SGBPs) and a TonB-dependent transporter(TBDT)[141]. These PUL-
encoded proteins work together to selectively facilitate capture and transport of glycans 
at the cell surface. The Sus from Bacteriodes thetaiotaomicron was the first PUL to be 
characterized and it frequently serves as a model system[140], [142]. Together, eight 
genes were identified as part of this single gene cluster. All proteins responsible for 
recognition and initial hydrolysis of starch at the outer membrane, translocation of 
glycans into the periplasm, further hydrolysis to monosaccharides and transcriptional 
regulation are encoded in the cluster[143]. Around 18% of all genes in B. thetaiotaomi-
cron str. VPI 5482 have been assigned as Sus-like systems because they target other 
glycans than starch using a similar mechanism as Sus[72]. All mammalian gut Bac-
teroidetes possess analogous Sus-like systems that typically target numerous diverse 
glycans[141]. A Sus-like system has at least one sequential pair of susC and susD hom-
ologs[142] that encode TBDT and an N-terminal lipidated SGBP, referred to as SGBP-
A[144] (Figure 13). TBDT are intimately associated with SGBP-A that forms a flexible 
“lid”[145] and deletion of SGBP-A eliminates or reduces PUL function[146], [147]. Gly-
can binding is often facilitated by one or more structurally distinct SGBPs (e.g., SGBP-
B as in figure 13) that may have a specificity identical or complementary to that of 
SGBP-A[144]. In Sus of B. thetaiotaomicron the assisted binding is performed by SusE 
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and SusF, thus, SGBPs are sometimes referred to as SusE and SusF homologs. Each 
Sus-like system also contain a repertoire of GHs and other CAZymes. An endo-acting 
GH hydrolyze glycans at the cell surface and the resulting fragments are actively shuttle 
into the periplasm by TBDT, where additional linkage specific enzymes act to generate 
monosaccharides for transport into the cytosol by MFS transporters for catabolism [144].  
 
1.16  Prebiotics 
 
The rich and diverse ecosystem of the HGM is a potential target for alterations that 
maintain or improve health or treat diseases. The ability to shift the composition and 
metabolic signature of these microbial populations by rational amendments is now pos-
sible through dietary or non-dietary interventions[148]. Dietary fibers represent by far 
the main source of energy for the HGM and offer opportunities as prebiotics for this 
beneficial manipulation via diet.  
 
Prebiotics were originally defined by Gibson and Roberfroid in 1995 as “non-digestible 
food ingredients that beneficially affects the host by selectively stimulating the growth 
and/or activity of one or a limited number of bacteria in the colon, and thus improve 
host health”[149]. The knowledge of the microbial diversity within the gut as well as 
the relative abundance of different members of the HGM was limited at the time, as it 
was based almost exclusively on culture- based approaches. Bifidobacteria and lactic 
acid bacteria, especially lactobacilli, were generally regarded as the main beneficial com-
ponents of the HGM, but newer molecular methods have since identified a broader range 
of bacterial taxa having beneficial impact on human health, such as Roseburia, Eubac-
terium or Faecalibacterium spp. The prebiotic concept has evolved and the definition 
been updated several times−latest in 2016. According to the current deﬁnition, a prebi-
otic is a substrate that is selectively utilized by host microorganisms conferring health 
benefit[148]. Thus, prebiotic effects are no longer limited to the colon but may invoke 
changes to any host microbial ecosystem.   
 
A number of prebiotic substrates have been reported (Table 8). Among the studied 
substrates, the best health effect has been reported for fructose-based carbohydrates 
(inulin and fructooligosaccharides) and galactooligosaccharides[150]. The effect of prebi-
otics depends not only on the substrate, but the DP of the substrate is also critical for 
determining the increase in growth of the beneficial bacteria and the site of fermentation. 
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Members of Bifidobacterium preferentially metabolize shorter fructooligosaccharides 
with a DP of 2-20, while the consumption decreased with DP>20[151]. In a study using 
a human colon model system the chain length of arabinoxylan-oligosaccharides (AXOS) 
was found to be critical for the determining the site of fermentation[152]. Shorter AXOS 
(average DP≤15) were fermented in the ascending and transverse colon, while longer 
AXOS (average DP=29) reached the distal colon. In the study, the SCFA concentration 
increased in all regions and the numbers of lactobacilli, Bacteroides-Prevotella and Clos-
tridium coccoides–E. rectale groups were increased[152]. In general, the carbohydrate 
gene repertoire, including GHs and transporters, in certain species or strains dictate 
their differential prebiotic substrate preference based on chain length, monomer constit-
uents, glycosidic linkages, and the overall structural complexity of the oligosaccha-
rides[153]. Ideally, prebiotics would selectively promote beneficial bacterial species, 
whose populations are decreased in situations associated with an increased disease 
risk[154]. This clearly requires detailed prior knowledge on the substrate utilization 
preferences and carbohydrate gene repertoire. Substrate utilization profiles and charac-
terization of carbohydrate gene machinery can be established for cultured strains, 
providing important information about a specific strain. However, the bacteria in the 
human gut exist within a complex community, where there is high competition for 
substrates and cross-feeding of metabolites. This may result in consequences that could 
not be predicted simply from the substrate preferences, underlining that care must be 
taken, when transferring results based on in vitro experiments to in vivo conditions in 
the evaluation of candidate prebiotics.       
 
Table 8 Selection of reported Prebiotics. Table modified from [155], [156] 
Simple prebiotics Complex prebiotics 
Inulin Pectin 
Fructooligosaccharides Human milk oligosaccharides 
Galactooligosaccharides Resistant starch 
Glucooligosaccharides Arabinoxylan 
Isomaltooligosaccharides Arabinoxylooligosaccharides 
Xylooligosaccharides Polydextrose 
Mannooligosaccharides  
Raffinose  
Lactulose   
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Chapter 2 Paper 1: Differential bacterial capture and transport 
preferences facilitate co-growth on dietary xylan in the human 
gut 
 
The present paper reports a significant part of the results obtained by during my Ph.D. 
project. The paper gives insight into xylan catabolism by the butyrate producing human 
gut symbiont R. intestinalis. The enzymatic degradation of xylan and transport of xylan 
derived oligosaccharides are described in detail in form of a transcriptomic study, enzy-
matic assays, microscopy, binding studies and NMR. A novel xylan esterase (RiAXE) 
and a novel xylan binding CBM family were identified. A central finding is that R. 
intestinalis, which was grown on different xylans and xylan components, is able to grow 
competitively in co-culture with the model xylan degrading Bacteroides ovatus. Strik-
ingly, R. intestinalis was shown to possess a preference for oligomers of 4–5 xylosyl units, 
in contrast to the B. ovatus competitor, which targets larger ligands. This differential 
preference was illustrated by the out-competition of B. ovatus in a mixed co-culture 
using a preferred ligand for the R. intestinalis ABC importer. I have aside from the 
NMR and expression + characterization of the transporter, performed and analyzed the 
all experiments in collaboration with the co-authors.   
 
Supplementary information is included in the end of the chapter     
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The human gut microbiota (HGM) is recognized as a determi-nant of human health and metabolic homeostasis1,2. Specific signatures of the HGM are associated with local and systemic 
disorders, including irritable bowel disease, obesity, type 2 dia-
betes and colon cancer3. The composition of the HGM is greatly 
affected by non-digestible dietary glycans4,5. Only a few species of 
the HGM are equipped to deconstruct and ferment distinct com-
plex glycans into short-chain fatty acids (SCFAs)6. The effect of 
SCFAs on host health and physiology remains an important aspect 
of the microbiota–host interaction. The SCFA butyrate, the pre-
ferred energy source for colonocytes, possesses anti-inflammatory 
roles and reduces the risks of colon cancer and enteric colitis7–10. 
Butyrate-producing Firmicutes are abundant in healthy indi-
viduals, but are markedly reduced in patients with inflammatory 
disorders11,12. Butyrate producers including Roseburia spp. are 
increased in patients with metabolic syndrome after faecal trans-
fer therapy and correlate positively to improvement of insulin 
resistance13. Investigations of the metabolic preferences of butyrate 
producers and their interplay with major HGM commensals are 
instrumental to develop interventions targeting butyrate deficiency-
related disorders.
Roseburia is a common genus of Clostridium cluster XIVa 
within Firmicutes that harbour prevalent butyrate producers14,15. 
This taxon adheres to mucin, reflecting intimate association with 
the host16. Roseburia intestinalis strains encode an impressive rep-
ertoire of carbohydrate-active enzymes (CAZymes) compared 
to most Firmicutes17. R. intestinalis, the taxonomically related 
Eubacterium rectale, and species from Bacteroides are the only 
known HGM taxa that utilize the hemicellulose xylan18–20. Xylan 
is particularly abundant in cereal grains (arabinoxylan) but is 
also found in fruits and vegetables (glucuronoxylan)21 (Fig. 1a). 
Xylan utilization by Bacteroides-dominant gut commensals has 
been investigated in detail22,23, but similar knowledge is lacking for 
Firmicutes counterparts.
Here, we show that R. intestinalis L1-82 grows on dietary-rele-
vant xylans, with a preference for cereal arabinoxylans. The growth 
is mediated by a multi-modular cell-attached xylanase and by an 
ATP-binding cassette (ABC) transporter. We have characterized the 
xylanolytic enzymes and the transport protein, which enabled mod-
elling xylan utilization by R. intestinalis and the identification of two 
previously undescribed xylan-specific CAZyme families. R. intes-
tinalis efficiently competes with a model xylan degrader from 
Bacteroides when grown on soluble and insoluble xylans. Strikingly, 
transport proteins that confer xylo-oligosaccharides capture in 
R. intestinalis and Bacteroides targeted ligands of different sizes, thus 
markedly reducing the competition for preferred ligands by either 
taxon. These results emphasize the competitiveness of butyrate-pro-
ducing Firmicutes in targeting key dietary fibres such as xylan and 
highlight differential glycan capture and transport as an important 
feature in co-growth on abundant dietary fibres such as xylan.
Results
Inducible cell-attached xylanase activity mediates growth of 
R. intestinalis on substituted xylans. Anaerobic growth of R. intesti-
nalis L1-82 was measured on soluble and insoluble xylans (Fig. 1b–d). 
R. intestinalis L1-82 grows rapidly on soluble xylans, especially wheat 
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arabinoxylan (WAX; μmax = 0.26 h−1), compared to birch glucuro-
noxylan (BGX; μmax = 0.13 h−1) (Fig. 1c). This bacterium also utilizes 
highly acetylated xylans and insoluble cereal arabinoxylans from 
wheat (InWAX) and oat spelt, but not cornbran glucuronoarabi-
noxylan (CBX). Xylo-oligosaccharides and xylan-derived monosac-
charides (except glucuronic acid) were also utilized. Extracellular 
endo-1,4-β -xylanase (hereafter xylanase) activity was induced upon 
growth on BGX, WAX and the poor growth substrate xylobiose 
(X2) (Fig. 1e). Xylanase activity was cell attached, but was released 
in the presence of high-salt concentration (Fig. 1f), suggesting non-
covalent attachment.
Genes encoding an ABC transporter and a multi-modular xyl-
anase are top upregulated in response to growth on xylan. We 
performed an RNA sequencing (RNA-seq) transcriptional analy-
sis of R. intestinalis grown on WAX, BGX, xylose and glucose. Of 
the 4,777 predicted genes, 1‒3.5% were highly upregulated (log2 
fold change > 5) on xylans compared to glucose (Supplementary 
Table 1) and the majority were involved in carbohydrate metabo-
lism. Besides a separate locus encoding a multi-modular xylanase 
of glycoside hydrolase family 10 (GH10 according to CAZy clas-
sification24), the top genes in the xylan transcriptomes cluster on 
a single locus (Fig. 2a,b) that contains 11 genes, including 4 xyl-
anolytic CAZymes: GH43, GH115, GH8 and GH3. Only one 
(ROSINTL182_08192, LacI type) of three transcriptional regulators 
was highly upregulated. Strikingly, the most upregulated gene in 
the xylan transcriptomes encodes a solute-binding protein (SBP) of 
an ABC transporter. The permease genes of this transporter were 
among the top six upregulated by xylans. Signal peptides were only 
predicted for the xylanase and the transporter SBP, which is consis-
tent with the extracellular breakdown of xylan followed by capture 
and uptake of xylo-oligosaccharides by the ABC transporter. The 
expression and the localization of the SBP and the xylanase at the 
cell surface were corroborated using immunofluorescence micros-
copy (Fig. 2c). Two additional loci, unique to the R. intestinalis L1-82 
strain, were also upregulated albeit markedly less (Supplementary 
Fig. 1a–d). One of these loci encodes a second active GH10 xyla-
nase, which is expressed at the cell surface (Supplementary Fig. 1e). 
The transcriptomic analyses enabled the assignment of the xylose 
ABC transporter and the genes involved in intracellular metabolism 
of xylose, arabinose and glucuronic acid (Supplementary Fig. 2).
A previously undescribed family of binding modules confers 
extended and dynamic xylan binding to the multi-modular xyla-
nase. The highly upregulated RiXyn10A, which is conserved within 
R. intestinalis (Supplementary Fig. 3), is one of the largest known 
xylanases from the HGM (Supplementary Table 2). RiXyn10A com-
prises an amino-terminal unassigned domain (residues 28− 165), a 
CBM22 xylan-binding module, a GH10 catalytic module, two tan-
dem CBM9 xylan-binding modules, a bacterial immunoglobulin-like 
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Fig. 1 | Growth of R.intestinalis and induction of extracellular activity. a, Schematic representation of cereal arabinoxylan and glucuronoxylan present in 
the dicot cell wall, for example, in fruits and vegetables. b, Growth level for 18hours on xylans, oligosaccharide and monosaccharides thereof, with glucose 
as a control. Green: OD600 increase of > 1.0 for soluble substrates and a pH drop of > 0.3 for insoluble xylans; yellow: 0.3< ∆ OD600< 0.5; red: ∆ OD600< 0.1. 
Asterisks indicate insoluble xylans. Data are means of triplicates. c, Growth curves on glucose (Glc), WAX, BGX and a no-carbon-source control.  
d, Growth on InWAX and oatspelt xylan (OSX) and no-carbon-source control. All growth measurements (c,d) are means of triplicates with standard 
deviations. e, Xylanase activity of R.intestinalis cells grown on glucose, xylo-oligosaccharides, BGX and WAX for 18hours. f, Cells grown on BGX were 
washed (PBS buffer± 1.5M NaCl) and xylanase activity was measured in wash and cell fractions to verify the localization of the enzymes. Xylanase activity 
(e,f) was measured using the DNS-reducing sugar assay, and data are triplicates with standard deviations.
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domain group 2 (pfam02368)25 and a Listeria-Bacteroides repeat 
domain (pfam09479)26. The two latter positively charged domains 
(residues 1,100–1,356; pI > 10) (Fig. 3a) probably mediate attach-
ment of the enzyme to the cell25–27.
RiXyn10A incubated with BGX, WAX and InWAX generated 
linear and decorated oligosaccharides (Fig. 3b,c), but was inactive 
on highly and heterogeneously substituted arabinoglucuronoxylan 
from corn bran, consistent with the growth profile (Fig. 1b). The 
enzyme was inactive on X2 and showed poor activity on xylotriose 
(X3) (Supplementary Fig. 4a). Xylotetraose (X4) and xylopentaose 
(X5) were efficiently hydrolysed, revealing the requirement for the 
occupancy of at least four substrate-binding subsites for high turn-
over.
A BLASTp search of the N-terminal domain (previously unde-
scribed carbohydrate-binding module (CBMx)) against UniProt 
gave no hits indicating the lack of homologues with assigned func-
tion. CBMx confers affinity to xylan based on a two-times higher 
Michaelis constant (Km) when CBMx was deleted from RiXyn10A 
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(Table 1 and Supplementary Fig. 4b–g). Affinity electrophoresis 
established CBMx as a xylan-binding module and revealed a 30-fold 
higher dissociation constant (Kd) on WAX compared with BGX 
(Fig. 3d–f and Supplementary Fig. 4h). Surface plasmon resonance 
(SPR) analysis revealed the highest affinity towards xylohexaose 
(X6) (Table 2, Fig. 3g and Supplementary Fig. 5a–e). The relatively 
low binding affinity to X6 (Kd ≈ 0.5 mM) was corroborated using 
isothermal titration calorimetry (ITC) (Table 2, Supplementary 
Fig. 5f and Supplementary Table 3). Deleting CBMx decreased 
the average Kd of RiXyn10A from 128 μ M to 65.4 μ M (RiXyn10A∆ 
CBMx) (Table 2 and Supplementary Fig. 5g–j), asserting that one 
or more of the other CBMs possess a higher affinity compared to 
the N-terminal module. Homologues (sequence identity: 55− 27%) 
of CBMx are present mainly in other Clostridium XIVa cluster 
Firmicutes (Supplementary Table 4).
Preference of the binding protein of the ABC transporter 
that mediates uptake of xylo-oligosaccharides. Complex xylo-
oligosaccharides decorated with arabinosyl and 4-O-methyl-
glucuronosyl are produced by RiXyn10, based on the decrease 
levels in some of these products and the increase levels in arabi-
nose, 4-O-methyl-glucuronic acid (MeGlcA) and un-substituted 
xylo-oligosaccharides after treatment with debranching enzymes 
(see the next section). Transcriptional analysis (Fig. 2a) identified a 
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Fig. 3 | A low-affinity xylan-binding module mediates extended xylan binding to the xylanase RiXyn10A. a, Domain organization of RiXyn10A 
and truncated variants, all produced recombinantly without the native signal peptide. BIG2, bacterial immunoglobulin-like domain group 2; CBM, 
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Table 1 | Xylan hydrolysis kinetics of RiXyn10A and truncated 
variants
Substrate Enzyme Km 
(mgml−1)
kcat   
(s−1)
kcat/Km  
(mlmg−1 s−1)
WAX RiXyn10A 2.4± 0.4 202± 14 84
RiXyn10A∆ CBMx 5.5± 1.2 386± 47 71
RiXyn10A-cata ND ND 34
BGX RiXyn10A 3.3± 0.7 196± 18 59
RiXyn10A∆ CBMx 6.6± 1.6 369± 45 56
RiXyn10A-cata ND ND 16
Kinetics of the RiXyn10A-cata are not modelled by the Michaelis–Menten expression, and 
catalytic efficiencies are estimated from the linear regression of the initial rate data. Data are 
means of triplicates with standard deviations. ND indicates low substrate affinity precluding 
determination of the kinetic parameters.
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plausible ABC transporter of xylo-oligosaccharides. The preference 
of SBPs associated with oligosaccharide-specific ABC transporters 
correlates with the bacterial uptake preference28,29. We measured the 
affinity of RiXBP, the SBP of the top upregulated ABC transporter 
on xylo-oligomers (Table 3 and Supplementary Fig. 6a–i). The pre-
ferred un-substituted ligand was X5 followed by X4, and the affin-
ity decreased steeply for smaller or larger oligosaccharides. Internal 
arabinosyl decorations (AX4) were preferred based on the 2.4-times 
higher affinity compared to X4. The tolerance and recognition of 
arabinosylated ligands are supported by the good growth on WAX. 
In summary, RiXBP is selective in capturing branched xylo-oligo-
saccharides with preference for a backbone of 4− 5 xylose residues.
The concentrations of oligosaccharides in spent supernatants 
from R. intestinalis cultures during growth on xylan were too low 
for reliable detection using high-performance anion-exchange 
chromatography with pulsed amperometric detection (HPAEC-
PAD), which suggests an efficient uptake of oligomeric products 
(Supplementary Fig. 6j,k).
R. intestinalis degrades internalized decorated xylo-oligosaccha-
rides by the concerted action of three hydrolases and a previously 
undescribed family of acetyl esterases. Xylo-oligosaccharides are 
degraded in the cytoplasm after uptake. We characterized the α - 
glucuronidase RiAgu115A (GH115), the α -l-arabinofuranosidase 
RiAbf43A (GH43), two xylosidases RiXyl8 (GH8) and RiXyl3A 
(GH3) as well as RiAXE (ROSITNL182_08194; GenBank accession 
EEU99941.1) from the core xylan utilization locus.
RiAgu115A released MeGlcA from glucuronoxylans (BGX 
and beechwood glucuronoxylan) and from BGX pretreated with 
RiXyn10A (Fig. 4a,c–f and Supplementary Fig. 7a). The kcat/Km of 
RiAgu115A was 16-fold higher on glucuronoxylan hydrolysate 
compared to intact glucuronoxylan (Supplementary Table 5), con-
sistent with the intracellular enzyme localization. This enzyme also 
cleaves MeGlcA decorations at the xylosyl penultimate to the reduc-
ing end (Supplementary Fig. 7b,c), but its activity was blocked by 
acetylations (Fig. 4d). The released MeGlcA is metabolized intracel-
lularly in agreement with the transcriptomic data (Supplementary 
Fig. 2a). The lack of growth on glucuronic acid (Fig. 1b) is probably 
due to the lack of an uptake system for this monosaccharide.
RiAbf43A is an α -l-arabinofuranosidase that exclusively releases 
arabinose from WAX (Fig. 4a and Supplementary Fig. 7d). Kinetic 
analysis against WAX and AX4 (Supplementary Table 6) revealed 
recognition of internal arabinosyl substitutions. Degradation of 
WAX by xylanases results in the production of significant amounts 
of double-arabinosyl-substituted oligomers. The lack of accumula-
tion of these to detectable levels (Supplementary Fig. 6j) is suggestive 
of their uptake and debranching by RiAbf43A or other upregulated 
arabinofuranosidases.
Both RiXyl3A and RiXyl8 generated xylose from xylo-oligosac-
charides, but lacked activity towards xylan (Supplementary Tables 
7,8 and Supplementary Fig. 7d–g). RiXyl3A degraded xylo-oligo-
saccharides to xylose, whereas RiXyl8 was inactive towards X2. 
Reduction of xylo-oligosaccharides abolished the activity of RiXyl8, 
assigning it as a reducing-end β -xylosidase30 (Supplementary Fig. 
7h), in contrast to RiXyl3A that recognizes non-reducing xylosyl 
units. The concerted and overlapping activities of these enzymes 
(Supplementary Fig. 7) result in rapid depolymerization of arabi-
nosyl- and MeGlcA-decorated xylo-oligosaccharides. Induction of 
extracellular xylanase activity by X2, but not by X3− X6, is intrigu-
ing as X2 is transiently formed during cytoplasmic degradation of 
X3− X6. A possible explanation is that the induction is mediated 
by X2 binding to an extracellular regulatory protein, similar to the 
xylose sensory system in clostridial Firmicutes31.
RiAXE, which lacks functionally described homologues, was 
highly upregulated on xylans (Fig. 2a). This enzyme shares con-
served residues with the SGNH lipase esterase superfamily (Pfam 
cd00229), but possesses low sequence identities to esterases from 
CAZy. Homologues of this enzyme are encoded by Clostridium 
cluster XIVa strains from the human gut and a range of Firmicutes 
(Supplementary Fig. 8a). Assaying RiAXE activity towards acety-
lated BGX (AcBGX) oligosaccharides (generated with RiXyn10A) 
using NMR revealed efficient deacetylation of both 2-O-acetylated 
xylose (C2) and 3-O-acetylated xylose (C3), but with a prefer-
ence for C2 decorations (Fig. 4b, Supplementary Tables 9,10 and 
Supplementary Fig. 8). RiAXE left a single acetyl group on the 
AcBGX oligosaccharides (Fig. 4e). Inclusion of RiAgu115A in 
this reaction resulted in complete deacetylation (Fig. 4f), suggest-
ing that close MeGlcA decorations protect closeby acetylations. 
Analysis of the deacetylation rates unveiled the concerted action 
with RiAgu115A and preference to hydrolysates of RiXyn10A rather 
than intact xylan (Supplementary Fig. 8b,c). RiAXE specifically rec-
ognizes acetylations on xylosyl units based on the lack of activity 
on acetylated chitin and very low activity on acetylated mannan 
and cellulose monoacetate (Supplementary Table 11). Accordingly, 
RiAXE is an efficient xylan-specific representative of a previously 
undescribed acetyl esterase family.
Table 2 | Binding parameters of the xylan-binding module CBMx 
and RiXyn10A and variants
Variant Ligand Kd (μ M)
RiXyn10A-CBMx WAX 0.02a
BGX 0.6a
X6 479± 26
X6 413± 125b
X5 490± 15
X4 998± 42
X3 1,900± 220
Man6 ND
RiXyn10A X6 128± 7.1
RiXyn10A∆ CBMx X6 65.4± 8.4
Kd determined by SPR are the means of a duplicate with the standard deviations. aKd (mgml−1) 
was determined by affinity electrophoresis. bKd was determined by ITC. The SPR experiments 
are performed in triplicates and the data are the means with standard deviations. The affinity 
electrophoresis and the ITC data are from single experiments. The error estimate in the ITC 
experiment is from the fit of a one-binding site model to the binding isotherm.
Table 3 | The preference of the xylo-oligosaccharide transport 
protein from R.intestinalis
Ligand Kd (μ M) N0 Δ H (kcal 
per mol)
TΔ S (kcal 
per mol)
Δ G (kcal 
per mol)
X6 112.7 1.19 − 9.01 − 3.6 − 5.4
X5 10.3 0.86 − 13.54 − 6.7 − 6.8
X4 16.5 0.68 − 12.8 − 6.3 − 6.5
X3 225.7 0.58 − 21.1 − 16.1 − 5.0
X2 ND
AX3 215.5 0.26 − 44.3 − 39.4 − 4.9
AX4 6.8 0.58 − 12.3 − 7.0 − 5.3
Binding energetics of the transport protein RiXBP to xylo-oligosaccharides determined by 
ITC. Data are the means of duplicate experiments. N0, Δ H, TΔ S and Δ G denote the binding 
stoichiometry, enthalpy, entropy and Gibbs free energy, respectively. ND indicates affinity too low 
to be determined. The cartoons to the right side depict the analysed susbtrates using the same 
code as in Fig. 1a, and the chemical structures of arabinosyl-decorated oligomers AX3 and AX4 
are shown in Supplementary Fig. 6h,i.
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In summary of the biochemical characterization presented 
above, we propose a model for the uptake and degradation of diet-
derived acetylated arabinoxylan and glucuronoxylan by R. intestina-
lis L1-82 (Fig. 5a).
R. intestinalis competes with Bacteriodes for xylans. The growth 
potential of R. intestinalis was compared to the efficient xylan-
degrader Bacteroides ovatus22, by observing the growth of individual 
cultures and in co-culture. Both strains displayed similar growth 
on xylan as a carbon source (Fig. 5b–d and Supplementary Fig. 
9a,b). In competition, both strains appeared to grow well on xylans, 
whereas R. intestinalis dominated the co-culture on X4 after 7 hours 
of growth (Fig. 5e–h). The results indicate that R. intestinalis is an 
efficient primary degrader of xylan that is able to compete with 
B. ovatus and outcompete this bacterium on preferred smaller xylo-
oligosaccharides.
Discussion
The human gut is dominated by bacteria from the Firmicutes and 
Bacteriodetes phyla. Firmicutes are regarded as metabolic special-
ists, whereas Bacteroidetes (mainly Bacteroides) are considered 
generalists based on narrow versus broad glycan utilization capa-
bilities, respectively6. The size and diversity of encoded CAZymes 
reflect these metabolic labels, which applies to R. intestinalis, based 
on the limited glycan growth profiles5. However, this species pos-
sesses distinctively larger CAZymes than most known gut clos-
tridial Firmicutes17. R. intestinalis has been proposed to be a key 
xylan degrader in the human gut along with specific species of 
Bacteroides18,19. Enumeration of R. intestinalis on xylans including 
wheat bran is reported in vitro and in vivo20,32. However, insight is 
lacking on the preferences and the molecular machinery evolved 
by R. intestinalis to target xylan compared to Bacteriodes members. 
In this study, we present a model underpinning the molecular basis 
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Fig. 4 | Intracellular xylo-oligosaccharide depolymerization. a, α -L-Arabinofuranosidase and α -glucuronidase activity on WAX and BGX for RiAbf43A and 
RiAgu115A, respectively, based on HPAEC-PAD analysis. b, Time-resolved NMR for RiAXE deacetylation of AcBGX treated with RiXyn10A and RiAgu115A. 
Deacetylation time course for the first 30min and after 18h (green: 0min, purple: 30min and orange: 18h). All verified signals with 2-O-acetylation 
decreased faster in the initial phase of the reaction. The proton spectra of the acetylated region show nearly complete deacetylation after 18h. The signal 
at 2.13p.p.m. is probably attributed to another acetylated sugar residue. Acetyl groups are designated as: C2; C3; C23, 2,3-di-O-acetylated xylose; C3-
MeGlcA, 4-O-methyl glucuronic acid 2-O-substituted and 3-O-acetylated xylose; C23(2), signal for the 2-O-acetylated of C23. The assignment of the 
acetylated sugar signals was based on homonuclear and heteronuclear NMR correlation experiments (Supplementary Fig. 8). c–f, Hydrolysis products 
from AcBGX by RiXyn10A (c), RiXyn10A and RiAgu115A (d), RiXyn10A and RiAXE (e), and RiXyn10A, RiAgu115A and RiAXE (f). Enzyme action was 
analysed by MALDI–TOF mass spectrometry. Xylo-oligosaccharides decorated with acetyl and MeGlcA are in green, acetyl in blue, MeGlcA in red and no 
sidechains in orange. Di-sodium adducts of a MeGlcA-decorated oligosaccharides (diamonds) are coloured as their corresponding single sodium adducts. 
Experiments were performed in duplicates, except for the NMR, where they were performed once. AU, arbitrary units.
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Fig. 5 | Model for xylan utilization by R.intestinalis and competition assay with B.ovatus. a, RiXyn10A on the cell surface efficiently captures diet-
derived acetylated arabinoxylan and acetylated glucuronoxylan by its CBMs and hydrolyses it into linear and decorated xylo-oligosaccharides, which are 
subsequently captured by RiXBP for uptake into the cytoplasm. Internalized xylo-oligosaccharides are debranched and hydrolysed into monosaccharides 
and acetate. Xylose and arabinose are converted to xylulose 5-phosphate before entering the pentose phosphate pathway, whereas MeGlcA is converted 
to 2-oxo-3-deoxygalactonate 6-phosphate. These precursors enter glycolysis, which generates pyruvate, some of which is converted to butyrate54. The 
asterisk next to RiAbf43A indicates activity on both α -1,2-linked and α -1,3-linked L-arabinose. The black solid arrows show steps established or confirmed 
in this study. The grey solid arrows indicate steps for the production of H2 and butyrate by R.intestinalis15, which has been demonstrated for this species 
during xylose fermentation19. The grey dashed arrows indicate that H2 and butyrate are externalized by unknown mechanisms. To make the model more 
general for the R.intestinalis species, the second less upregulated extracellular xylanase RiXynB, which is unique for the L1-82 strain, is not included in the 
model, although it is expressed at the cell surface. The figure keys in Figs. 1a and 3a also apply here. b–d, Growth of the monoculture and co-cultures  
of R.intestinalis and B.ovatus on WAX (b), InWAX (c) and BGX (d). Data are the means of a biological triplicate with standard deviations. e–h, Time  
course of the relative strain abundance during growth of co-cultures on xylans and X4 determined by quantitative PCR. All data are the means of  
a biological triplicate.
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for xylan utilization by R. intestinalis L1-82 as a representative for 
prevalent butyrate-producing clostridia (Fig. 5a). R. intestinalis is a 
primary degrader equipped with a highly efficient machinery for 
the utilization of complex dietary xylans, including insoluble ara-
binoxylan from cereals. Key components of the R. intestinalis xylan 
utilization strategy include a multi-modular extracellular xylanase 
and an ABC transporter, which confer the capture, breakdown and 
internalization of decorated xylo-oligosaccharides. In the cyto-
plasm, internalized oligomers are degraded without loss to compet-
ing species. R. intestinalis grows on acetylated xylan, which reflects 
an adaptation to this abundant decoration in dietary xylans (Fig. 1b). 
Internalized acetylated xylo-oligosaccharides are metabolized 
by an intracellular previously unknown esterase family that is 
capable of removing C2, C3 and double acetylations (Fig. 4b and 
Supplementary Fig. 8).
The extracellular xylanase RiXyn10A, the ABC transporter and 
enzymes conferring cytoplasmic breakdown of xylan oligosac-
charides were assigned as the core xylan utilization apparatus of 
R. intestinalis (Fig. 2a,b). This was based on (1) conservation of this 
apparatus within this species (Supplementary Fig. 3), (2) the high-
est transcriptional upregulation (Fig. 2a), and (3) biochemical data 
from the present study. The two additional xylan-upregulated loci in 
R. intestinalis L1-82 (Supplementary Fig. 1) are lacking in the xylan-
utilizing R. intestinalis XB6B4 and R. intestinalis M50/1 (ref. 20). 
The expression and activity of the xylanase RiXyn10B, encoded by 
an auxiliary locus (Supplementary Table 12 and Supplementary 
Fig. 1c,e), supports the participation of more than one locus in 
xylan breakdown in R. intestinalis L1-82. Multiplicity of xylan uti-
lization loci is implicated in targeting a larger structural diversity of 
naturally occurring xylans by Bacteroides22, which may also apply 
for R. intestinalis.
The R. intestinalis core xylanase RiXyn10A mediates the capture 
and breakdown of arabinoxylan and glucuronoxylan (Figs. 1,3). 
This enzyme possesses four CBMs from two known and one 
previously undescribed xylan-binding families, representing 
the most complex organization of HGM xylanases (Fig. 3a and 
Supplementary Table 2). This organization is conserved within cur-
rently sequenced R. intestinalis species, whereas other Clostridium 
XIVa taxa possess simpler enzymes that lack one or more of the 
RiXyn10A CBMs. The N-terminal CBMx of RiXyn10A displays 
approximately 7-fold lower affinity for X6 than the average affin-
ity measured for the enzyme variant lacking this module (Table 2). 
Nonetheless, CBMx is selective for arabinoxylan and contributes 
to the overall affinity of the enzyme (Table 1). Low-affinity CBMs 
may potentiate multivalent cooperative substrate binding, with less 
reduction of kcat (that is, promote relatively high kcat/koff33), compared 
to higher-affinity counterparts that evoke higher energetic penalty 
during substrate displacement. The extended binding mediated by 
the CBMs seems to confer an advantage in the capture and pro-
longed contact of the enzyme with xylan. Deletion of the CBMs 
(RiXyn10A-cata) caused a substantial decrease in the apparent affin-
ity towards WAX and BGX and deviation from Michaelis–Menten 
kinetics (Table 1 and Supplementary Fig. 4b–g). These findings are 
consistent with the importance of CBMs in catalysis under substrate 
limitations, whereas similar turnover rates were obtained by the 
catalytic module and the full-length RiXyn10A at high (9 mg ml−1) 
substrate concentrations. Multiplicity and variability of CBMs seem 
to be a signature of extracellular enzymes from butyrate-producing 
Firmicutes34,35. By contrast, Bacteriodes members possess simpler 
xylanases with an inserted tandem CBM4 repeat within the cata-
lytic module23. However, xylan capture by Bacteriodes is additionally 
orchestrated by moderate-affinity (Kd ≈ 60 μ M) binding proteins22.
R. intestinalis was able to compete with B. ovatus for xylans dur-
ing the log-phase (Fig. 5e–g). Notably, R. intestinalis seemed to out-
compete B. ovatus after propagation of the co-culture (in the late log 
phase) in fresh medium for two additional passages, underscoring 
the competitiveness of the xylan utilization machinery of this 
Firmicute (Supplementary Fig. 9c). R. intestinalis association to 
insoluble xylans, including wheat bran was reported, whereas 
Bacteriodes spp. were enriched in solubilized xylan fractions18,36. 
The extended binding by RiXyn10A may have an important role 
in the association to insoluble substrates. Indeed, the expression of 
this enzyme seemed similarly high in the mono- and mixed xylan 
cultures with B. ovatus (Supplementary Fig. 9e), in contrast to the 
reported downregulation of hydrolases by the taxonomically realted 
E. rectale during co-growth with Bacteriodes thetaiotamicron on a 
fibre-rich diet in mice37.
The gene encoding the binding protein (RiXBP) of the ABC 
transporter that confers xylo-oligosaccharide uptake in R. intesti-
nalis was the most upregulated in the xylan transcriptomes, attest-
ing the crucial role of oligosaccharide capture and transport in the 
densely populated gut ecological niche. The affinity and size pref-
erence of RiXBP were found to be very different from the corre-
sponding protein from Bifidobacterium29, which prefers shorter 
xylo-oligosaccharides with a different side-chain decoration pat-
tern. Importantly, striking differences in binding affinities and 
preference are observed when RiXBP is compared to the SusD-like 
xylan-binding counterpart from Bacteriodes. Indeed, both SusD-
like proteins from B. ovatus, which mediate the capture and inter-
nalization of xylo-oligosaccharides ≥ X6 by SusC TonB-dependent 
permeases, displayed no measurable binding to X4 and X5 (ref. 22), 
the preferred ligands of RiXBP (Table 3). These differential trans-
port protein preferences are likely to be instrumental in establish-
ing competitive uptake profiles to select oligosaccharides of specific 
sizes and decorations for each taxon. This is supported by the 
dominance of R. intestinalis when the co-culture with B. ovatus was 
grown on X4 (Fig. 5h).
Our study highlights the molecular apparatus that R. intestinalis, 
as a model Clostridium group XIVa Firmicute, has evolved to com-
pete for abundant dietary glycans with other dominant commensal 
bacteria. Strikingly, complex enzymes with multiple ancillary mod-
ules mediate multivalent substrate capture and breakdown. Highly 
expressed ABC transporters mediate efficient capture and uptake 
of xylan oligosaccharides with a different preference than the cor-
responding transport systems of currently known competing taxa. 
These findings suggest that the differentiation of glycan capture and 
uptake preferences may contribute to co-growth on dietary fibres 
by establishing competitive windows for distinct fibre breakdown 
oligomers by different taxa. Our study sets the stage for further 
investigations to evaluate the generality of this hypothesis.
Methods
Chemicals. All chemicals were of analytical grade. BGX, beechwood 
glucuronoxylan, corncob xylo-oligosaccharides and xylose were from Carl Roth 
(Karlsruhe, Germany). CBX was a kind gift from M. Yadav (US Department 
of Agriculture, Agricultural Research Service). Soluble wheat arabinoxylan 
(low viscosity: 10 centiStokes (cSt)) (WAX), insoluble wheat arabinoxylan 
(high viscosity: 48 cSt) (InWAX), xylobiose through to xylohexaose (X2− X6), 
arabinoxylotriose (AX3), arabinoxylotetraose (AX4) and mannohexaose (Man6) 
were from Megazyme. d-Glucuronic acid was from Sigma-Aldrich. l-Arabinose 
was from VWR International. Xylo-oligosaccharides Longlive 95 P (XOS) were 
from Shandong Longlive Bio-technology. AcBGX, acetylated aspen glucuronoxylan 
and acetylated spruce galactoglucomannan were prepared with steam explosion 
as previously described38. Cellulose acetate was a kind gift from A. Deutschle 
(University of Hamburg, Germany). Acetylated chitin-oligosaccharides were 
prepared as previously described39.
Growth experiments and RNA-seq transcriptional analysis. R. intestinalis DSM 
14610 was grown in a Whitley DG250 Anaerobic Workstation (Don Whitley 
Scientific) in YCFA medium14 supplemented with autoclaved-sterilized 0.5% (w/v) 
carbohydrates. Cultures (5 ml) were grown in triplicates, and optical denisty at 
600 nm (OD600) and pH (for insoluble substrates) were measured to assess bacterial 
growth until the stationary phase was reached. Growth rates were calculated from 
the exponential growth phase.
For the RNA-seq analysis, total RNA was extracted at mid- to late-log phase 
(OD600 = 0.5− 0.7) from biological triplicate cultures (10 ml) grown in YCFA 
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supplemented with 0.5% (w/v) glucose, xylose, WAX or BGX. Cells were harvested 
(4,000g for 5 min at room temperature) and the pellets were frozen at − 80 °C until 
RNA extraction. The RNA was extracted using the RNeasy Mini Kit (Qiagen) 
according to the manufacturer’s protocol after enzymatic lysis followed by 
mechanical disruption of the cells. A DNase treatment was included to ensure 
removal of DNA. The purity and quantity of the extracted RNA were assessed 
by an Agilent 2100 Bioanalyzer (Agilent Technologies). Removal of ribosomal 
RNA and library construction for RNA-seq were performed using the ScriptSeq 
Complete Kit (Epicentre). High-throughput sequencing was performed in a single 
lane in paired-end reads on an Illumina Hiseq 4000 platform at Beijing Genomics 
Institute (BGI). In total, 400 million paired-end reads were obtained and the read 
quality was assessed by FastQC v0.11.5 (http://www.bioinformatics.babraham.
ac.uk/projects/fastqc/). The R1 reads were chosen for downstream analysis. 
Adaptor trimming and de-multiplexing were performed using custom python 
scripts (based on the Biopython SeqIO module40) and the FASTX-Toolkit v0.0.13.2 
(http://hannonlab.cshl.edu/fastx_toolkit/). Reads were further trimmed with fastx_
trimmer and subsequently filtered with fastq_quality_filter with minimum quality 
score of 30 (-q 30), where 95% of base pairs (bp) meet the minimum quality score 
(-p 95). The resulting reads were kept if they were longer than 20 bp (-m 20).  
The R. intestinalis L1-82 reference genome and genome annotations are based 
on assembly GCA_000156535.1_ASM15653v1, obtained from the NCBI (ftp://
ftp.ncbi.nlm.nih.gov/genomes/genbank/bacteria/Roseburia_intestinalis/). Reads 
were mapped to the reference genome using Tophat2 (refs 41,42), and gene counts 
were determined with HTseq43. Differential gene expression was performed using 
DeSeq2 in R44.
Xylanase activity measurements on whole cells. Cell-associated xylanase activity 
was determined by growing R. intestinalis cells in 800 μ l YCFA containing 0.5% 
(w/v) xylo-oligosaccharides, WAX, BGX or glucose for 15 h. Cells were harvested 
(4,000g for 5 min at room temperature), resuspended in PBS to OD600 = 0.3 and 
xylanase activity was assayed using the 3,5-dinitrosalicylic acid (DNS) assay as 
described below. To determine the effect of high ionic strength on the localization 
of xylanase activity, R. intestinalis cells were grown in 6 ml YCFA containing 0.5% 
(w/v) BGX for 15 h. Subsequently, the culture was divided into two 3 ml aliquots 
and harvested as described above. Cell pellets were resuspended in 300 μ l PBS 
with or without 1.5 M NaCl. The suspensions were spun down and both pellets 
and supernatants (wash fractions) were collected. Cell pellets were washed with 
excess PBS and resuspended in 300 μ l PBS. The xylanase activity of cells and wash 
fractions was assayed using the DNS assay.
Expression and purification of R. intestinalis proteins mediating xylan 
utilization. Open reading frames of the proteins without signal peptide, as 
predicted by SignalP v.3.0 (http://www.cbs.dtu.dk/services/SignalP-3.0), were 
amplified from R. intestinalis DSM 14610 genomic DNA using specific primers 
(Supplementary Table 13). Amplicons were cloned into the EcoRI and NcoI 
restriction sites of a pETM-11 (a kind gift from G. Stier, EMBL, Center for 
Biochemistry, Heidelberg, Germany)45 or the XhoI and NcoI restriction site of 
a pET28a(+ ) (Novagen) using In-Fusion cloning (Takara) to express proteins 
as fusions with either cleavable N-terminal His6 tags or C-terminal His6 tags, 
respectively. Standard protocols were used for recombinant protein expression and 
purification using His-affinity and size-exclusion chromatography.
Enzymatic activity assays. Enzymatic assays were carried out in a 50 mM HEPES 
0.005% (v/v) Triton X-100, pH 7.0 standard assay buffer unless otherwise stated. 
Hydrolysis kinetics of full-length or truncated xylanases (10− 200 μ M) were assayed 
towards 1− 9 mg ml−1 of BGX, WAX or InWAX (900 μ l at 37 °C for 12 min). Initial 
hydrolysis rates were determined by removing 200 μ l aliquots every 3 min and 
quenching the reaction in 300 μ l DNS reagent46. Next, samples were incubated for 
15 min at 90 °C followed by absorbance at 540 nm (A540) measurement in 96-well 
microtitre plates. Xylose was used as a standard (0− 2.5 mM). Xylanase activity was 
assayed for R. intestinalis cells washed with PBS ± 1.5 M NaCl, and wash fractions, 
as above with the following modification: 180 μ l of 1% (w/v) BGX was incubated 
with 20 μ l cell suspension or wash fraction for 4 h.
Hydrolysis kinetics of α -glucuronidase were analysed on 1− 9 mg ml−1 
beechwood glucuronoxylan or a hydrolysate thereof (prepared by incubation with 
4 mM RiXyn10A xylanase for 15 h at 37 °C followed by heat inactivation). The 
initial rates of MeGlcA release were measured using a coupled enzymatic assay 
(Megazyme). Reactions (770 μ l) were incubated for 2 min at 37 °C with 10− 180 nM 
enzyme with intermittent removal of 175 μ l aliquots every 15 s into 125 μ l 1 M Tris 
pH 10 to quench the reaction. This was followed by mixing 270 μ l of the stopped 
reaction with 45 μ l of the NAD+ and uronate dehydrogenase reagents. Conversion 
of NAD+ to NADH was measured at A340. Glucuronic acid was used as standard 
(0− 500 μ M).
Hydrolysis kinetics of RiXyl8 and RiXyl3A were determined towards X2 
through to X6 (0.5–12 mM) in McIlvaine buffer pH 6.8 (10 mM citric acid and 
20 mM sodium phosphate) as described previously47,48. Reactions (350 μ l) were 
incubated for 12 min at 37 °C with 36− 78 nM RiXyl3A or 2.4 nM RiXyn8. Aliquots 
of 50 μ l were removed every 2 min and stopped in 250 μ l p-bromoaniline (2% w/v) 
in glacial acetic acid with thiourea (4% w/v). The stopped reactions were incubated 
in darkness for 10 min at 70 °C, followed by incubation at 37 °C for 1 h before 
measuring A520. The concentration of released pentoses was determined using a 
xylose standard (0− 5 mM)49.
α -l-Arabinofuranosidase activity for RiAbf43A was assayed in McIlvaine 
buffer pH 6.8 (10 mM citric acid and 20 mM sodium phosphate) using a coupled 
enzymatic l-arabinose/d-galactose assay (Megazyme) towards WAX (1− 
24 mg ml−1). Reactions (75 μ l) were incubated for 12 min at 37 °C with 0.4− 1.7 μ M  
enzyme. Aliquots of 15 μ l were removed every 2 min, and the enzyme was 
inactivated (10 min at 90 °C) and thereafter 10 μ l of this solution were mixed 
with 10 μ l of the provided NAD+, 20 μ l of provided assay buffer and 2 μ l galactose 
mutaotase/β -galactose dehydrogenase mix. The formation of NADH was measured 
as above. Arabinose was used as standard (0− 5 mM).
The acetyl esterase-specific activity of RiAXE was determined in 250 μ l 
reactions containing para-nitrophenyl-acetate (4 mM) and 0.14 μ M enzyme. A405 
was measured every 60 s for 10 min at 37 °C in a microtitre plate reader and pNP 
(0− 1 mM) was used as standard. The specific activity was determined in units (U) 
per mg, where a U is defined as the amount of enzyme that produces 1 μ mol of 
pNP min−1.
Kinetic parameters were calculated by fitting the Michaelis–Menten equation 
to the initial rate data using GraphPad Prism 7. The catalytic efficiency kcat/Km, 
determined from the slope of the normalized initial rate (V0/[E]) in the Michaelis–
Menten plot, is reported when saturation was not attained. All experiments were 
performed in triplicates.
Action patterns of individual and mixtures of xylanolytic enzymes. Hydrolysis 
of xylan and xylo-oligosachharides was performed at 37 °C for 15 h in the standard 
assay buffer used above. Oligosaccharide hydrolysates, used to assay the sequential 
action of the debranching xylanolytic enzymes, were generated using RiXyn10A, 
which was separated by ultrafiltration (3 kDa cut-off) before the addition of 
debranching enzymes. The hydrolysis profiles were analysed as detailed below. 
To verify the mode of reducing-end attack of RiXyl8, 30 mg XOS in standard 
assay buffer were reduced by NaBH4 (1 M in 100 μ M NaOH). A total of 200 μ l of 
the NaBH4 was added dropwise to 800 μ l of the xylo-oligossaccharides solution, 
which was kept on ice. As a control, 100 μ M NaOH was added to an 800 μ l xylo-
oligossaccharides solution. The mixture was incubated for 1 h at room temperature, 
then quenched by 400 μ l 1 M acetic acid and diluted 10× in assay buffer.
Matrix-assisted laser desorption/ionization. Oligosaccharides were analysed 
with an Ultraflex matrix-assisted laser desorption/ionization–time of flight 
(MALDI–TOF)/TOF instrument (Bruker Daltonics). The samples were applied 
with 2,5-dihydroxybenzoic acid (DHB) as matrix to a MTP 384 ground steel target 
plate (Bruker Daltonics). All spectra were obtained in positive reflection mode and 
processed using Bruker flexAnalysis 3.3.
Thin layer chromatography and HPAEC-PAD. Aliquots of 1 μ l of enzymatic 
reactions were spotted on a silica gel 60 F254 plate (Merck). The chromatography 
was performed in a butanol:acetic acid:water (2:1:1 v/v) mobile phase. The plates 
were dried at 50 °C and carbohydrate hydrolysis products were visualized by 
spraying with a 5-methylresorcinol:ethanol:sulfuric acid (2:80:10 % v/v)  
developer and tarred briefly at 350 °C until bands appeared. Release of  
xylo-oligossaccharides and monosaccharides was analysed by HPAEC-PAD  
on an ICS-3000 (Dionex) using a 3 × 250 mm CarboPac PA1 column, a 3 × 50 mm 
guard column and 10 μ l injections. Xylo-oligosaccharide and standards were  
eluted with mobile phase of constant 0.1 mM NaOH (flow rate: 0.35 ml min−1) 
and a two-step linear gradient of sodium acetate: 0− 25 min of 0− 75 mM and 
25− 30 min of 75− 400 mM. Monosaccharides and standards (0.1 mg ml−1) of 
galactose, arabinose, glucose and xylose were eluted with 1 mM KOH for 35 min at 
0.25 ml min−1.
NMR spectroscopy. For the time-resolved NMR recordings: 4 mg AcBGX or 
acetylated spruce galactoglucomannan were dissolved in 500 μ l 50 mM phosphate 
buffer pH 7.0 (99.9% D2O). 2.5 μ L of RiAXE to a final concentration of 64 nM was 
added. The recorded spectrum is a pseudo-two dimensional (2D)-type experiment 
recording a 1D proton NMR spectrum every 5 min with in total 220 time points. 
The 1D proton spectrum was recorded with 24 scans using a 30° flip angle and a 
relaxation delay of 1 s (total recording time of 73 s). For enzyme treatment, 2.5 μ 
l of RiXyn10A and RiAgu115A were added to the AcBGX sample to 167 nM and 
13 nM, respectively, and the sample was incubated at 37 °C for 24 h prior to RiAXE 
addition. All homonuclear and heteronuclear NMR experiments were recorded 
on a BRUKER AVIIIHD 800 MHz (Bruker BioSpin) equipped with 5 mm with 
cryogenic CP-TCI, and all acquisitions were done at 37 °C. For the chemical shift 
assignment of AcBGX, the following spectra were recorded: 1D proton, 2D double-
quantum-filtered correlation spectroscopy (DQF-COSY), 2D total correlation 
spectroscopy (TOCSY), 2D 13C-heteronuclear single-quantum coherence (HSQC), 
2D 13C-heteronuclear 2 bond correlation (H2BC), 2D 13C-HSQC-[1H,1H]TOCSY 
and 2D heteronuclear multiple bond correlation (HMBC). The acetate signal 
to 1.903 p.p.m. (pH 7.0 at 37 °C, in relation to 4,4-dimethyl-4-silapentane-1-
sulfonic acid (DSS)50) was used as chemical shift reference for protons, whereas 
13C chemical shifts were referenced indirectly to acetate, based on the absolute 
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frequency ratios51. The spectra were recorded, processed and analysed using 
TopSpin 3.5 software (Bruker BioSpin).
SPR. Xylo-oligosaccharide binding to RiXyn10A, RiXyn10AΔ CBMx and 
RiXyn10A-CBMx was analysed using SPR on a BIAcore T100 (GE Healthcare). 
Immobilization of the proteins on a CM5 chips was performed using a random 
amine coupling kit (GE Healthcare) according to the manufacturer’s protocol 
with 50–150 μ g ml−1 protein in 10 mM sodium acetate pH 3.6–4.2, to a density of 
1,362, 10,531 and 4,041 response units (RU) for RiXyn10A∆ CBMx, RiXyn10A 
and RiXyn10A-CBMx, respectively. The analysis comprised 90 s of association 
and 240 s of dissociation at 30 μ l min−1. Sensograms were recorded at 25 °C in 
20 mM phosphate/citrate buffer (pH 6.5), 150 mM NaCl and 0.005% (v/v) P20 (GE 
Healthcare). Solutions were filtered prior to analysis (0.22 μ m). Experiments were 
performed in duplicates with seven concentrations in the range: 156 μ M–10 mM 
for X3, 75 μ M–4 mM for X4, X6 and Man6 and 62.5 μ M–4 mM for X5. Data 
analysis was carried out using the Biacore T100 evaluation software, and Kd were 
determined by fitting a one-binding site model to the steady-state sensograms.
ITC. Titrations were performed using a Microcal ITC200 calorimeter (GE 
Healthcare) at 25 °C with RiXBP (0.1 mM) or RiXyn10A∆ CBMx (0.25 mM) in the 
sample cell and xylo-oligosaccharides (2.2–5 mM) in 10 mM sodium phosphate 
pH 6.5 in the syringe. An initial injection of 0.5 μ l was followed by 19 × 2 μ 
l injections separated by 120 s. The data were corrected for the heat of dilution, 
determined from buffer titration and a non-linear single-binding model was 
fitted to the normalized integrated binding isotherms using the MicroCal Origin 
software v7.0 to determine the binding thermodynamics.
Affinity electrophoresis. Binding of CBMx to WAX (0− 0.1% w/v) or BGX (0− 
1.0% w/v) was assessed by affinity electrophoresis52 in 10% native polyacrylamide 
gels (70 V for 3 h at 4 °C) using purified recombinant RiXyn10A-CBMx (3.0 μ g)  
and β -lactoglobulin (1.5 μ g) as a negative control. The relative mobility (r) was 
calculated as the migration of RiXyn10A-CBMx relative to migration of the 
dye front. A linear regression of the 1/r versus xylan concentration allowed the 
determination of Kd as the intercept of this x axis.
Western blot and immunofluorescence microscopy. Custom antibodies against 
the recombinant for the two xylanases RiXyn10A, RiXyn10B and the transport 
protein RiXBP were raised in rats and rabbit, respectively (Eurogentec). The 
specificity of the antibodies was tested by western blots using a standard protocol. 
The membranes were blocked for 1 h in 1% (w/v) BSA in TBST buffer (Tris-
buffered saline, 0.1% (v/v Tween 20)) and incubated for 2 h with the anti-sera 
(500× dilution in TBST-buffer). Subsequently, the membranes were washed 
three times in TBST buffer and incubated for 2 h with 6,000× diluted secondary 
polyclonal goat anti-rabbit IgG-AP antibodies coupled to alkaline phosphatase 
(AP) (Dako) and rabbit anti-rat IgG-AP (Sigma). After three washes, the proteins 
were visualized by exposure to Sigma-Fast BCIP/NBT reagent (Sigma).
R. intestinalis cells were grown in 6 ml YCFA containing 0.5% (w/v) WAX to 
OD600 ≈ 0.8, harvested (4,000g for 5 min at room temperature) and washed twice 
in PBS. The cells were resuspended in 3 ml 4% (w/v) paraformaldehyde in PBS 
and fixed by incubation on ice for 15 min. Thereafter, the cells were washed twice 
in PBS and resuspended in 2 ml PBS. 50 μ l of cell suspension were added to glass 
slides coated with poly-l-lysine, cells were blocked for 1 h in blocking buffer (1% 
(w/v) milk powder in PBS) and washed twice in PBS. For labelling, the cells were 
incubated with 50 μ l anti-sera diluted 50× in blocking buffer for 2 h, washed twice 
in PBS and incubated for 1 h with 50 μ l goat anti-rat IgG Alexa-Flour 555 or goat 
anti-rabbit IgG Alexa-Flour 488 (Thermo Scientific). Secondary antibodies were 
diluted 500× PBS. Finally, cells were washed twice in PBS, one drop of ProLong 
Gold antifade (Thermo Scientific) was applied and the cells were secured with 
a cover slide. Fluorescence was visualized using Zeiss Axioplan 2 microscope 
equipped with a CoolSNAP cf color camera and a Zeiss Plan-Neofluar × 
100/1.3 NA, oil immersion objective.
Co-culture competition assay. B. ovatus DSM 1896 and R. intestinalis DSM 14610 
were grown anaerobically in 20 ml YCFA supplemented with 0.5% (w/v) glucose 
to late-log phase, and an approximately equal number of cells (estimated by OD600) 
were inoculated into CFA medium (YCFA lacking the yeast extract to minimize 
B. ovatus growth on yeast extract53) containing 0.5% (w/v) WAX, BGX, InWAX or 
X4. The co-cultures were grown in triplicates and samples (2 ml) were taken during 
growth. In the propagation experiment, the co-culture was passaged into fresh 
media after 9 h of growth (start OD600 = 0.01), then grown for 12 h and passaged 
again into fresh media and grown for 12 h. Genomic DNA was extracted from 
samples using DNAClean Microbial DNA isolation kit (Qiagen). Relative bacterial 
abundance was estimated by qPCR. The extracted DNA was diluted to 0.5 ng μ l−1 
and amplified in technical triplicates using strain-specific primers (Supplementary 
Table 14). The amplification mix contained 2 μ l DNA, 5.5 μ l LightCycler 480 
SYBR Green I Master mix (Roche), 0.22 μ l of each primer (10 pmol μ l–1) and 3 μ l 
sterile water. Amplification conditions were 1 cycle of 95 °C for 5 min, 45 cycles of 
95 °C for 10 s, 60 °C for 15 s and 72 °C for 45 s using a LightCycler 480 II (Roche). 
Relative bacterial concentrations were estimated by comparing gene copy numbers 
calculated using standard curves prepared with the respective reference DNA. 
Western blot was performed as described above but with cell cultures instead of 
purified proteins.
Life Sciences Reporting Summary. Further information on experimental design is 
available in the Life Sciences Reporting Summary.
Code availability. Adaptor trimming and demultiplexing was performed using 
custom python scripts (based on the Biopython SeqIO module40) and the FASTX-
Toolkitv0.0.13.2 (http://hannonlab.cshl.edu/fastx_toolkit/). The fastx_barcode_
splitter script (from FASTX-toolkit) was modified to demultiplex large fastq files 
provided from BGI. The modified version of this script is available upon request.
Data availability. The proteins characterized in this study are available from the 
NCBI with the following accession numbers: EEV01588.1 (ROSINTL182_06494), 
EEU99940.1 (ROSINTL182_08193), EEU99941.1 (ROSINTL182_08194), 
EEU99942.1 (ROSINTL182_08195), EEU99943.1 (ROSINTL182_08196), 
EEU99894.1 (ROSINTL182_08199) and EEU99897.1 (ROSINTL182_08202). The 
authors declare that the data supporting the findings of this study are available 
within the paper and the supplementary information or from the corresponding 
author on request. The fastx_barcode_splitter script (from the FASTX-toolkit) 
was modified to demultiplex large fastq files provided from the BGI. The modified 
version of this script is available upon request.
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05034 05035 05036 05037+ 05107
NHL repeatSBP PP PP Hypothe. Hypothe. PP PP SBP GH115 CE
05108 05109 05110 05111+ 05114 05115
0511205106
5 μm 5 μm 5 μm
GH27GH43 GH43 Trans. R. GH43 GH95 GH43 GH10 GH43 CE GH43
NBD PP ABC? ABC? Man DH Man DHDP
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06344+ 06346 06347 06348 06349 06350
06345
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05113
Locus ID SP Protein Annotation
WAX/Glc BGX/Glc
05034 -0.84 6.48 5.54 Yes SBP ABC transporter, solute-binding protein
05035 -0.79 5.99 5.44 No PP ABC transporter, permease protein
05036 -0.80 6.04 5.26 No PP ABC transporter, permease protein
05037+05106 -0.33 6.44 5.95 Yes NHL repeat protein
05107 -1.48 5.98 5.53 No Hypothetical protein
05108 -0.42 5.91 5.48 No Hypothetical protein
05109 -0.61 5.87 4.92 No PP ABC transporter, permease protein
05110 -0.63 5.11 3.92 No PP ABC transporter, permease protein
05111+05112 0.34 5.73 5.07 Yes SBP ABC transporter, solute-binding protein
05113 -0.77 4.95 4.78 No Hypothetical protein
05114 -0.95 4.09 4.08 No GH115 Xylan ?-1,2-glucuronidase
05115 -0.73 4.35 4.17 No CE Putitativ esterase
Log2-fold change
X1/Glc
Locus ID SP Protein Annotation
WAX/Glc BGX/Glc
06331 -0.63 5.26 4.76 No GH43 ?-xylosidase/?-L-arabinofuranosidase
06332 -1.60 5.46 4.74 No GH43 ?-xylosidase/?-L-arabinofuranosidase
06333 -0.70 0.44 2.24 No AraC Transcriptional regulator
06334 -1.22 1.03 2.44 No GH27 ?-galactosidase/?-L-arabinopyranosidase
06335 -0.69 3.58 3.44 No GH43 ?-xylosidase/?-L-arabinofuranosidase
06336 -1.04 3.61 3.21 No GH95 ?-L-galactosidase/?-L-fucosidase
06337 -0.57 3.45 4.08 No GH43 ?-xylosidase/?-L-arabinofuranosidase
06338+06339 -0.99 3.47 3.62 Yes RiXyn10B Endo-1,4-?-xylanase
06341 -1.12 4.09 3.80 No GH43 ?-xylosidase/?-L-arabinofuranosidase
06342 -1.32 4.28 4.07 No CE1 Esterase
06343 -1.23 4.49 4.21 Yes GH43 ?-xylosidase/?-L-arabinofuranosidase
06344+06345 -1.57 4.49 4.68 No ABC-NBD ABC transporter, nucleotide binding domain
06346 -2.45 5.12 4.74 No ABC-PP ABC transporter, permerase protein
06347 -2.38 5.49 5.35 No Hypothetical ABC transporter
06348 -1.62 4.52 4.04 No Hypothetical ABC transporter
06349 -0.95 6.49 5.44 No UxuA Mannonate dehydratase
06350 -1.50 5.84 5.12 No UxuB Mannitol/D-arabinitol dehydrogenase domain protein
Log2-fold change
X1/Glc
?                       ?
Log2-fold change
z
?
-10 100
?                       ?
Log2-fold change
z
?
-10 100
e
Supplementary Figure 1 R. intestinalis L1-82 unique xylan upregulated loci. (a) Upregulation of a putative xylan metabolism gene
cluster unique for the R. intestinalis L1-82 strain on xylan. (b) Organization of genes in (a). (c) Second unique R. intestinalis L1-82 gene
cluster upregulated on xylan. (d) Organization of putative xylan-metabolism genes upregulated in (c). (e) Fluorescence microscopy of R.
intestinalis grown on xylan showing the extracellular localization of RiXyn10B. Experiments were performed three times and locus IDs
ROSINTL182_xxxxx are abbreviated with the last numbers after the hyphen. Signal peptides (SP) were predicted using SignalP v.3.0.
Genes residing between two contigs have two locus IDs.
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a                                                              
b
Locus ID SP Protein Annotation
WAX/Glc BGX/Glc
08977 9.09 5.79 5.26 Yes XylBP ABC transporter, solute-binding protein
08976+06802+06803 8.98 6.15 5.65 No XylNBD ABC transporter, nucleotide binding domain
06804 8.73 5.56 4.43 No XylPP ABC transporter, permease protein
06805 8.42 5.50 4.75 No XylPP ABC transporter, permease protein
08058 5.51 4.34 4.16 No XylA Xylose isomerase
08060 5.05 4.28 3.77 No XylB Xylulokinase
08023 -0.66 5.89 3.11 No AraA L-arabinose isomerase
08024 -0.44 5.55 2.90 No AraK L-ribulokinase
08017 4.40 5.06 4.96 No AraD L-ribulose-5-phosphate 4-epimerase
05880 0.70 0.58 0.59 No UxaC Glucuronate isomerase
06618+06619 0.18 -0.24 5.77 No UxuB Mannonate oxidoreductase
06622 -1.06 1.11 4.06 No UxuA Mannonate dehydratase
05688 -0.18 -0.69 1.26 No KdgK 2-keto-3-deoxy-D-gluconate kinase
05375 -0.61 -0.86 1.26 No KdgA 2-dehydro-3-deoxy phosphogluconate aldolase
06244 6.80 7.15 5.93 No tkt D-xylulose 5-phosphate/D-fructose 6-phosphate phosphoketolase
08021 5.29 5.72 4.85 No tal Fucose isomerase
08020 4.33 4.75 4.37 No tkt Transketolase
08019 4.06 4.44 3.76 No tkt Transketolase
08018 4.19 4.65 4.47 No tkt Transketolase
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?
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Supplementary Figure 2 R. intestinalis L1-82 xylose metabolism. (a) Proposed model for the metabolism of the monosaccharides
xylose, arabinose and glucuronic acid in R. intestinalis L1-82 based on the RNA-seq data in Supplementary Table 1, and literature. (b)
Upregulation of xylose import and metabolism genes in the model. The RNA-Seq heatmap depicts Log2-fold changes of genes expressed
by cells grown on xylose (X1), wheat arabinoxylan (WAX) and birch glucuronoxylan (BGX) relative to glucose (Glc). Locus numbers
ROSINTL182_xxxxx are abbreviated with the last numbers after the hyphen.
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GH115GH10 Trans. R. GH43 CE GH8 SBP PP PP Trans.R. Trans.R. GH3
99% 99% 99% 99% 99% 99% 100% 100% 97% 100% 99% 100%
GH115GH10* Trans. R. GH43 CE GH8 SBP PP PP Trans.R. Trans.R. GH3
99% 99% 99% 99% 99% 99% 100% 100% 97% 100% 99% 99%
PPGH8 GH115 CE Hypothe. PP SBP GH3 GH43 CE
67% 45% 12% 85% 82%  73%  49% 46% 59% 59% 61%
Trans.R. Trans.R.
Trans. R.PP PP SBP Trans. R. GH3 GH43 Hypothe. GH8 GH115
88% 83% 70% 43% 52%  60%  57% 60% 68% 46%
CE GH10
49%
R. intestinalis L1-82
ROSTINL182_06494, 
ROSTINL182_08192-202
R. intestinalis XB6B4
RO1_31190, RO1_26400-300
R. intestinalis M50/1
ROI_37900-790
R. hominis A2-183
RHOM_05800-5745
GH115GH10 Trans. R. GH43 CE GH8 SBP PP PP Trans.R. Trans.R. GH3
RiAgu115ARiXyn10A RiLac1 RiAbf43A RiAXE RiXyl8 RiXPP-A RiXPP-B RiXBP Trans.R. Trans.R. RiXyl3A
R. faecis M72
M72_00381-501
Supplementary Figure 3 Conservation of R. intestinalis core xylan utilization genes within the Roseburia genus. Genes are denoted
according to their protein products; glycoside hydrolase (GH), carbohydrate esterase (CE), transcriptional regulators (Trans.R.), ABC
transporter solute binding protein (SBP), ABC transporter permease protein (PP) and hypothetical proteins (Hypothe.). Sequence
identities to R. intestinalis L1-82 genes are shown above the genes; Locus IDs for the genes are denoted under the respective strains.
The asterisk indicates that the GH10 is not assigned in the genome.
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Supplementary Figure 4 Properties of the extracellular xylanases from R. intestinalis (a) Action patterns of R.Xyn10A on X2ĀX5 
analyzed by TLC; +: reaction with enzyme, -: controls without enzyme. The dotted line indicates that lanes not relevant to the figure 
were spliced out for clarity. (b-g) Hydrolysis kinetics of R.Xyn10A, R.Xyn10A CBMx lacking the N-terminal module and R.Xyn10A-cata, 
the catalytic module on WAX, and BGX. (h) Binding of xylans to R.Xyn10-CBMx by affinity gel electrophoresis using native 
polyacrylamide gels with different concentrations of WAX (0.0-0.1% w/v) or BGX (0.0-1.0% w/v). No polysaccharides were added to the 
control. Lane 1+2; R.Xyn10A-CBMx (3.0 μg), Lane 3  -lactoglobulin (1.5 μg), M; marker. (i) Domain organization of the xylanase 
R.Xyn10B encoded by a locus upregulated on xylan and which is unique for the R i.ntest.nal.s L1-82 strain used in the present study 
(Supplementary Fig. 1c-d). The bottom cartoon represents the recombinant enzyme. Experiments in (a) and (h) are performed twice and 
in triplicates for (b-g). 
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a                                                           b                                                         c
d                                                           e                                                                  f
g                                                           h 
i                                                           j                     
RiXyn10A-CBMx, [X6]
Supplementary Figure 5 Binding of CBMx and RiXyn10A to xylo-oligosaccharides. (a-e) Reference and blank corrected sensograms
depict binding of xylo-oligosaccharides (X3-X6) and mannohexaose (Man6) as negative control to CBMx (RiXyn10A-CBMx) using SPR
analysis. (f) ITC analysis of CBMx binding to X6. (g,i) Reference and blank corrected SPR sensograms depicting the binding of X6 to
RiXyn10A and RiXyn10AĀCBMx respectively. (h,j) One binding model fitted to the binding isotherms from the sensograms in (g,i). The
experiments were in triplicates, except for the ITC run once.
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Supplementary Figure 6 Binding preference of R.XBP associated to the xylo-oligomer ABC transporter of R i.ntest.nal.s. (a-g) ITC
analysis of R.XBP binding to linear and branched xylo-oligosaccharides. (h,i) Structures of the branched arabinosylated xylo-
oligosaccharides AX4 and AX3, which are mixtures with arabinofuranosyl decoration either at the C2 or C3 of xylosyl units. (j,k) Time
course HPAEC-PAD analysis of culture supernatants of R i.ntest.nal.s grown in YCFA with 0.5% WAX or BGX. The observed peaks
between 0 and 5 minutes are likely unutilized medium components. Experiments in (a-g) are duplicates, and in (j,K) from a duplicate.
59
GH30 + RiAgu115A
GH30
X1
X2
X3
X4
X5
MeGlcA
GlcA
  +      -     +      - 
  BGX      BeGX 
a
X1
X2X3
X4X5
RiXyl3A                        
RiXyl8              
NaBH4              
-
+
-
-
+
+
+
-
-
+
-
+
-
-
-
-
-
+
b
c
d
e f
g
h
Supplementary Figure 7 Intracellular xylo-oligosaccharide degrading enzymes from R. intestinalis (a) TLC analysis of the release of 4-
O-methylglucuronic acid (MeGlcA) from BGX and BeGX by RiAgu115A. Glucuronic acid (GlcA) is used as standard. (b,c) Activity of 
RiAgu115A on a GH30-hydrolyzed BeBGX monitored using MALDI-ToF MS; (b) is the GH30 control and (c) is the treatment with GH30 
and RiAgu115A.  Activity indicates RiAgu115A releases MeGlcA from the penultimate xyloxyl to the reducing end in xylo-
oligosaccharides based on the GH30 strict specificity1, whereas a GH10 generates xylo-oligosaccharides with a MeGlcA substitution at 
the non-reducing end2. This data shows that the RiAgu115A is able to act on both internal and terminal non-reducing end substitutions 
on glucuronoxylan-derived xylo-oligosaccharides. Di-sodium adducts of MeGlcA decorated oligomers (diamonds) are colored as their 
corresponding single sodium adducts. (d,g) Monosaccharide hydrolysis products from enzymatic treatment of WAX and BGX with 
RiXyn10A, RiAbf43A, RiXyl3A and RiXyl8 by HPAEC-PAD. Standards were 1; arabinose, 2; galactose, 3; glucose, 4; xylose. (e,f) RiXyl3A 
and RiXyl8 hydrolysis of xylo-oligosaccharides analyzed with HPAEC-PAD. (h) Ā-Xylosidase activity for RiXyl3A and RiXyl8 towards xylo-
oligosaccharides (XOS) by TLC. The + and - indicate the presence and absence of the different components, respectively. Lack of activity 
on substrate reduced with NaBH4 (converts reducing end unit to its alditol) provided evidence that RiXyl8 acts on the reducing end as 
the alditol is not accommodated in the active site. Experiments are performed in duplicates. 
 
 1. St John, F. J., Hurlbert, J. C., Rice, J. D., Preston, J. F. & Pozharski, E. Ligand bound structures of a glycosyl hydrolase 
family 30 glucuronoxylan xylanohydrolase. J. Mol. Biol. 407, 92–109 (2011). 
2. Dodd, D. & Cann, I. K. Enzymatic deconstruction of xylan for biofuel production. Glob Chang. Biol Bioenergy 1, 2–
17 (2009). 
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Supplementary Figure 8 Activity, specificity and taxonomic distribution of the novel xylan acetyl esterase RiAXE. (a) Phylogenetic tree 
of RiAXE and homologs identified by a BLASTP search against the non-redundant database. Sequences with coverage >86% and identity 
>42% were selected. All sequences were from Firmicutes members. The resulting 131 protein sequences were aligned using Muscle1 
and a phylogenetic tree constructed by the maximum likelihood algorithm in MEGA72. Bootstraps were performed with 500 replicates. 
The phylogenetic tree was visualized using Figtree (http://tree.bio.ed.ac.uk/software/figtree). Asterisk indicates position of RiAXE. (b) 
Time course deacetylation of AcBGX treated with RiXyn10A and RiAgu115A by RiAXE determined by NMR. (c) Rates of deacetylation by 
RiAXE on AcBGX and AcSpruce mannan (AcSGGM) in D2O, which may influence absolute reaction rates. (d) 
13C HSQC spectrum of 
RiXyn10A treated AcBGX showing the acetyl region and with the 1D proton projection. (e)  same as (d) but showing the spectral region 
for anomeric and O-acetylated xylose signals. RiXyn10a treatment enhances signal-to-noise of resonances in the NMR spectra for the 
assignment and increases the total number of observable individual signals. (f,g) 13C HSQC spectra for O-acetylated regions before (f) 
and after (g) deactylation by RiAXE. Nearly complete deacetylation of AcBGX is reached during the time resolved NMR experiment. 
Chemical shifts of the most dominating signal for the monosaccharide residues mark by “+”, peaks encircled by dotted lines indicate 
cluster of chemical shifts likely to belong to the same type of monosaccharide residue as dominating signal. 
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Supplementary Figure 9 Co-culture experiment with R. intestinalis and B. ovatus. (a-b) Growth curves for monoculture and co-cultures
after growth of R. intestinalis and B. ovatus with water as controls instead of carbon source. (c) Relative abundance determined by qPCR
in a propagation experiment with co-cultures on WAX. After 9 hours of growth, the co-culture was passaged into fresh media, passage
(I) (start OD600 nm=0.01). This culture was grown for 12 hours and passaged into fresh media again (passage II). The western blots were
carried out with (d) anti-RiXBP, (e) anti-RiXyn10A, (f) anti-RiXyn10B. R: R. intestinalis, B: B. ovatus, C: co-culture of R. intestinalis and B.
ovatus. Asterisk denotes the position of the band based on theoretical molecular mass. The molecular markers size is shown in kDa.
Lower molecular mass signals than expected indicate proteolytic cleavage occurring particularly with the multi-modular RiXyn10A.
Experiments are performed in biological triplicates in (a-c) and in duplicates in (d-f).
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Chapter 3 Paper 2: 1H, 13C and 15N backbone and side-chain 
assignment of a carbohydrate binding module from a xylanase 
from Roseburia intestinalis 
The present paper reports the backbone and side-chain assignment by NMR of the novel 
CBMx from a GH10, discovered in the paper “Differential bacterial capture and 
transport preferences facilitate co-growth on dietary xylan in the human gut” (Chapter 
2). In addition, analysis of the secondary structure elements indicates three α-helices 
and ten β-sheets. The paper is prerequisite for the NMR study reported in chapter 4. 
The NMR experiments were performed by Finn Lillelund Aachmann and his group, 
while I contributed to the publication by cloning of the CBMx together with establish-
ment of protein expression and purification conditions.   
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Abstract
The N-terminal domain (residues 28–165) from the glycoside hydrolase family 10 from Roseburia intestinalis (RiCBMx), has 
been isotopically labeled and recombinantly expressed in Escherichia coli. Here we report 1H, 13C and 15N NMR chemical 
shift assignments for this carbohydrate binding module (CBM).
Keywords Carbohydrate binding module (CBM) · Xylan binding module · Xylanase · Roseburia intestinalis · Gut 
microbiota
Biological context
Most of the dietary fibers in the human diet comes from the 
plant cell walls present in fruits and vegetables. Here we find 
complex polysaccharides such as, cellulose, pectin and xylan 
(Koropatkin et al. 2012). The latter has a β-1,4-linked xylose 
backbone with varying degrees of polymerization and side-
chain substitution (Rennie and Scheller 2014). Xylan can be 
substituted with carbohydrate side-chains, e.g. arabinofura-
nosyl and glucuronosyl residues or acetyl groups. A variety 
of linkages to side-chain residues necessitate the deployment 
of different enzymes for xylan degradation.
Members of the human gut microbiota (HGM) are able 
to ferment xylan into short-chain fatty acids (SCFAs) e.g. 
butyrate, propionate and acetate. Butyrate is known to have 
a beneficial effect on the host’s health by being an energy 
source for colonocytes as well as reducing the risk of colon 
cancer and enteric colitis (Donohoe et al. 2012; Morrison 
and Preston 2016; Xu et al. 2017). As the population of 
butyrate-producers are more abundant in healthy individu-
als, there is a particular interest in the role they play in the 
HGM (Sheridan et al. 2016). One of the key known butyrate-
producers from the HGM is Roseburia, a common genus in 
the clostridial cluster XIVa within Firmicutes (Louis and 
Flint 2009). Roseburia intestinalis has shown xylanolytic 
activity, and is together with species from Bacteroides, one 
of the few taxa that can utilize xylan (Chassard et al. 2007; 
Mirande et al. 2010). The ability of Bacteroides to degrade 
xylan have been investigated in detail (Martens et al. 2011; 
Rogowski et al. 2015; Zhang et al. 2014), but insight into the 
strategy used by Firmicutes to harvest energy from xylan has 
until recently been lacking.
A recent study (Leth et al. 2018) showed that R. intes-
tinalis is able to breakdown xylan through a modular 
cell-attached xylanase of glycoside hydrolase family 10 
(RiGH10A) that is conserved within the species. This 
enzyme is highly upregulated when R. intestinalis is grown 
on xylan and comprises of four xylan-binding modules: Two 
carbohydrate binding modules (CBMs) of family 9 (CBM9), 
one from family 22 (CBM22) and an N-terminal of a previ-
ously unknown family (CBMx). This representative of a new 
CBM family possesses low affinity for xylan, but displays 
selectivity for arabinoxylan, which makes it an interesting 
candidate for both structural and functional characterization 
studies by nuclear magnetic resonance (NMR).
 * Finn Lillelund Aachmann 
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Methods and experiments
Protein expression and purification
13C, 15N and 15N samples were expressed in Escherichia 
coli BL21 (DE3). Pre-culture was grown in LB medium 
(10 g/L tryptone, 5 g/L yeast extract and 5 g/L NaCl) 
supplemented with 10 µL kanamycin (50 mg/mL) in a 
shaking incubator at 30 °C, 225 rpm overnight. From the 
pre-culture, 1% (v/v) was used to inoculate 450 mL M9 
media (6 g/L  Na2HPO4, 3 g/L  KH2PO4, 0.5 g/L NaCl) 
supplemented with 500 µL kanamycin (50 mg/mL), 1 mL 
1 M  MgSO4, 10 mL Trace Metal solution (0.1 g/L  ZnSO4, 
0.8 g/L  MnSO4, 0.5 g/L  FeSO4, 0.1 g/L  CuSO4, 1 g/L 
 CaCl2), 5 mL Gibco™ MEM Vitamin Solution (100×), 
10 mL 15N Bioexpress Cell Growth Media (Cambridge 
Isotope Laboratories, Tewksbury, MA; USA), 2 g glu-
cose (15N label)/98% 13C6-D-glucose (13C, 15N label) in 
20 mL milliQ. After inoculation the medium was supple-
mented with 1 mL anti-foam and the cells were grown 
using Lex-24™ (Epiphyte) at 30 °C until  OD600 = 0.8. The 
expression was induced with IPTG (isopropyl-1-thio-β-
d-galactopyranoside) to a final concentration of 1 mM, 
and incubated with Lex-24™ (Epiphyte) at 16 °C over 
night. The cells were harvested by centrifugation (Sorvall) 
at 4 °C, 6000×g, 5 min. The pellet was resuspended in 
lysis buffer (50 mM  NaH2PO4, 50 mM NaCl and 0.05% 
TritonX-100) and ½ tablet cOmplete™ ULTRA protease 
inhibitor (Roche) in 20 mL milliQ, and sonicated using a 
Branson Sonifier equipped with a microtip for 10 min. Iso-
lation of the lysate was done by centrifugation (Eppendorf) 
at 4 °C, 15,000×g, for 2.5 h.
An Econo-Column® (Bio-Rad) containing 2  mL 
Ni–NTA Agarose (QIAGEN) was equilibrated with 20 
column volumes WEB (50 mM  Na2HPO4, 300 mM NaCl), 
pH 8.0. The lysate was incubated in the column for 45 min, 
and eluted with WEB with an increased amount of imi-
dazole: 10 mM, 15 mM, 20 mM, 100 mM, 200 mM and 
400 mM. Fractions containing CBMx were collected and 
purity confirmed with SDS–PAGE. To remove imidazole, 
the fractions were dialysed (MWCO 3.5  kDa) against 
5 mM  NaH2PO4, pH 5.5 over night.
To cleave the His-tag of the fraction containing CBMx, 
TEV-protease was added in 1/100 (w/w) and dialysed 
(MWCO 3.5  kDa) against 20  mM sodium phosphate, 
1 mM DTT, 0.5 mM EDTA, pH 8.0. Purification of CBMx 
was done using a gravity flow column containing 2 mL 
cOmplete His-tag purification resin (Roche) equilibrated 
with the dialysis buffer. The dialyzed sample was applied 
to the column and the flow through was collected. The 
resin was washed with 1–5 column volumes of the same 
buffer and the sample was collected by combining this 
fraction with the flow through. Regeneration of the column 
was done with dialysis buffer containing 50 mM imida-
zole. An SDS–PAGE was run to confirm the separation 
and purity of the mature CBMx.
The CBMx containing fractions were concentrated and 
buffer exchanged into the NMR-buffer (50 mM sodium 
phosphate, pH 6.5. Samples for NMR was made with 
CBMx in NMR-buffer with  D2O added to a final ratio of 
90%  H2O/10%  D2O) by centrifugation using Vivaspin® 6 
protein spin concentrators (MWCO 5 kDa, Sartorius) at 
10 °C, 7000×g.
NMR spectroscopy
All CBMx NMR samples were prepared in 50 mM sodium 
phosphate buffer and 10%  D2O, pH 6.5.
All spectra were recorded at 25 °C on a Bruker Ascend 
800  MHz spectrometer Avance III HD Bruker Biospin 
equipped with a 5 mm Z-gradient CP-TCI (H/C/N) cryo-
probe at the NV-NMR-Centre/Norwegian NMR Platform at 
NTNU Norwegian University of Science and Technology, 
Trondheim, Norway. 1H shifts were referenced internally to 
HDO, while 13C and 15N chemical shifts were referenced 
indirectly to HDO, based on the absolute frequency ratios 
(Zhang et al. 2003). Backbone and side-chain assignments 
of CBMx were elucidated using 15N-HSQC, 13C-HSQC, 
HNCA, HNcoCA, HNCO, HNcaCO, HNCACB, HNco-
CACB, HNHAHB, HNcoHAHB and HcCH-TOCSY. The 
NMR data were recorded and processed with TopSpin ver-
sion 3.5 and the data was analyzed with CARA version 1.5 
(Keller 2004). Secondary structure elements were evaluated 
using TALOS-N (https ://spin.niddk .nih.gov/bax/softw are/
TALOS -N/) (Shen and Bax 2013) and chemical shits of N, 
 HN,  Cα,  Cβ,  Hα,  Hβ and C′.
Assignment and data deposition
Here we report the backbone and side-chain assignment of 
CBMx. Figure 1 shows the 15N-HSQC spectrum of CBMx 
together with the assigned resonances. The backbone assign-
ment is essentially complete (N, HN,  Cα,  Hα and C′ > 98%). 
The mature protein contains two extra amino acids (Gly-Ala) 
at the N-terminus (for purification purpose) that were only 
partially assigned. Side-chain assignment is almost complete 
(H and C side-chains > 78%). The overall percentage of com-
pletion is affected by the missing assignment of exchange-
able side-chain protons of Arg, Lys, Asn and Gln as well as 
aromatic residues. Chemical shift data have been deposited 
at the Biological Magnetic Resonance Data Bank (BMRB) 
under the accession number 27536.
Analysis of the secondary structure elements (Fig. 2) 
indicates three α-helices and ten β-sheets. A high degree of 
β-sheets is consistent with previously reported structures of 
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Fig. 1  1H, 15N HSQC spectrum 
of 13C, 15N-labeled CBMx 
(1.7 mM) from the glycoside 
hydrolase family 10 xylanase 
from Roseburia intestinalis 
(RiXyn10A) in 50 mM sodium 
phosphate, pH 6.5 with  D2O 
added to a final ratio of 90% 
 H2O/10%  D2O. Residue number 
and type are indicated on the 
figure
Fig. 2  Secondary structure 
probability of CBMx using 
TALOS-N. The probability of 
helical structure is shown as 
positive values, while negative 
values are used for the probabil-
ity of an elongated structure
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carbohydrate binding modules. The typical β-sheet scaffold 
support the evolution of a variety of binding specificities 
and affinities in xylan-specific CBMs which merits further 
analyses.
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Chapter 4 Structure and functional insight into a new xylan binding 
module of the multi-modular xylanase from Roseburia intestinalis 
(Manuscript in preparation)  
The present chapter is a manuscript in preparation, which is envisioned to include ad-
ditional studies. It is of interest to identify unique properties of the CBMx (reported in 
chapter 2 and 3) and to assign it into a new CBM family. The manuscript includes a 
solved crystal structure of CBMx and its binding to xylans and decorated XOS are 
explored by NMR. The NMR results demonstrate structural changes of CBMx upon 
binding and that the preferred ligand is WAX. Further analysis of the NMR data will 
explore the dynamics of the protein. Additional experiments planned to be included in 
the manuscript are; mutations studies of crucial residues in the binding site and cryo-
EM of the full length GH10. The crystallization was performed by Morten Ejby and the 
NMR experiments were performed by Finn Lillelund Aachmann and his group. I con-
tributed to the presented study by writing the manuscript and by cloning of the CBMx, 
together with establishment of protein expression and purification conditions.   
   
Supplementary information is included in the end of the chapter     
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Abstract 
Efficient capture of glycans, the prime metabolic resource in the human gut, confers a key competitive 
advantage for gut microbiota members equipped with extracellular glycoside hydrolases (GHs) to 
target these substrates. The association of glycans to the bacterial cell surface is typically mediated by 
carbohydrate binding modules (CBMs). Here we report the structure of RiCBMx, a representative of a 
new family of xylan binding CBMs present in xylanases from human gut Clostridiales that correlate 
with a healthy microbiota. RiCBMx of the GH10 xylanase from Roseburia intestinalis adopts a canonical 
β-sandwich fold, but shows structural divergence from known CBMs. The open and shallow ligand-
binding site of RiCBMx is more similar to CBMs that target crystalline substrates (Type-A) than 
counterparts that bind glycan chains in deep clefts (type-B). Curiously, RiCBMx recognizes only a single 
xyloxyl ring with direct polar bonds, which is unprecedented amongst previously reported type-B 
CBMs that display more extensive and less focused polar ligand recognition patterns. The architecture 
of RiCBMx is consistent with an atypically low binding affinity compared to most xylan binding CBMs. 
Titration analyses using NMR spectroscopy indicated that ligand binding induces conformational re-
arrangements and that RiCBMx prefers arabinoxylan over glucuronoxylan, consistent with the apolar-
negativley charged surface flanking the binding site. Altogether, this study provides insight into the 
structural features that shape low-affinity CBMs, which are intermediate of type A and type B.  
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Introduction 
The gut microbiota (HGM) consists of trillions of microorganisms that exert a profound impact on 
human health, especially via modulation of host immune- and metabolic homeostasis1,2. The 
molecular dialogue of the microbiota with the host is typically communicated via microbial 
metabolites, whereby short chain fatty acids (SCFAs) produced from fiber fermentation play a key 
role3. The most common SCFAs are acetate, propionate and butyrate, all of which are considered 
beneficial to human health4. Notably, the fiber fermentation SCFA profiles generated are specific to 
distinct taxonomic groups, for example members of the dominant genus Bacteroides produce mainly 
acetate (and lower amounts of propionate) , whereas members from Clostridium group XIVa group5,6 
are key butyrate producers7. Butyrate has received increasing attention due to its role in enforcing the 
gut barrier by increasing the proliferation rate of colonocytes and strengthening tight junctions. 
Moreover, butyrate down-regulates the expression of inflammatory cytokines and increases colonic 
regulatory T cells by via inhibition of host histone deacetylases8,9. Thus, butyrate producers are 
considered an indicator of a healthy HGM and seem to make a marked contribution to maintaining a 
balanced and healthy community in the human gut10. Despite these pronounced physiological roles, 
little attention has been dedicated to understating the interactions of butyrate producing members 
of the HGM with dietary glycans, as opposed to other taxonomic groups that are ascribed a probiotic 
status, e.g. bifidobacteria11–13 and lactobacilli14,15.  
Roseburia intestinalis from the Clostridium cluster XIVa group of Firmicutes is an abundant (up to 5 % 
of the total microbiota) and prevalent butyrate producer7,16. The abundance of R. intestinalis is 
reduced in type 2 diabetes17, Chron’s disease18–20, and colorectal cancer21 patients, which is consistent 
with the association of this species to a balanced microbiota in healthy humans. R. intestinalis has also 
been shown to adhere to mucin22, reflecting intimate association with the host and production of 
butyrate close to the surface of the enterocytes. R. intestinalis is atypical amongst other human gut 
Firmicutes by encoding a considerable repertoire (>130) of glycoside hydrolases and polysaccharide 
lyases23 indicative of extensive saccharolytic potential. Accordingly, R. intestinalis is an appropriate 
model to investigate the strategy of complex glycan utilisation by butyrate producing Clostridium XIVa 
members.  
R. intestinalis and Eubacterium rectale, both affiliated to the Clostridium XIVa cluster of Firmicutes, 
have been proposed to be key primary degraders of the structural glycan xylan based on enrichment 
from faecal samples and in vitro growth on xylan24,25, which is one of the most abundant glycans in 
human diet. Xylan comprises a β-(1→4)-xyloxyl backbone with a variety of sidechain substitutions that 
70
3 
 
vary considerably according to botanic origin and tissue. Arabinoxylan (AX), the dominant structural 
component in the cereal cell wall26, is substituted with L-arabinosyl residues at C2, C3 or both positions 
of backbone xyloxyl units. Xylan is also present in lower amounts in vegetables and fruits as 
glucuronoxylan27 (GX), which is decorated with (4-O-methyl)glucuronic acid at the C2 position of 
xylosyl units. Both AX and GX are further acetylated at C2, C3 or both positions. The molecular 
apparatus of xylan utilisation by R. intestinalis has been recently described5. Extracellular capture and 
break down of xylan is mediated by a modular xylanase of GH10 (RiGH10A). This enzyme, which is 
conserved within the species, comprises an N-terminal carbohydrate binding module (CBM) from a 
previously unknown family (henceforth designated as RiCBMx) followed by a CBM22, a GH10 catalytic 
module, a tandem repeat of CBM9 and two C-terminal putative cell-attachment domains. Curiously, 
RiCBMx was specific to xylan, but it displayed relatively low affinity (KD≈0.5 mM for xylohexaose (X6) 
compared to about 7-fold higher average affinity of the truncated enzyme lacking this CBM for the 
same ligand. Interestingly, RiCBMx prefers the nutritionally more abundant arabinoxylan as compared 
to glucuronoxylan judged by retardation in affinity electrophoresis gels5.  
Association to complex glycans, such as xylan, offers a competitive advantage for bacteria in the 
competitive milieu of the gut. Firmicutes from Clostridium XIVa cluster frequently have large modular 
cell-attached glycoside hydrolase (GHs) containing multiple carbohydrate binding modules (CBMs) for 
capture and hydrolysis of polysaccharides5,6,28,29. To examine the mode of recognition and 
discrimination of RiCBMx to different xylans as well as the contribution of this domain to the dynamic 
binding of the appended xylanase RiGH10A, we have determined the structure of this module and 
performed binding analyses to glucurono- and arabinoxylan and oligosaccharides thereof using NMR 
spectroscopy.  
RiCBMx shares a β-sandwich fold with other CBMs, but displays very low structural similarity to 
functionally characterized orthologues, which merit its assignment in a new CBM that currently 
represents about 19 sequences from taxonomically related human gut Lachnospiraceae. The ligand-
binding site of RiCBMx is open and shallow, with only three residues recognising a single xylosyl unit 
out of four observed in the crystal structure in complex with X6. The binding site architecture and the 
focused direct polar interactions to a single saccharide ring are atypical for type B CBMs that 
frequently possess deep clefts and more extensive polar ligand contacts along their binding sites. 
These features are discussed in relation to the measured affinity and in comparison to other described 
xylan-binding modules, especially those occurring in GH10 endo-xylanases.  
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Results 
Crystal structure 
We determined the structure of RiCBMx in complex with xylohexaose (X6). The structure was solved 
in the hexagonal space group P65 (with 6 molecules in the asymmetric unit) using single-wavelength 
anomalous diffraction (SAD) with the experimental phase information obtained from data collected 
on crystals soaked with Tb-Xo430 using the Tb anomalous scattering for phasing. The data collection 
and refinement statistics are shown in Table 1. The structure of RiCBMx was solved to 1.9 Å resolution 
revealing a β-sandwich fold, consisting of two sheets formed by 11 antiparallel β-strands and 2 helical 
turns (right handed 310-helices) connected by loops (Fig. 1A). β-Sheet 1 forms the concave face of the 
β-sandwich and consists of the strands β2(K39-G43), β5(Y62-T68), β7(I92-Y97), β8(T108-L112) and 
β10(D129-I135). β-Sheet 2 is formed by β1(V29-T34), β3(D46-A50), β4(G53-F58), β6(N79-A86), 
β9(E117-I120) and β11(A143-L154). A striking feature of the CBM is the open solvent accessible ligand-
binding site (described in more detail below) that runs almost orthogonal to the β-strands of sheet 1 
(Fig. 1A). A search of the DALI server against the protein data bank (PDB) suggested that the closest 
structural relative of CBMx is the CBM29.2, from the anaerobic fungus Piromyces equi31 (1W9F, Z-
score=12.8, primary structure identity 12%), which has specificity for β-mannan32. The second closest 
structural hit is a CBM84 from a from a xanthan lyase family 8 from Paenibacillus nanensis33. Although 
the overall structural fold is shared between these modules, the low (<12%) shared sequence identity 
and the divergence of the binding sites (none of the residues that provide aromatic stacking 
interactions to the ligand are conserved) justify the assignment of RiCBMx as a representative of a 
new CBM family.    
 
Ligand binding site 
The crystal structure of RiCBMx in complex with X6 shows relatively densities for four xylosyl units. 
The ligand-binding site features an open and shallow surface with the ligand bound in a relaxed helical 
conformation34(Supplementary 1). The ligand-binding site is defined by Y62, which stacks onto the 
terminal reducing end moiety of the xylosyl, which defines position 1 (Fig. 1B). Xylo-oligosaccharide 
(XOS) ligands can, however, be accommodated in the opposite directionality with equivalent contacts 
(non-reducing end xylosyl stacking onto Y62, Supplementary 2). Our description will focus on the 
former orientation for clarity. The second aromatic ridge is provided by Y110 that stacks onto the 
xylosyl unit at position 3. A third potential stacking residue is W42, which is resembles one side of a 
sugar tong (Fig. 1C), but the indole face is blocked by a sidechain from a neighboring molecule in the 
crystals. The recognition of the helical conformation of the XOS, is facilitated by the planes of the 
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aromatic rings of Y62 and Y110 being almost orthogonal (≈100˚) to each other (Fig. 1B). The only direct 
potential polar interactions are observed at position 3 (Xyl3) between the C2-OH and K95 Nζ, C3-OH 
and -Q64 Nε2, and K95 Nζ and D102 Oδ2 (Supplementary 2). Additional water mediated potential 
hydrogen bonds may also contribute to the recognition (Supplementary 2). 
 
Table 1. Data collection and refinement statistics  
 CBMx 
Beamline PETRA III P13 
PDB ID - 
Wavelength (Å) 1.649 
Resolution range (Å) 70.9  - 1.9 (1.98  - 1.91) 
Space group P65 
Unit cell 141.87 141.87 60.6 90 90 120 
Unique reflections a 53405 (5006) 
Multiplicity a 9.6 (6.8) 
Completeness (%)a 99.30 (93.65) 
CC½a 0.997 (0.898) 
Mean I/σ(I) a 14.48 (3.21) 
Wilson B-factor 19.18 
R-factor b 0.2059 (0.2095) 
R-free b,c 0.2522 (0.2640) 
Number of atoms 6885 
Macromolecules 5954 
Ligands 282 
Water 649 
Protein residues 786 
RMS bonds (Å) 0.011 
RMS angles (°) 1.43 
Ramachandran favored (%) 98.19 
Ramachandran outliers (%) 0 
Clash score 3.60 
Average B-factor 20.54 
Macromolecules 19.58 
Ligands 29.99 
Water 25.25 
a Values in the parenthesis are for the highest resolution shell. 
b Values in the parenthesis are for before refinement. 
c Refinement is incomplete as the model will be moved to a higher 
resolution dataset  and the Tb-Xo4 and other solvent has not 
been finalized in this model. 
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Figure 1. Crystal structure of RiCBMx. A) Cartoon model of β-sandwich structure of RiCBMx. The left panel is a top view of 
sheet 1 formed by five β-strands. The four visible rings of the soaked xylohexoase ligand are shown in sticks. The view is 
rotated 180˚ in the right panel to show sheet 2 formed by six β-strands. B) The left panel is a close-up of the ligand bindings 
site with subsites numbered in Arabic numerals starting from the reducing end at position 1. The two aromatic residues Y110 
and Y62 that stack onto xylosyl rings at positions 1 and 3, respectively. The only direct polar interactions that recognize the 
C2 and C3 hydroxyl groups the xylosyl group at position 3 are shown and the 2Fobs–DFcalc  electron map for the bound ligand 
is shown at a contour level of 1σ (blue mesh). The right panel is the binding site in position 1 from another angle and the 
conservation of the binding residues is shown for clarity. C) The electrostatic potential of RiCBMx (at pH=7) is shown to 
highlight the topology and the chemistry of the ligand binding site of RiCBMx. The two aromatic stacking residues Y62 and 
Y110 are shown in add on to the potential aromatic binding residue W42. 
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Ligand binding analysis using NMR spectroscopy 
The changes in 15N-HSQC (Heteronuclear single quantum coherence spectroscopy) spectra of RiCBMx 
were monitored and the change in chemical shifts for both the N and H atoms upon titration with 
undecorated xylotetraose (X4), a 1:1 mixture of 33-α-L- and 23-α-L-arabinofuranosyl-xylotetraose 
(XAXXX) and 23-(4-O-methyl-α-D-glucuronyl)-xylotetraose (XUXXX) was followed. Here we describe the 
preliminary analysis of the result. The affinity of the RiCBMx was lowest for XUXXX, while the higher 
affinity for XAXXX and X4 resulted in a chemical shift difference in the same order (Fig. 2, Table 2). The 
change in chemical shift occurred mainly at the binding site and the flanking area (Fig. 2). The amino 
acids Y62, Q64, K95, D102 and Y110, which are observed to interact with the ligand in the crystal 
structure, showed a significant chemical shift difference after titration with the three ligands, except 
for Q64 with XUXXX. An interesting observation is that G111 undergoes a change in chemical shift in 
the 1H dimension only for the decorated substrates, which is suggestive this region of CBMx being 
involved in the accommodation of ligand units not observed in the crystal structure. Neighboring 
G111, is Y110 which provides aromatic stacking interactions for substrate.  
 
Figure 2 Chemical shift differences for RiCBMx. The chemical shift differences are after titration with xylo-
oligosaccharides; glucurono-xylotetraose (XUXXX), α-L-arabinofuranosyl-xylotetraose (XAXXX) and xylotetraose (X4). 
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Table 2 Binding parameters determined by NMR 
 KD (mM) Bmax (Δδ at saturation) 
X4 1.09 0.19 
XAXXX 1.23 0.17 
XUXXX 22.89 0.15 
Binding parameters are calculated from a single titration experiment 
  
The interactions between RiCBMx and the polymeric substrates birch glucuronoxylan (BGX) and wheat 
arabinoxylan (WAX) were followed in 15N-HSQC spectra upon titration (Fig. 3). Due to the strong 
interaction between RiCBMx and WAX, some of the signals were broadened beyond detection. The 
signals for WAX expanded as the only tested substrate to the backside of the protein, which likely 
stems from an induced fit conformational change upon ligand binding. The chemical shift difference 
was lower for BGX, indicating weaker binding affinity to RiCBMx than WAX. This, in addition to the 
observations made with oligomeric substrates, is evidence for that RiCBMx prefers arabinosyl 
substitutions compared to glucurono acids substitutions both on XOS and polymeric xylan. 
 
Figure 3 Chemical shift differences for RiCBMx. The chemical shift differences are after titration with birch glucuronoxylan 
(BGX) and wheat arabinoxylan (WAX). 
 
Close homologue of RiCBM are observed in a taxonomically related Lachnospiraceae  
We have previously described that RiCBMx confers affinity to xylan and xylo-oligosaccharides but lacks 
homologues with an assigned function5. A blast search against the non-redundant database identified 
19 homologs from different butyrate producing strains from the Lachnospiraceae family of gut 
Firmicutes. An analysis of these sequences revealed that several structural residues and binding 
76
9 
 
residues are conserved (Fig. 1B, Supplementary 3,4,). This and the narrow distribution among related 
gut bacteria points to a highly specialized nature of these binding modules. 
Discussion  
In this study, we have determined the crystal structure for RiCBMx in complex with X6. Despite the 
typical β-sandwich fold, RiCBMx did not display high structural similarity to any CBM families or other 
characterized proteins. Notably, the closest structural homologues were CBMs with affinity to 
polysaccharides with a different structural symmetry than xylan, such as β-mannan or xanthan. The 
lack of conserved ligand binding residues between RiCBMx and distant functionally described 
orthologues, is consistent with the functional divergence of the new CBM family represented by 
RiCBMx. Currently, 19 non-redundant sequences are retrieved from the NCBI database. Both the 
aromatic and the polar residues that interact with the bound ligand in RiCBMx are highly conserved in 
these sequences (Fig. 1B, Supplementary 3,4,). 
 
The architecture of the ligand-binding site of RiCBMx is consistent with low affinity for xylo-
oligosaccharide ligands. 
The ligand-binding site of RiCBMx features an extended shallow and open binding surface that 
accommodates four xyloxyl units. The experimental data from our previous work show about a 4-fold 
increase in affinity for X6 as compared with X4, consistent with the presence of additional contacts 
that stabilise the binding beyond the observed X4 ligand as observed in other xylan binding modules 
of CBM635 and CBM1536. The solvent exposed W42 constitutes a potential stacking residue, but the 
space in front of the indole ring is blocked by a sidechain from a neighboring molecule in the crystal 
packing, which hampers evaluating the relevance of this residue in ligand binding. The chemical shift 
changes of this residue, however, are just above significance threshold for XAXXX and X4 and below 
that for the lower affinity XUXXX. Notably, W42 is conserved in all but two homologues of RiCBMx, 
which together with the location and solvent accessibility of this residue merit further mutational 
analysis to evaluate possible role in ligand binding.  
The architecture of the binding site of RiCBMx is different from the type-B xylan specific CBMs37 e.g. 
from CBM438, CBM639, CBM1536, CBM2240. The deeper and more occluded binding site in these latter 
CBM families is defined by loops connecting the sandwich β-strands and pointing into the binding site. 
By contrast, the equivalent loops in RiCBMx are pointing downwards and away from the ligand, which 
creates a relatively flat open binding surface topology (Fig. 1C) that better resembles type-A CBMs, 
specific to crystalline flat substrates, e.g. cellulose and chitin37. To our knowledge, the only 
characterized xylan specific CBM, which has a similar open binding site to RiCBMx, is CfCBM2b from 
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Cellulmonas fimi assigned into CBM241. This latter family harbors mostly cellulose binding type A CBMs 
(CBM2a) and xylan specific CBM2b modules. Interestingly, the affinity of CfCBM2b to X6 (KD=0.2 mM) 
similarly to RiCBMx is substantially lower than typical type B xylan-specific CBMs, which have affinities 
about 10-fold higher to X639,40,42. A unique feature of RiCBMx, appears to be that the direct polar 
interactions are recognizing only a single xylosyl unit (Supplementary 2), as opposed to counterparts 
from other families, where direct hydrogen bonds distributed to recognize 2−3 xylosyl rings along the 
binding site. Finally, the type of sidechains decorations appears to impact substrate affinity, as 
glucuronic acid substitution seem to reduce affinity, possibly due to electrostatic repulsion. This is 
consistent with the apolar or negative surface electrostatic potential around the binding site (Fig. 1C). 
In contrast, arabinosyl decorations are either tolerated or recognized, based on the similar affinities 
for the undecorated and decorated ligand X4 and the markedly higher affinity for WAX as compared 
to BGX (Fig. 3). 
 
Rationale for having lower affinity xylan binding in modular xylanase? 
 
Having large extracellular enzymes with a variety of CBMs seems to be common in Lachnospiraceae 
form the human gut. R. intestinalis has a large modular GH26 mannanase with two CBMs6 and both 
Eubacterium rectale and Butyrivibrio fibrisolvens possess large modular α-amylases with 5 and 2 CBMs, 
respectively for capturing starch28,43. RiCBMx is joint to a CBM22, which precedes the catalytic GH10 
module that is flanked by a tandem CBM9 repeat. Notably the architecture of characterized CBM22 
and CBM9 are different from each other and from the RiCBMx. Members of CBM9 are type-C CBMs 
that possess a binding slot able to accommodate two terminal saccharide units of polysaccharides44, 
whereas CBM22 possess a deep extended binding cleft45,46. Thus, the three different families of CBMs 
in RiXyn10A orchestrate the binding of substrate by being able to capture either the terminal reducing 
ends or internal regions of xylan by the CBM9 (assuming similar binding mode to known members) or 
CBM22/CBMx, respectively. These CBMs also appear to have variable affinities as judged from affinity 
measurements of RiCBMx, the full-length enzyme and a truncated variant lacking RiCBMx, which have 
affinities of 479 µM, 128 µM and 65 µM, respectively5. This variable affinity and multiplicity of CBMs 
may confer a dynamic binding where the substrate is anchored to the enzyme surface in between 
consecutive catalytic cycles to minimize diffusional loss. The evolution of low affinity CBMs may be an 
adaptation to increase the area of substrate binding with minimal reduction of turnover, i.e. 
maximizing kcat/koff. Additional experiments are required to evaluate the dynamics of substrate binding 
and translocation to RiXyn10A.   
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Materials and Methods 
Chemicals 
All chemical were of analytical grade. Wheat arabinoxylan (WAX), Xylohexaose (X6), xylotetraose (X4), 
33-α-L- and-23-α-L-arabinofuranosyl-xylotetraose (XAXXX) in mixture of ~1:1 were from Megazyme 
(Wicklow, Ireland). 23-(4-O-methyl-α-D-glucuronyl)-xylotetraose (XUXXX) was from Cambridge 
Glycoscience (Cambridge, United Kingdom). Birchwood glucuronoxylan (BGX) was from Carl Roth 
(Karlsruhe, Germany). 
Cloning 
The gene fragment encoding the RiCBMx from Roseburia intestinalis L1-82 was amplified from a 
plasmid encoding the full length xylanase RiXyn10A (EEVO1588.1, ROSINTL182_06494)5 using the 
sense primer: 5’ TTTCAGGGCGCCATGGGGGTAAAAAAAGTTTTTACTGCAGAT 3’ and antisense primer: 5’ 
GACGGAGCTCGAATTTTAATCCCCCAATTTTGCA 3’. The amplicon was cloned into the EcoRI and NcoI 
restriction site of a pETM-11 vector (kind gift from Dr. Gunter Stier, EMBL, Center for Biochemistry, 
Heidelberg, Germany)47 using In-Fusion cloning (Takara). The construct was transformed into 
Escherichia coli DH5α and verified by full sequencing. 
Expression and purification 
Recombinant plasmids were transformed into BL21(DE3) (Novagen) for expression of unlabeled and 
13C/15N double labeled protein and B834(DE3)(Novagen) expression selenomethionine labelled 
protein. Protein production was performed as previously described for unlabeled protein5, 
selenomethionine labelled protein11, and double labelled 13C/15N labelled protein used for the NMR 
studies48. Cell pellets were resuspended in buffer (20 mM HEPES pH 7.5, 0.5 M NaCl, 10% glycerol) and 
disrupted at 1000 bar by a single passage in a high pressure homogenizer (Standsted Fluid Power, 
Essex, UK). Recombinant proteins were purified from the supernatant by affinity chromatography 
using a 5 mL His-Trap HP column (GE Healthcare) and a standard protocol. Pure fractions were 
concentrated and loaded onto a Hiload 16/60 Superdex 75 pg size exclusion chromatography column 
(GE Healthcare) mounted on an ÄKTA-AVANT chromatograph (GE Healthcare). For crystallization the 
His-tag was removed using a TEV-protease. This was done by buffer exchange into buffer (50 mM Tris-
HCL pH 8.0, 0.5 mM EDTA, 1 mM DTT) and next adding TEV-protease in a ratio of 1:100 (v/v). After 
incubation for 24 hours at room temperature, the mixture was passes through a His-Trap column, and 
the flow through containing the cleaved protein dialyzed into buffer (20 mM MES pH 6.5, 150 mM 
NaCl). Protein purity was determined by SDS-PAGE and protein concentration were measured 
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spectrophotometrically and calculated from the theoretical molar extinction coefficient (ε280nm= 26930 
and 23950 M-1 cm-1, for tagged and non-tagged proteins, respectively). 
Crystallization and structure determination 
Crystals were only obtained in the presence of 1 mM X6 by vapor diffusion in hanging or sitting drops, 
and grew for 2 days at 5 °C with a 1:1 ratio of the protein (18 mg mL-1  in 10 mM MES pH 6.5 and 150 
mM NaCl) and reservoir solution (0.2 M Cadmium chloride hemi(pentahydrate) 0.1 M Sodium acetate 
pH 4.8 and PEG 400 35 % v/v). An initial crystallisation condition (0.1 M Cadmium chloride 
hemi(pentahydrate), 0.1 M Sodium acetate pH 4.6 and PEG400 30 % v/v at 5 °C) was identified with 
the Structure Screen (Molecular Dimensions Ltd, UK), using a Mosquito® liquid handling robot (TTP 
Labtech, UK). The crystals were flash frozen in liquid nitrogen without cryo-protectant. Diffraction data 
were collected to a maximum resolution of 1.9 Å, at the DESY beamlines, Hamburg, Germany. The 
dataset was processed with XDS49. The structure was solved in the hexagonal space group P65 using 
single-wavelength anomalous diffraction (SAD) with the experimental phase information obtained 
from data collected at 7.575 KeV for crystals soaked for 1 min with 100 mM Tb-Xo430 (Molecular 
Dimensions) using the Tb anomalous scatterer for phasing. Experimental phasing, initial model 
building and refinements were performed in the Phenix software suite50. Manual structure 
improvement was done in Coot51. Ligand molecules were included after the protein parts were build 
and water molecules were added with Coot or manually. The overall quality of all models was checked 
using MolProbity52.  The data collection and refinement statistics are presented in Table 1. The PyMOL 
Molecular Graphics System, Version 2.0.6 Schrödinger, LLC was used to explore the models and for 
rendering. 
NMR spectroscopy 
NMR spectra of ≈0.10 mM RiCBMx in 50 mM sodium phosphate buffer pH 6.5 and 10 % D2O were 
recorded at 25 °C on a Bruker Ascend 800 MHz spectrometer Avance III HD (Bruker Biospin) equipped 
with a 5 mm Z-gradient CP-TCI (H/C/N) Cryoprobe at the NV-NMR-Centre/Norwegian NMR Platform 
at NTNU.  
A single NMR titration was preformed with three oligomeric substrates: X4, XAXXX or XUXXX. Titration 
points for X4: 0.5 mM, 1.0 mM, 2.5 mM, 5 mM and 10 mM; XAXXX: 0.2 mM, 0.5 mM, 1.0 mM, 2.5 mM, 
5.0 mM and 10 mM; XUXXX: same as for XAXXX with the addition of the following four points of 12.5 
mM, 15.0 mM, 20.0 mM and 25.0 mM. In addition, NMR titrations were also carried out with two 
xylans: BGX and WAX. The titration with BGX was performed with nine concentrations within 0.04−1.0 
mg mL-1 and a final point at 2.0 mg BGX. For WAX eight concentrations within 0.04−0.73 mg·mL-1 and 
80
13 
 
a final point of 1.4 mg WAX. 1D and 15N-HSQC spectra were recorded for each titration point and 
processed with Topspin version 3.5 and CARA version 1.5 using backbone and side-chain assignments 
of CBMx have been published elsewhere48. The chemical shift perturbation upon titration was 
followed in 15N-HSQC. Binding parameters were estimated by Gnuplot 5.2 (www.gnuplot.info) using 
an average of the chemical shift difference (Δδ) from the titration of three amino acids, KD X4 (A59, 
N63, N93), KD XAXXX (N63, N93, G111) and KD XUXXX (N63, N93, G111). 
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Supplementary 1 
 
 
 
 
 
 
 
 
 
S4: CArbohydrate Ramachandran Plot (CARP) output34. The output shows 
that the ligand has a relaxed helical conformation 
 
  
1: 
                                                                         
                                                                         
                                                                      
b-D-Xylp-(1-4)-b-D-Xylp-(1-4)-b-D-Xylp-
(1-4)-b-D-Xylp         
                                                                         
                                                  
Linkage Path: [4] 
PDB Residues: XYP1I,XYP2I 
phi: 21.4, psi: 32.3  
2: 
                                                                 
                                                                         
                                                                         
           b-D-Xylp-(1-4)-b-D-Xylp-(1-
4)-b-D-Xylp-(1-4)-b-D-Xylp         
                                                                         
                                                                         
Linkage Path: [4 4] 
PDB Residues: XYP2I,XYP3I 
phi: 32.7, psi: 46.6  
3: 
                                                                         
                                                                         
                                                                         
           b-D-Xylp-(1-4)-b-D-Xylp-(1-
4)-b-D-Xylp-(1-4)-b-D-Xylp         
                                                                         
                                                                     
Linkage Path: [4 4 4] 
PDB Residues: XYP3I,XYP4I 
phi: 30.2, psi: 29.6  
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Supplementary 2 
 
S2. Close-up of the binding site. A) Xylotetraose bound in directionality 1 with the reducing end bound at position 1. Both 
the direct and water mediated potential hydrogen bonds are shown in addition to the two aromatic stacking residues. B) 
Same as A, but with the xylotetraose bound with the opposite directionality.  
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Supplementary 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S3. Multiple alignment of RiCBMx homologs. CBMx 
was used as a query in a blast search against the non-
redundant database. The search gave 45 sequences 
with identity>30 % and coverage>55 %. Redundant 
sequence from the different strains were discarded, 
giving 19 sequences that were aligned using 
MUSCLE53 and visualized using ESPript54. The 
sequences are identified by the Genbank accession 
and the genus names are shown. 
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Supplementary 4 
 
S4: Consensus logo for CBMx. The sequence logo was created with the multiple alignment of RiCBMx and visualized using 
WebLogo 3.6 (weblogo.berkeley.edu).   
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Chapter 5 Paper 3: Molecular and Biochemical Basis for Com-
plex β-Mannans Catabolism by the Human Gut Firmicutes Bac-
terium Roseburia intestinalis 
The present paper provides insight into the molecular machinery used by the butyrate 
producing human gut symbiont R. intestinalis to utilize dietary mannan. A tran-
scriptomic study on mannans was performed in parallel with the study on xylan in 
chapter 2. The transcriptomic data revealed two gene loci responsible for mannan utili-
zation and is the initial foundation for the study. In the paper a proteomics study 
confirms the transcriptomic results and detailed characterization of mannan degradation 
and uptake apparatus are presented. In this paper R. intestinalis demonstrated that it 
is able to compete for mannan with B. ovatus in vitro and curiously, in vivo experiment 
showed that β-mannan can increase the number of R. intestinalis in mice after one day, 
together with other fiber degrading species, whereas the counts of mucolytic taxonomic 
group are significantly reduced. The data and analysis for the presented paper are 
mainly performed by Sabina Leanti La Rosa together with Bjørge Westereng and mem-
bers of his group. Mice experiments were performed by Eric Martens and his group. 
Initial establishment of growth on mannans by R. intestinalis and transcriptomic studies 
were performed by me.  
 
The paper has been accepted for publication in Nature Communication (January 2019).  
 
Supplementary information is included in the end of the chapter     
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Abstract 19 
-Mannans are plant cell wall polysaccharides that are commonly found in human20 
diets. However, a mechanistic understanding into the key populations that degrade 21 
this glycan is absent, especially for the dominant Firmicutes phylum. Here, we show 22 
that the prominent butyrate-producing Firmicute Roseburia intestinalis expresses two 23 
loci conferring metabolism of -mannans. We combine multi-omic analyses and24 
detailed biochemical studies to comprehensively characterize loci-encoded proteins 25 
that are involved in -mannan capturing, importation, de-branching and degradation26 
into monosaccharides. In mixed cultures, R. intestinalis shares the available -27 
mannan with Bacteroides ovatus, demonstrating that the apparatus allows 28 
coexistence in a competitive environment. In murine experiments, -mannan29 
selectively promotes beneficial gut bacteria, exemplified by increased R. intestinalis, 30 
and reduction of mucus-degraders. Our findings highlight that R. intestinalis is a 31 
primary degrader of this dietary fiber and that this metabolic capacity could be 32 
exploited to selectively promote key members of the healthy microbiota using -33 
mannan-based therapeutic interventions. 34 
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Introduction 35 
The human gastrointestinal tract harbors an extremely dense and diverse microbial 36 
community, known as the gut microbiota1. In a mutually beneficial relationship, the 37 
gut microbiota supplies enzymes able to depolymerize dietary carbohydrates that 38 
cannot be hydrolyzed by human enzymes2,3. The monosaccharides generated are 39 
further fermented into host-absorbable metabolites, including the short-chain fatty 40 
acids butyrate, acetate and propionate. In particular, butyrate produced by 41 
commensal bacteria serves as the main energy source for colonocytes4,5 and it 42 
exhibits anti-carcinogenic, anti-inflammatory and barrier protective properties in the 43 
distal gut6,7,8. The relevance of this metabolic output to human health has prompted 44 
increasing interest in intentionally modulating the composition of the gut microbiota 45 
to promote wellbeing and combat disease, e.g. by the use of prebiotics9. Established 46 
prebiotics have been traditionally developed based on their selective fermentation by 47 
bifidobacteria and lactobacilli generally regarded as conferring health benefits to the 48 
host.  Notably, other potentially beneficial targets are the butyrate-producing 49 
Firmicutes9. 50 
Roseburia spp., together with Faecalibacterium prausnitzii and Eubacterium rectale, 51 
constitute a group of dominant butyrate-producing Firmicutes, estimated to account 52 
for 724% of the total bacteria in the healthy human colon10,11. Interest in Roseburia 53 
spp. has increased with reports that the abundance of these bacteria is reduced in 54 
individuals affected by inflammatory diseases12-14 and colorectal cancer15,16. 55 
Complementary studies have shown that Roseburia spp. play an important role in 56 
the control of gut inflammatory processes17, amelioration of atherosclerosis18 and in 57 
the maturation of the immune system, primarily through the production of butyrate19. 58 
R. intestinalis preferentially colonizes the mucin layer20,21 and this intimate 59 
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association to the host may contribute to the local level of butyrate available for the 60 
colonic epithelial cells22. This species appears to be a specialist able to grow only on 61 
a few glycans23,24 and has been recently shown to be a prominent xylan degrader in62 
vitro25 and in the healthy human colon26.  63 
-Mannans are widespread in the human diet: they are widely used in food as 64 
thickening, stabilizing and gelling agents27 (glucomannan and galactomannan, 65 
Fig.1). They are found in the endospermic tissue of nuts (homopolymeric mannan), 66 
coffee beans, coconut palm, tomato and legume seeds (galactomannan) (Fig.1)27-29, 67 
and play vital roles in the cell wall structure and as storage polysaccharides in plants. 68 
Notably, the structure of galactoglucomannan29 from non-edible sources (softwood) 69 
shares striking similarities with that from edible sources (Fig.1).  70 
Prevalent Gram-negative Bacteroides spp. encode -mannan polysaccharide 71 
utilization loci (PULs) and have been recently shown to utilize mannans30-32. Despite 72 
members of the Firmicutes phylum being numerically dominant in the gut, insight is 73 
lacking into the metabolic strategies adopted by these Gram-positive bacteria to 74 
utilize -mannans.  75 
Here, using a combination of microbiology,omic and enzymology approaches, we 76 
unravel the molecular mechanism evolved by R. intestinalis L1-82 to depolymerize -77 
mannans that are potentially available in the large intestine. Our findings show that 78 
R. intestinalis growth on -mannan is dependent on the expression of a highly 79 
specific multi-modular cell attached endomannanase, an ATP-binding transporter 80 
and an intracellular enzyme cocktail through which linear and substituted manno-81 
oligosaccharides are completely hydrolyzed to component monosaccharides for 82 
further metabolism. Using germ-free mice colonized with a model gut microbiota, we 83 
demonstrate that -mannan alters the community composition, facilitating bacteria 84 
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that have mannan degrading machineries.  Besides extending the knowledge on the 85 
enzymatic basis of -mannan-metabolism by members of the most numerous 86 
Firmicutes phylum, our results have implications for the design of targeted 87 
intervention strategies to manipulate the gut microbiota via supplementation of 88 
prebiotics to the diet to restore or improve health. 89 
90 
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RESULTS 91 
Two multi-gene loci mediate -mannan utilization. R. intestinalis L1-82 grows 92 
efficiently on a variety of complex -mannans as a sole carbon source (Fig. 2a), 93 
causing a concomitant acidification of the medium (Fig. 2b). To evaluate which 94 
fractions of -mannan breakdown products are internalized, we analyzed the culture 95 
supernatants during R. intestinalis growth on AcGGM using high-performance anion-96 
exchange chromatography with pulsed amperometric detection (HPAEC-PAD) 97 
(Supplementary Fig. 1a-b). Neither oligosaccharides nor monosaccharides 98 
accumulated in the stationary phase culture (Supplementary Fig. 1a-b), indicating 99 
that the bacterium possesses a highly efficient apparatus to cleave and import all the 100 
sugars derived from the breakdown of this complex glycan.  101 
To examine the molecular basis underlying -mannan utilization by R. intestinalis, 102 
we performed an RNA sequencing (RNAseq) transcriptional analysis during growth 103 
on konjac glucomannan (KGM), spruce acetylated galactoglucomannan (AcGGM) 104 
and glucose (Glc). The top 20 upregulated genes in -mannan transcriptome encode 105 
a -mannanase belonging to the glycoside hydrolase (GH) 26 family (GH26 106 
according to the CAZy classification33), a solute binding protein (MnBP) and two 107 
permeases (MPP) of an ABC transporter, two phosphorylases (GH130), one 108 
epimerase (Mep), two -glucosidases (GH3) and two carbohydrate esterases (CEs) 109 
(Fig. 2c and Supplementary Data 1). These genes are located in two loci, which 110 
were designated mannan-utilization locus large (MULL: ROSINTL182_05469-83) 111 
and mannan-utilization locus small (MULS: ROSINTL182_07683-85) (Fig. 2d). 112 
Among the MULL genes expression of a LacI-type transcriptional regulator, 113 
predicted glycosyl hydrolases belonging to GH113, GH36, GH1 and a 114 
phosphomutase also increased. The response was specific to -mannan as no 115 
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differential expression of these genes was observed during growth of R. intestinalis 116 
on galactose, a building block in mannan (Supplementary Table 1).  117 
Proteomic analysis under the same growth conditions corroborated the RNAseq 118 
results; indeed, proteins encoded by the genes located in MULL and MULS were 119 
abundant in the AcGGM samples compared to the glucose samples (Fig. 2e, 120 
Supplementary Data 2).  121 
We carried out a comparative genomic analysis to establish the distribution of -122 
mannans utilization loci equivalent to the identified MULL and MULS in other 123 
representative Roseburia spp. and Clostridium cluster XIVa members. The results 124 
showed that R. faecis and R. hominis shared an overall MULL and MULS 125 
organization with that of R. intestinalis (Supplementary Fig. 2, Supplementary Table 126 
2), suggesting that the utilization of -mannan is shared by these three Roseburia 127 
spp. However, the lack of the critical GH26 endomannanase, required to break down 128 
mannan (see later results for R. intestinalis -mannanase RiGH26), is likely to render 129 
R. hominis only able to metabolize manno-oligosaccharides. Orthologous mannan 130 
utilization loci were identified in specific members of the Clostridium cluster XIVa, 131 
although a similar organization and complete conservation of all MULL and MULS 132 
components was not observed (Supplementary Fig. 2). 133 
Degradation of the -mannan backbone. RiGH26, (locus tag: 134 
ROSINTL182_07683), is a predicted extracellular modular -mannanase comprising 135 
a carbohydrate binding module of family 27 (CBM27), a catalytic module of GH26 136 
followed by a CBM23 (Supplementary Fig. 3a). Furthermore, two C-terminal Ig-like 137 
domains and a proline-glycine rich region likely mediate cell attachment34 and 138 
binding within the cell wall35. The extracellular localization of RiGH26 was 139 
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corroborated experimentally by immunofluorescence microscopy (Fig. 3). RiGH26 140 
exhibited activity toward decorated mannans including KGM, carob galactomannan 141 
(CGM) and AcGGM (Fig. 4a and Supplementary Fig. 3b), generating linear and 142 
substituted manno-oligosaccharides. The enzyme was active on mannopentaose 143 
(M5) and mannotetraose (M4) but not mannobiose (M2) (Supplementary Fig. 3c). 144 
Overall, the product profiles suggest capability of endo-action and indicates that 145 
RiGH26 targets large polymers and can accommodate the galactose and acetyl 146 
decorations present in these substrates. Further analysis indicated that RiGH26 is a 147 
potent enzyme as, when used at the concentration of 10 nM, it was able to hydrolyze 148 
high concentrations of spruce AcGGM (50 mg ml-1) into oligosaccharides in 1 h at 149 
standard assay conditions (Supplementary Fig. 3d). No detectable activity was 150 
measured when RiGH26 was incubated with linear cello-oligosaccharides, birch 151 
xylan, curdlan, lichenan or barley derived -glucan, thus confirming the specificity of 152 
RiGH26 towards -mannan (Supplementary Fig. 3c).  153 
BlastP searches showed that homologs of RiGH26, including the two predicted 154 
carbohydrate binding modules CBM27 and CBM23, were exclusively found in -155 
mannanase encoded by Firmicutes belonging to various other members of the 156 
Clostridium cluster XIVa (Supplementary Fig. 4, Supplementary Table 3-5). To 157 
investigate the biochemical properties of the two modules, RiCBM27 and RiCBM23 158 
were expressed in Escherichia coli and their capacities to bind to a range of different 159 
soluble cello- and manno-oligosaccharides were evaluated using surface plasmon 160 
resonance (SPR). Recombinant RiCBM27 and RiCBM23 bound only manno-161 
oligosaccharides (Table 1), but differed in their binding profiles. Similar to a 162 
previously described GH26-associated CBM2736, RiCBM27 preferred 163 
mannohexaose (M6) (Kd=165 ± 10 µM, two independent experiments, ± indicates 164 
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standard deviation), (Table 1, Supplementary Fig. 5a) and its affinity dropped for 165 
ligands smaller than a tretrasaccharide (Table 1). By contrast, RiCBM23 was 166 
selective for shorter oligosaccharides with its highest affinity for M4 (Kd=130 ± 50 µM, 167 
two independent experiments) (Table 1, Supplementary Fig. 5b), although 168 
mannotriose (M3) was also bound with good affinity (Table 1).  169 
Internalization of break-down products from -mannan. Within the MULL cluster, 170 
the three genes (ROSINTL182_05477  ROSINTL182_05479) that encode an ATP-171 
binding cassette (ABC) importer were shown to exhibit the highest level of increased 172 
expression during growth on -mannan (and when compared to growth on glucose). 173 
The thermodynamic binding parameters of the ABC-transporter associated solute 174 
binding protein, RiMnBP, to linear and substituted manno-oligosaccharides were 175 
determined using isothermal titration calorimetry (ITC). RiMnBP bound a range of 176 
unsubstituted manno-oligosaccharide with a preference for M5 (Kd of 2.55 µM) 177 
followed by M3 and M4 (Table 2, Supplementary Fig. 6). Acetylations had a marginal 178 
effect on the binding affinities, thus providing evidence that these fragments are 179 
efficiently captured by the transport protein. Overall, these results support the 180 
predicted role of RiMnBP in the uptake of manno-oligosaccharides generated by 181 
RiGH26, showing optimal affinity for undecorated or acetyl substituted ligands with a 182 
degree of polymerization (DP) of 4 5. 183 
Decomposition of internalized -manno-oligosaccharides. The affinity of the 184 
solute binding protein RiMnBP to manno-oligosaccharides and the predicted 185 
intracellular location of the debranching and exo-acting enzymes is consistent with a 186 
hierarchical degradation of the internalized manno-oligosaccharides following 187 
extracellular degradation of the -mannan polymers by RiGH26. 188 
97
10 
 
The ROSINTL182_05471 (RiCEX) and ROSINTL182_05473 (RiCE2) gene products 189 
possess SGNH hydrolase-type esterase domain signatures37. Comparison to 190 
previously characterized CEs revealed that RiCE2 showed 25- 30% identity to a CE2 191 
from Clostridium thermocellum38 and the acetyl xylan esterase Axe2C of Cellvibrio 192 
japonicus38. In contrast, RiCEX did not display significant relatedness to other 193 
characterized CE catalogued in the CAZy database33, which excluded RiCEX from 194 
being classified in any of the 16 CE families. RiCEX and RiCE2 showed mannan 195 
acetyl esterase activity on a mixture of oligosaccharides generated via RiGH26 196 
hydrolysis of AcGGM (Fig. 4b). RiCE2 partially removed acetyl groups from the 197 
acetylated oligosaccharide substrate (Fig. 4b). RiCEX deacetylated the substrate 198 
mainly to free and monoacetylated oligosaccharides (Fig. 4b). These results indicate 199 
that RiCEX has a preference for oligosaccharides with a degree of acetyl substitution 200 
 2, but is less efficient on mono-substituted substrates. At the same time, it 201 
suggests that an acetyl group present at a specific position (O-2 or O-3) is resistant 202 
to enzymatic deacetylation by RiCEX. The combination of RiCEX and RiCE2 203 
resulted in the almost complete deacetylation of the manno-oligosaccharides, 204 
indicating a cooperative interaction of the two esterases (Fig. 4b). 205 
RiGH36 released galactose from internally substituted CGM and AcGGM after the 206 
treatment with the RiGH26 -mannanase (Fig. 4c and Supplementary Fig. 7). 207 
Interestingly, RiGH36 released galactose from CGM-endomannanase products with 208 
100% efficiency (Fig. 4c, Supplementary Fig. 8a) as no oxidized product could be 209 
observed after treatment of these samples with galactose oxidase. The enzyme 210 
exhibited limited activity on large polymers (Supplementary Fig. 8b) consistent with 211 
the activity on internalized oligosaccharides in vivo. Similarly, -galactosidase activity 212 
increased after de-acetylation of the oligosaccharides (Supplementary Fig. 8c-d). 213 
98
11 
 
Beside cleaving single internal galactose residues from manno-oligosaccharides, this 214 
enzyme was capable of removing -1,6-galactose from the reducing-end of a 215 
substituted manno-oligosaccharide (Supplementary Fig. 8e) and from an 216 
oligosaccharide containing two consecutive substitutions (Supplementary Fig. 8f). 217 
Corroborating these results, RiGH36 cleaved galactose decorations from 218 
endomannanase products of highly substituted guar gum galactomannan 219 
(Supplementary Fig. 8b). 220 
Sequence searches showed that the protein encoded by ROSINTL182_05483 221 
(MULL, RiGH113) exhibited 40% identity to the only characterized enzyme from this 222 
family, the endo- -mannanase AaManA from Alicyclobacillus acidocaldarius39 223 
(Supplementary Fig. 9a). Alignment of RiGH113 and AaManA showed that the 224 
catalytic and substrate interacting residues are conserved (Supplementary Fig. 9a). 225 
When RiGH113 was assayed for activity on linear manno-oligosaccharides, it 226 
revealed an ability to cleave linear manno-oligosaccharides to yield mannose and M2 227 
(Supplementary Fig. 9b). Strikingly, time-course analysis of RiGH113 activity 228 
revealed that this enzyme displays a different sub-specificity by hydrolyzing manno-229 
oligosaccharides to mannose and a minor amount of M2 (Supplementary Fig. 9c). 230 
After overnight incubation with RiGH113, M2 was partially degraded to mannose 231 
(Supplementary Fig. 9d), confirming the exo-mannosidase activity as opposed to the 232 
endo-fashion cleavage reported for the AaManA. The substituted manno-233 
oligosaccharides galactosylmannobiose (Gal1Man2) and digalactosylmannopentaose 234 
(Gal2Man5) were hydrolyzed to a lesser extent than non-substituted substrates 235 
(Supplementary Fig. 9e); no activity could be detected on Gal1Man2 while Gal2Man5 236 
was hydrolyzed to yield mannose and digalactosylmannotetraose (Gal2Man4), which 237 
was resistant to further hydrolysis. When the reducing end of manno-238 
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oligosaccharides was blocked (Supplementary Fig. 10a-d), no RiGH113 activity 239 
could be detected demonstrating that this enzyme possesses a previously unknown 240 
reducing end mannose-releasing exo-oligomannosidase activity. Consistent with the 241 
view that RiGH113 is an intracellular enzyme, release of mannose was detected 242 
after incubation of the enzyme with RiGH26-generated CGM-oligosaccharides (Fig. 243 
4d). The closest homologues of this enzyme are encoded by Clostridium cluster 244 
XIVa strains and a range of Firmicutes (Supplementary Fig. 10e). 245 
Product analysis of end point assays and a time course study revealed that both 246 
RiGH3A (ROSINTL182_07684) and RiGH3B (ROSINTL182_07685) were -247 
glucosidases, with redundancy in structure (Supplementary Fig. 11a-b), active on 248 
linear cello-oligosaccharides (Fig. 4e). RiGH3B completely hydrolyzed cellotetraose 249 
(G4) and cellopentaose (G5) into glucose monomers, whereas RiGH3A released 250 
glucose and a range of oligosaccharides with lower efficiency compared to that of 251 
RiGH3B (Supplementary Fig. 11c-d). Neither of these enzymes were active on 252 
manno-oligosaccharides (Supplementary Fig. 11e-f). While RiGH3B was able to 253 
hydrolyze glucosylmannose (G1M1) and, partially, mannosylglucose (M1G1) into 254 
monomers (Supplementary Fig. 11f), RiGH3A displayed activity only towards G1M1. 255 
No activity was detected on polymeric KGM (Supplementary Fig. 12a), while glucose 256 
was released after incubation of both RiGH3A and RiGH3B with RiGH26-generated 257 
KGMhydrolysate (Supplementary Fig. 12b). Importantly, the latter results 258 
demonstrate that RiGH26 can accept a glucose moiety at the subsite +1, generating 259 
oligosaccharides with a glucose residue at the non-reducing end. 260 
Recombinant RiGH130_2 (MULL, ROSINTL182_05474) phosphorolyzed M4 into M3, 261 
M2 and mannose-1-phosphate (M1P) while M3 was processed to M2 and M1P (Fig. 262 
4f). The enzyme was inactive on cello-oligosaccharides (Supplementary Fig. 13). 263 
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RiGH130_2 was functional only in the presence of inorganic phosphate, confirming 264 
that RiGH130_2 is a mannosyl-phosphorylase.  265 
Catabolism of mannobiose and mannosylglucose units. The concerted action of 266 
the MULL and MULS encoded enzymes described above on the oligosaccharides 267 
generated by RiGH26, suggest an intracellular accumulation of M2. Hydrolysis of this 268 
product into monosaccharides is accomplished through the action of two enzymes 269 
encoded by the co-transcribed genes ROSINTL182_05476 (RiMep) and 270 
ROSINTL182_05475 (RiGH130_1). 271 
RiMep was active on M2 and cellobiose (G2), releasing M1G1 and G1M1, respectively 272 
(Fig. 5a). These data show that RiMep is an enzyme active on the reducing end 273 
sugar and catalyzes the conversion of disaccharide substrates to the corresponding 274 
C2 epimer. This enzyme exhibited epimerization activity not only for the substrate 275 
but also for the product as, under high enzyme amount and long reaction time, it was 276 
able to convert M1G1 and G1M1 to M2 and G2, respectively (Supplementary Fig. 14a). 277 
In addition, RiMep exhibited epimerization activity towards oligosaccharides with a 278 
DP greater than 2 but not on monosaccharides (Supplementary Fig. 14b).  279 
ROSINTL182_05475 encodes a specific mannosylglucose phosphorylase belonging 280 
to the GH130 subfamily 140. RiGH130_1 was inactive on G1M1 and oligosaccharides 281 
with a DP  2 (Supplementary Fig. 15). RiGH130_1 displayed activity only towards 282 
M1G1 in the presence of inorganic phosphate, releasing glucose and M1P (Fig. 5b 283 
and 5c).  284 
Catabolism of phosphorolysis products. RiPgm catalyzes the interconversion of 285 
M1P and mannose 6-phosphate (M6P) (Fig. 5d). In addition, the enzyme displayed 286 
activity also against D-glucose 1-phosphate (G1P) yielding D-glucose 6-phosphate 287 
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(G6P) (Supplementary Fig. 16a), thus indicating that RiPgm is a 288 
phosphomannomutase (PMM) / phosphoglucomutase (PGM) which can use either 289 
glucose or mannose as substrate. Consistent with the presence of a predicted 290 
magnesium-binding loop (Supplementary Fig. 16b), the RiPgm-mediated catalytic 291 
activity was detected only when MgCl2 was present in the reaction.  292 
ROSINTL182_05469/70 encodes a predicted bi-functional protein consisting of an N-293 
terminal glucosidase domain (RiGH1_D1, aa 1-246) and a C-terminal family GH1 294 
isomerase domain (RiGH1_D2, aa 247-768). RiGH1_D1 shares 44% identity to the 295 
previously characterized -glucosidase TmGH1 from Thermotoga maritima41. The 296 
recombinant RiGH1_D1 displayed no catalytic activity against all the tested 297 
substrates, including G4, M4, M5, M6P, G6P and fructose 6-phosphate (F6P). Thus, 298 
RiGH1_D1 functional significance is currently unclear. RiGH1_D2 is a 299 
phosphomannose isomerase catalyzing the interconversion of M6P into F6P (Fig. 300 
5e). 301 
R. intestinalis competes with Bacteroides for -mannans. The ability of R. 302 
intestinalis to capture, breakdown -mannan and efficiently internalize manno-303 
oligosaccharides may increase its fitness to compete with other resident -mannan 304 
degraders, including the glycan generalist Bacteroides 30. To test this hypothesis, we 305 
performed in vitro co-cultivation of R. intestinalis and the efficient -mannan 306 
degrader Bacteroides ovatus ATCC 848330. Both bacteria showed similar growth 307 
rates in individual cultures supplemented with AcGGM (Fig. 6a). Population 308 
estimates using qPCR indicated that, in the mixed cultures, both B. ovatus and R.309 
intestinalis grew well during the exponential growth phase, suggesting that the 310 
bacteria shared the available carbon source and maintained coexistence. (Fig. 6b). 311 
During the stationary phase, when glycan availability is limited, the mean relative 312 
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abundance of R. intestinalis and B. ovatus in the culture was approximately 72.5% 313 
versus 27.5%, respectively. In contrast, R. intestinalis showed slow growth on 314 
mannose (Fig. 6c) and was outcompeted when co-cultured in this carbon source with 315 
B. ovatus (Fig. 6d). 316 
R. intestinalis responds rapidly to -mannan supplementation. To elucidate 317 
whether dietary supplementation of -mannan can result in expansion of key gut 318 
bacteria able to utilize this hemicellulose, germfree mice were colonized with a 319 
synthetic microbiota composed of 14 sequenced strains of human commensal gut 320 
bacteria42. Colonized mice were fed a high-fiber diet for 14 days before being 321 
switched to a series of diet regimes with a varying amount of AcGGM (Fig. 6e). 322 
Overall, the levels of four species (R. intestinalis, Bacteroides uniformis, B. ovatus 323 
and Marvinbryantia formatexigens) gradually increased at both AcGGM doses (Fig. 324 
6f - i) and these strains were able to suppress the bacteria foraging on the glyco-325 
protein rich mucus layer (Akkermansia muciniphila, Bacteroides caccae, Bacteroides 326 
thetaiotamicron, Bacteroides intestinihominis) (Fig. 6e and 6j-m) and the amino acids 327 
degraders (E. coli, Clostridium symbiosum and Collinsella aerofaciens) (Fig. 6e and 328 
6n).  Upon feeding of a fiber-deficient diet, the fecal bacterial abundance of the 329 
mucin-eroding bacteria, the sulfate-reducer Desulfovibrio piger and the three amino 330 
acid degraders (Fig. 6e) rapidly increased with a corresponding decline of the fiber-331 
degrading species.  332 
DISCUSSION 333 
-Mannans are widely present in the human diet as constituents of hemicellulose in 334 
beans, some nuts and food additives, but are recalcitrant to intestinal digestion by 335 
host enzymes. These glycans instead serve as a carbon source for mannanolytic 336 
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bacteria in the distal gastrointestinal tract, primarily Firmicutes and Bacteroidetes. 337 
Recent studies have characterized a few enzymes encoded by two polysaccharide 338 
utilization loci (PULs) implicated in the metabolism of galactomannan in B.339 
ovatus30,43 and homopolymeric mannan in Bacteroides fragilis32. To date, a full 340 
understanding of -mannan utilization by Firmicutes, however, remains341 
underexplored. The human gut butyrate-producing Firmicute R. intestinalis has 342 
previously been shown to utilize galactomannan and glucomannan as a carbon 343 
source42 and possesses predicted genes for the utilization of these substrates24. 344 
However, no data are available relating the mannanolytic activity at a biochemical 345 
level. In this study, we show that two conserved loci, MULL and MULS, collectively 346 
provide R. intestinalis the capacity to depolymerize this plant polysaccharide. 347 
Detailed biochemical studies of the encoded enzymes allowed us to construct a 348 
model of sequential action for the mannan utilization system encoded by MULL-349 
MULS (Fig. 7). The RiGH26 and the mannan ABC uptake system components 350 
RiMnBP/RiMPP1/RiMPP2 transcripts and proteins were the most upregulated in 351 
both the RNA sequencing and proteomic analyses, respectively (Fig. 2c and Fig. 2e). 352 
This highlights the crucial role of this endomannanase and the ABC transport system 353 
in the -mannan metabolic pathway. RiGH26 is the only enzyme displayed on the354 
cell surface (Fig. 3), allowing direct access to the intact -mannan polymers through355 
dynamic capture mediated by two appended carbohydrate binding modules 356 
(RiCBMs). The SPR data showed that RiCBM23 displays approximately 7- and 5-357 
fold higher affinity for M3 and M4, respectively, than RiCBM27, suggesting that the 358 
two CBMs play different roles to mediate binding of RiGH26 to mannans. The 359 
RiCBMs Kd values for the preferred manno-oligosaccharides were in the 100 200 360 
µM range (Table 1). This moderate affinity to the bound substrate constitutes an 361 
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advantage as it has lower impact on the catalytic activity compared to canonical 362 
counterparts from other organisms, and suggests an evolutionary adaptation of R.363 
intestinalis to compete with other microbial enzymes with canonical higher- affinity 364 
CBMs, but with reduced catalytic rates44. Reliance on multi-modular cell-wall 365 
anchored enzymes is a common feature in Firmicutes45; consistently, RiGH26 366 
organization was primarily found in -mannanase from other Roseburia species and 367 
members of the Clostridium cluster XIVa (Supplementary Fig. 4, Supplementary 368 
Table 3-5). Multiplicity of CBMs provides a contrast with the system for mannan 369 
metabolism in Bacteroides ovatus30,43, where the binding and catalytic activity are 370 
distributed between two surface located binding proteins and the single domain 371 
mannanase BoMan26B. 372 
Collectively, our results point to a model in which the smaller manno-373 
oligosaccharides generated by RiGH26 are imported through a dedicated -mannan 374 
transport system consisting of RiMnBP/RiMPP1/RiMPP2 (Fig. 7). In the cytoplasm, 375 
acetylated and galactosylated manno-oligosaccharides are systematically 376 
debranched by RiCE2, RiCEX and RiGH36, and subsequently depolymerized. 377 
Removal of glucose units from glucomannan-oligosaccharides is carried out by 378 
RiGH3A and RiGH3B. Based on the highest transcriptional and protein regulation, 379 
the main depolymerization strategy for breakdown of unsubstituted manno-380 
oligosaccharides is mediated by the activity of two synergistic mannoside 381 
phosphorylases (RiGH130_2 and RiGH130_1) and an epimerase (RiMep), similar to 382 
the mannan catabolic pathway proposed in the ruminal bacterium Ruminococcus 383 
albus46. A similar system has been reported in B. fragilis32 and B. ovatus30, although 384 
only composed of an epimerase and a mannosylglucose phosphorylase (GH130_1) 385 
that, together, process GH26s-generated M2 units. The presence of the manno-386 
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oligosaccharide phosphorylases RiGH130_2 allows R. intestinalis to process 387 
undecorated manno-oligosaccharide of DP >2, consistent with the internalization of 388 
large manno-oligosaccharides generated by RiGH26-hydrolysis of polymeric 389 
mannan. However, GH130_2s mainly catalyze the phosphorolysis of undecorated 390 
manno-oligosaccharides47. Removal of mannose units from substituted substrates is 391 
mediated by the reducing end mannose-releasing exo-oligomannosidase RiGH113, 392 
which displays a previously undescribed specificity. The two different approaches 393 
based on the phosphorylases and the GH113 are likely to be a functional adaptation 394 
to accelerate the depolymerization process of mannan. Eventually, mannan 395 
catabolism fuels monosaccharide fermentation via glycolysis and leads to the 396 
production of butyrate, which is the primary energy source for host colonocytes5,48. 397 
Colonocytes oxidize butyrate to carbon dioxide49, thereby keeping the epithelium 398 
hypoxic (<1% O2). This condition promotes gut homeostasis by stabilizing the 399 
hypoxia-inducible transcription HIF that coordinates barrier protection in the 400 
mucosa50,51. Recently, it has been shown that antibiotic-mediated depletion of 401 
butyrate-producing Clostridia increases colonocytes oxygenation and drives aerobic 402 
pathogen expansion in the gut lumen, resulting in Salmonella enterica-induced 403 
gastroenteritis52. Importantly, R. intestinalis has been found to affect host histone 404 
epigenetic states, direct colonic epithelial cells metabolism away from glycolysis and 405 
towards fatty acid metabolism, reduce the levels of inflammatory markers and 406 
ameliorate atheriosclerosis in a diet-dependent fashion18. The athero-protective 407 
effect was in part attributed to butyrate, as this SCFA has been shown to inhibit key 408 
inflammatory pathways involved in cardiovascular disease development18.  409 
The absence of oligosaccharides from R. intestinalis AcGGM-spent supernatant 410 
(Supplementary Fig. 1a-b) demonstrates that the -mannan degradation apparatus 411 
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is optimized for efficient uptake of all the products released by RiGH26, maximize 412 
intracellular breakdown and avoid nutrient leakage. This will limit the access to other 413 
bacteria, such as Bacteroides spp., competing for the same resource. Using 414 
AcGGM, we have shown that R. intestinalis and B. ovatus, which possesses an 415 
equally complex -mannan degrading system, shared the available resources and 416 
maintained coexistence (Fig. 6b). Notably, R. intestinalis outcompeted B. ovatus in 417 
the late exponential and stationary phase of growth; these results show that R. 418 
intestinalis is capable to bind and import the remaining -mannan breakdown 419 
products (preferred by the RiMnBP transport protein) more efficiently than B. ovatus. 420 
Thus, it is likely that the -mannan utilization apparatus provides R. intestinalis with a 421 
selective advantage during nutrient limitation when microbial competition for the 422 
available carbohydrates in the gut is intense. Understanding the mechanism by 423 
which -mannan is degraded by key commensal members of the gut is crucial to 424 
designing intervention strategies through the use of targeted prebiotics which aim to 425 
program or reprogram the composition of the microbiota to maximize human health. 426 
Our in vivo study demonstrates that a diet supplemented with AcGGM can be used 427 
to manipulate the gut microbiota and to facilitate the growth of species equipped with 428 
a -mannan degrading system, including R. intestinalis (Fig. 6e). This is supported 429 
by the increase in the relative abundance of R. intestinalis, B. uniformis and B. 430 
ovatus, which all possess enzymes able to degrade AcGGM (BACUNI_00371 - 431 
BACUNI_00383; BACOVA_02087-02097 and BACOVA_03386-03406 respectively). 432 
R. intestinalis was highly responsive to the AcGGM within a day, with a 10 to 30 fold 433 
increase at the 2.5% and 7.5% AcGGM diet, corroborating its ability to respond 434 
dynamically to variation in this dietary fiber. Intriguingly, R. intestinalis response did 435 
not last over the 7 day feeding treatment and the acetogen M. formatexigens 436 
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seemed to replace it. A cluster of genes with predicted functions in -manno-437 
oligosaccharide utilization (BRYFOR_07194- BRYFOR_07206) was identified in the 438 
genome of M. formatexigens (Supplementary Fig.17a). The results shown in 439 
Supplementary Fig. 17b-d suggest that R. intestinalis and M. formatexigens occupy 440 
different metabolic niches in the distal gut; the former consumes complex -441 
mannans, whereas the acetogen feasts on mono- and oligosaccharides. When in co-442 
culture with either R. intestinalis or B. ovatus, M. formatexigens was outcompeted in443 
vitro (Supplementary Fig. 17e-f). A previous study with gnotobiotic mice bi-444 
associated with the prominent saccharolytic bacterium B. thetaiotamicron and M. 445 
formatexigens showed that the presence of M. formatexigens caused a decrease in 446 
the cecal levels of B. thetaiotaomicron, compared with mono-associated controls. 447 
Transcriptional and metabolic analyses demonstrated that M. formatexigens is 448 
capable of consuming a variety of plant-derived oligosaccharides and microbial and 449 
host-derived N-glycans (such as N-acetylglucosamine), suggesting that this ability 450 
could confer a fitness advantage when competing with the glycan-consuming 451 
Bacteroides53. Thus, it is likely that, when present as part of the synthetic microbial 452 
community described in this paper, M. formatexigens may be indirectly benefiting of 453 
either manno-oligosaccharides feeding/cross-feeding with other microorganisms or 454 
by its ability to grow mixotrophically, simultaneously utilizing organic carbon sources 455 
and formate or H2 for energy53. Notably, M. formatexigens outcompeted B. ovatus at 456 
the 7.5% AcGGM diet, underscoring the competitiveness of this acetogen in a 457 
community setting. In the context of a complex microbial community, it is likely that 458 
M. formatexigens makes an important contribution to host nutrition improving 459 
fermentation by acting as a formate or H2 sink and by generating acetate as main 460 
metabolic product 53. 461 
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Collectively, diet-induced changes involved the promotion of mannanolytic bacteria 462 
producing propionate, acetate and butyrate, metabolites that are known to regulate 463 
hepatic lipid, glucose homeostasis and health of the intestinal hepithelium11. These 464 
SCFA-producers gained a competitive advantage over colonic mucin-degrading 465 
bacteria. Given that intermittent dietary fiber-deprivation results in a thinner mucus 466 
layer in mice, eventually enhancing pathogen susceptibility42, our results support the 467 
concept that -mannan-based interventions not only could contribute to preventing 468 
mucus barrier dysfunctions but also maintaining a gut environment that keeps 469 
pathogenic bacteria away. If confirmed in humans, these findings may help to 470 
prevent diseases affecting the integrity of the colonic mucus layer, such as ulcerative 471 
colitis54. Indeed, the fact that the -mannan degradation pathway is a core trait found 472 
in the majority of the human gut microbiota55 highlights the relevance of potential 473 
therapeutic interventions through the use of -mannan formulations to the general 474 
population.  475 
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METHODS 476 
Glycans. Carbohydrate substrates used in this study are listed in Supplementary 477 
Table 6. All glycan stocks were prepared at 10 mg ml-1 in ddH2O and sterilized by 478 
filtration using a 0.22 µm membrane filter (Sarstedt AG & Co, Germany). 479 
Bacterial Strains and Growth Conditions. Unless otherwise stated, R. intestinalis 480 
L1-8223 was routinely grown at 37 °C without agitation in an anaerobic cabinet 481 
(Whitley A95 workstation, Don Whitley, UK) under an 85% N2/ 10% H2/ 5% CO2482 
atmosphere. Growth experiments were carried out in YCFA medium (YCFA - Yeast 483 
extract-Casein hydrolysate-Fatty Acids)56 supplemented with 0.5 % (w/v) of the 484 
specific carbohydrate to be examined. Overnight cultures (300 µl) were used to 485 
inoculate 30 ml aliquots of YCFA plus the carbohydrate to be tested. These pre-486 
cultures were passaged at least three times on the same media to ensure cell growth 487 
adaptation on a single carbon source prior to inoculation of the final cultures for 488 
growth experiments, RNA-sequencing and proteomic analysis. Bacterial growth was 489 
determined spectrophotochemically by monitoring changes in the optical density at 490 
600 nm (OD600). In addition, growth on turbid substrates was assessed by measuring 491 
differences in pH compared to that of starting medium. Growth and pH curves are 492 
averages of three biological replicates, with two technical replicates each. Routine 493 
culturing of Bacteroides ovatus ATCC 8483 and M. formatexigens DSM 14469 was 494 
in anaerobic Chopped Meat Medium57 under static conditions at 37 °C. 495 
Transcriptomic Analysis by RNA Sequencing. R. intestinalis was cultured in 496 
triplicate on YCFA supplemented with 0.5% (w/v) glucose, galactose, KGM or 497 
AcGGM as described above. Cells were harvested at mid-exponential phase and 498 
RNA was extracted using the RNeasy Mini Kit (Quiagen) according to the 499 
manufacturers instructions. RNA-seq libraries were prepared using the ScriptSeq 500 
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Complete kit from Epicentre. Samples were paired-end sequenced on an Illumina 501 
Hiseq 4000 instrument at Beijing Genomics Institute (BGI). Analysis of the RNA-seq 502 
results was performed exactly as described in25. Differential gene expression 503 
analysis was performed with the DeSeq2 package58.  504 
Cloning, Overexpression, and Protein Purification. The genes encoding mature 505 
forms of the proteins described in this study were amplified from the R. intestinalis 506 
L1-82 genomic DNA (BioProject accession number PRJNA30005 507 
[https://www.ncbi.nlm.nih.gov/bioproject/PRJNA30005]) by PCR, using appropriate 508 
primers (Supplementary Table 7). PCR products were generated using the Q5 High-509 
Fidelity DNA Polymerase (New England BioLabs, United Kingdom) with 50 ng DNA 510 
as template. Prior to cloning the DNA fragment encoding RiGH1_D2 511 
(ROSINTL182_05469), sequence ambiguities at the 3-end of ROSINTL182_05470 512 
were corrected through sequencing the PCR product generated with the primers 513 
listed in the Supplementary Table 8. The gene ROSINTL182_07683 was synthesized 514 
without the N-terminal signal sequence predicted by SignalP v.4.159 (residues 1-27 515 
from transcription start). The PCR amplicons were cloned into the pNIC-CH 516 
expression vector by ligation-independent cloning (LIC)60. The gene encoding 517 
RiMnbp (ROSINTL182_05479) was cloned in the vector pETM-11 following the 518 
method described elsewhere25. Recombinant proteins generally contained a C-519 
terminal His6-tag, although, in some cases, His-tag translation was prevented by the 520 
introduction of one or two stop codons at the end of the open-reading frame (RiMep, 521 
RiGH36, RiPgm and RiGH113). The His6-tag was excluded to prevent interaction 522 
with putative C-terminal active or catalytic residues that could be detrimental to the 523 
enzymes activity. Constructs were verified by sequencing (Eurofins, UK). Proteins 524 
were produced in E. coli BL21 Star (DE3) cells (Invitrogen) as previously 525 
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described61. Briefly, cells were cultured to mid-exponential phase in Tryptone Yeast 526 
extract (TYG) containing 50 mg ml-1 kanamycin at 25 °C. Protein overexpression 527 
was induced by adding isopropyl -D-thiogalactopyranoside (IPTG) to a final 528 
concentration of 200 M, followed by incubation for a further 16 h at 25 °C. Cells 529 
were harvested by centrifugation, sonicated and recombinant proteins were purified 530 
by either immobilized metal ion affinity chromatography (IMAC) or hydrophobic 531 
interaction chromatography (HIC). For IMAC purification, the clarified cell lysate was 532 
loaded onto 5 ml HisTrap HP Ni Sepharose columns (GE Healthcare) connected to 533 
an ÄKTA purifier FPLC system (GE Healthcare). Protein elution was achieved by 534 
using a linear gradient from 5 to 500 mM imidazole RiGH113, RiGH36, RiMep and 535 
RiPgm were purified by HIC by loading the cell-free broth, adjusted to buffer A (1.5 M 536 
ammonium sulfate), onto a 5 ml HiTrap Phenyl FF (GE Healthcare) equilibrated with 537 
the same buffer. Protein was eluted by using a linear reverse gradient to 100 mM 538 
NaCl over 90 min at a flow rate of 2.5 ml min-1. After IMAC and HIC, samples were 539 
concentrated and further purified by Size Exclusion Chromatography (SEC) using a 540 
HiLoad 16/60 Superdex G75 size exclusion column (GE Healthcare) and a running 541 
buffer consisting of 20 mM Tris-HCl pH 8.0 with 200 mM NaCl. Fractions containing 542 
the pure protein were combined, concentrated and buffer exchanged to 20 mM Tris 543 
pH 8.0 using a Vivaspin 20 (10-kDa molecular weight cutoff) centrifugal 544 
concentrators (Sartorius Stedim Biotech GmbH, Germany). Protein purity was 545 
estimated to be over 95% for all the enzymes using SDS-PAGE. Protein 546 
concentrations were determined using the Bradford assay (Bio-Rad, Germany). 547 
Glycoside Hydrolase and Phosphorylase Activity Assays. Enzyme assays, 548 
unless otherwise stated, were carried out in 10 mM sodium phosphate buffer, pH 549 
5.8, for up to 16 h at 37 °C and 700 rpm. Reactions with RiGH130_1 and 550 
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RiGH130_2 were prepared in 100 mM sodium phosphate buffer, pH 5.8. The activity 551 
of RiPgm against M1P and G1P was tested in 10 mM sodium phosphate buffer, pH 552 
5.8, supplemented with 1 mM MgCl2. To determine the specificity of RiGH113, the 553 
recombinant protein was sequentially incubated with 0.1 mg ml-1 pre- reduced or 554 
oxidized manno-oligosaccharides at 37 °C overnight. Reduction of manno-555 
oligosaccharides was conducted by incubating 1 mg ml-1 manno-oligosaccharides in 556 
a volume of 75 l with sodium borodeuteride (NaBD4; 0.5 M in 100 mM NaOH) 557 
solution. The reaction was incubated overnight at room temperature then quenched 558 
by adding 25 µl of 25 mM sodium acetate. Oxidation of manno-oligosaccharides 559 
reducing-end was obtained by incubating the substrates (1 mg ml-1) withthe 560 
Neurospora crassa cellobiose dehydrogenase (NcCDH) overnight at 37 °C. Both 561 
NaBD4 and NcCDH pretreated samples were diluted 10X in standard assay buffer 562 
before addition of RiGH113. Between three and five independent experiments were 563 
performed to determine the enzyme activities.  564 
MALDI-TOF Mass Spectrometry of Reaction Products. Reaction products 565 
generated by the enzymes used in this study were analyzed by matrix-assisted laser 566 
desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) as 567 
described previously62. Briefly, 2 µl of a matrix, consisting of 9% 2,5-568 
dihydroxybenzoic acid (DHB) in 30% acetonitrile, were applied to an MTP 384 569 
ground steel target plate TF (Bruker Daltonics, Germany). Sample (1 µl) was then 570 
mixed with the matrix and dried under a stream of warm air. Samples were analyzed 571 
with an Ultraflex MALDI-ToF/ToF instrument (Bruker Daltonics, Germany), equipped 572 
with a Nitrogen 337 nm laser beam and operated in positive acquisition mode. 573 
Results were analyzed using the Bruker FlexAnalysis software (version 3.3). 574 
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HPAEC-PAD. Mono- and oligosaccharides products were analyzed on a Dionex 575 
ICS-3000 HPAEC system operated by the Chromeleon software version 7 (Dionex, 576 
Thermo Scientific), as described previously62. Sugars were injected onto a CarboPac 577 
PA1 2×250-mm analytical column (Dionex, Thermo Scientific) coupled to a 578 
CarboPac PA1 2×50-mm guard column kept at 30 °C. Manno-oligosaccharides and 579 
phosphorylated monosaccharides were eluted in 0.1 M NaOH at a flow rate of 0.25 580 
ml min-1 by increasing the concentration of sodium acetate (NaOAc) exponentially 581 
from 0 to 0.3 M over 26 min (from 9 to 35 min after injection), before column 582 
reconditioning by 0.1 M NaOH for 10 min. Commercial manno-oligosaccharides with 583 
DP2 6 were used as standards. For cello-oligosaccharides, the separation was done 584 
using a multistep linear gradient going from 0.1 M NaOH to 0.1 M NaOH0.1 M 585 
NaOAc over 10 min, 0.1 M NaOH0.14 M NaOAc after 14 min, 0.1 M NaOH0.3 M 586 
NaOAc at 16 min followed by a 2 min exponential gradient to 1 M NaOAc, before 587 
reconditioning with 0.1 M NaOH for 9 min. Cellooligosaccharides with DP 26 were 588 
used as standards. For the analysis of disaccharides (G1M1 or M1G1) and 589 
phosphorylated monosaccharides generated from the activity of RiGH130_2, RiMep, 590 
RiGH130_1, RiPgm and RiGH1, the elution was done at 0.25 ml min-1 using a 40 591 
min program. The program started with 0.01 M potassium hydroxide (KOH) for 15 592 
min, reaching the concentration of 0.1 M KOH at 25 min after injection and was kept 593 
for additional 5 min at the same KOH concentration. Between each sample, the 594 
column was re-equilibrated by running initial conditions for 10 min.  595 
Protein Cellular Localization. Proteins of interest were detected using anti-sera 596 
raised in rats (Eurogentec) against the corresponding recombinant RiGH26 or the 597 
previously characterized RiXyn10A25. 598 
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For immunofluorescence microscopy, R. intestinalis cells were grown in YCFA 599 
containing 0.5% AcGGM, wheat arabinoxylan (WAX) or glucose to an OD600 of 0.8, 600 
collected by centrifugation (4,000 x g for 5 min) and washed twice in phosphate 601 
buffered saline (PBS). Cells were resuspended in 500 µl PBS and fixed by adding an 602 
equal volume of 2 X formalin (9% formaldehyde in PBS) on ice for 30 min. The 603 
bacterial pellet was washed twice with 1 ml PBS prior to resuspension in 1 ml of 604 
blocking buffer (1% bovine serum albumin, BSA, in PBS) and incubation at 4 °C for 605 
16 h. After incubation the cell pellets were harvested by centrifugation and the 606 
supernatant discarded. For labelling, the bacteria were incubated with 0.5 ml of anti-607 
sera (diluted 1:500 in blocking buffer) for 2 h at 25 °C. The cells were then pelleted, 608 
washed with 1 ml PBS and resuspended in 0.5 ml goat anti-rat IgG Alexa-Fluor 488 609 
(Sigma-Aldrich), diluted 1:500 in blocking buffer and incubated 1 h at 25 °C. The 610 
cells were again harvested, washed with 1 ml PBS and suspended in 100 µl PBS 611 
containing  one drop of ProLong Gold antifade reagent (Life Technologies). Labeled 612 
bacterial cells were mounted onto glass slides and secured with coverslips. 613 
Fluorescence microscopy was performed on a Zeiss AxioObserver equipped with the 614 
ZEN Blue software. Images were acquired using an ORCA-Flash4.0 V2 Digital 615 
CMOS camera (Hamamatsu Photonics) through a 100x phase-contrast objective. A 616 
HXP 120 Illuminator (Zeiss) was used as a fluorescence light source. 617 
Analysis of the Bacterial Proteome. 618 
R. intestinalis was grown in triplicate on YCFA supplemented with either 0.5 % (w/v) 619 
glucose or AcGGM, respectively, as a sole carbon source. Samples (10 ml) were 620 
harvested at the mid-exponential growth phase. Cell pellet was collected by 621 
centrifugation (4,500 x g, 10 min, 4 °C), resuspended in 50 mM Tris-HCl, 0.1% (v/v) 622 
Triton X-100, 200 mM NaCl, 1 mM dithiothreitol and disrupted by bead-beating using 623 
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three 60s cycles with a FastPrep24 (MP Biomedicals, CA). Proteins were 624 
precipitated with ice-cold trichloroacetic acid (TCA), final concentration of 10% (v/v), 625 
incubated on ice for 1 h, centrifuged (15,000 × g, 15 min, 4 °C) to pellet the 626 
precipitated proteins and washed with 300 l ice-cold 0.01 M HCl in 90% acetone. 627 
Proteins were separated by SDS-PAGE with a 10% Mini-PROTEAN gel (Bio-Rad 628 
Laboratories, CA) and then stained with Coomassie brilliant blue R250. The gel was 629 
cut into five slices, after which proteins were reduced, alkylated, and in-gel digested 630 
according to a method published previously63. The peptides were dried under 631 
vacuum, solubilized in 0.1% (v/v) trifluoroacetic acid (TFA) and desalted using C18 632 
ZipTips (Merck Millipore, Germany) according to the manufacturers instructions.  633 
The peptide mixture from each fraction was analyzed using a nanoHPLC-MS/MS 634 
system as described previously63, using a Q-Exactive hybrid quadrupole-orbitrap 635 
mass spectrometer (Thermo Scientific) equipped with a nano-electrospray ion 636 
source. Mass spectral data were acquired using Xcalibur (v.2.2 SP1). 637 
MS raw files were processed with the MaxQuant software suite64 (version 1.4.1.2) for 638 
identification and label-free quantification (LFQ) of proteins. Proteins were identified 639 
by searching MS and MS/MS data of peptides against the UniProtKB complete 640 
proteome of R. intestinalis L1-82 (4,698 sequences) supplemented with common 641 
contaminants (e.g. keratins, trypsin, and bovine serum albumin). In addition, 642 
reversed sequences of all protein entries were concatenated to the database for 643 
estimation of false-discovery rates (FDRs). Trypsin was set as proteolytic enzyme 644 
and two missed cleavages were allowed. Protein N-terminal acetylation, oxidation of 645 
methionines, deamidation of asparagines and glutamines and formation of pyro-646 
glutamic acid at N-terminal glutamines were defined as variable modifications while 647 
carbamidomethylation of cysteines was used as a fixed modification. The match 648 
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between runs feature of MaxQuant, which enables identification transfer only 649 
between samples from the same carbon source based on accurate mass and 650 
retention time, was applied with default parameters. All identifications were filtered in 651 
order to achieve a protein false discovery rate (FDR) of 1%. A protein was 652 
considered present if it was detected in at least two of the three biological 653 
replicates in at least one glycan substrate. Missing values were imputed from a 654 
normal distribution (width of 0.3 and down shifted 1.8 standard deviations from the 655 
original distribution) in total matrix mode and differential abundance analysis was 656 
performed using an unpaired two-tailed Students t-test with a permutation-based 657 
FDR set to 0.05. Hierarchical clustering and heat map representations were 658 
generated using Euclidean distance measure and average linkage using Perseus65 659 
(version 1.5.5.3).  660 
Substrate Binding Assay using SPR. The affinity of RiCBM27 and RiCBM23 to 661 
soluble manno- and cello-oligosaccharides was evaluated by SPR using a Biacore 662 
T100 (GE Healthcare). The two CBMs, diluted into 10 mM sodium acetate (pH 4.1) 663 
to 2.3 M, were immobilized on a NTA sensor chip (GE Healthcare) to a density of 664 
3000 4000 response units (RU). Sensograms were recorded at 25 °C in 665 
phosphate/citrate buffer (20 mM phosphate/citrate buffer; 150 mM NaCl; pH 6.5, 666 
0.005% (v/v) P20 surfactant) at 30 l per min with association and dissociation times 667 
of 90 s and 240 s, respectively. CBMs binding was tested towards 0.2 nM  1 mM of 668 
carbohydrate ligands dissolved in the same buffer as above. Data were analyzed 669 
using the Biacore T100 evaluation software, and equilibrium dissociation constants 670 
(Kd) were obtained by fitting a single-site binding model to either the steady-state 671 
response data or the full sensograms.  672 
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ITC. Binding of manno-oligosaccharides to RiMnBP was measured at 25 °C in 10 673 
mM sodium phosphate pH 6.5 using an ITC200 microcalorimeter (MicroCal). RiMnBP 674 
in the sample cell was titrated by 19 injections of carbohydrate ligand separated by 675 
120 s. The following concentrations were used:   900 µM of M3 in the syringe and 676 
76.5 µM RiMnBP in the sample cell; 1365 µM of M4 or M5 in the syringe and 91 µM 677 
RiMnBP in the sample cell; 2270 µM of M6 in the syringe and 117 µM RiMnBP in the 678 
sample cell; 750 µM of diacetylated mannotetraose (M4Ac2) in the syringe and 50 µM 679 
RiMnBP in the cell; 1500 µM of diacetylated mannopentaose (M5Ac2) in the syringe 680 
and 100 µM RiMnBP in the cell. Thermodynamic binding parameters were 681 
determined using the MicroCal Origin software (version 7.0). 682 
Competition experiments. R. intestinalis, B. ovatus and M. formatexigens cells 683 
were grown overnight under anaerobic conditions in YCFA containing 0.5% (w/v) 684 
AcGGM (YCFA-AcGGM) as the sole carbon source. These subcultures were used to 685 
inoculate, in approximately equal proportions (estimated by OD600), 30 ml of the 686 
same medium. A control culture of YCFA-AcGGM was also inoculated with either R.687 
intestinalis, B. ovatus or M. formatexigens. Growth (OD600) was monitored for up to 688 
24 h, withdrawing 1 ml samples for quantitative PCR (qPCR) analysis at selected 689 
time points. Cells were pelleted, combined with 200 l of TE buffer (pH 7.8) and 690 
bead-beated for 2 min (FastPrep96, MP Biomedicals, CA) using 106 m acid-691 
washed glass beads (Sigma-Aldrich). Genomic DNA was extracted using the Mag 692 
Midi kit (LGC Group, UK) according to the manufacturers instructions. qPCR was 693 
performed in a LightCycler 480 II system (Roche, Germany) using specific primers 694 
for each strain (Supplementary Table 9). In addition, a High-Resolution Melting 695 
(HRM) analysis was conducted to evaluate the specificity of the amplification and the 696 
lack of primer dimers. The raw data were imported into the LinReg PCR program66 697 
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and the calculated Cq values and PCR efficiency were used to deduce the ratio of R.698 
intestinalis, B. ovatus and M. formatexigens at each time point. Statistically 699 
significant differences were determined using the unpaired two-tailed Students t-700 
test. 701 
Human Gut Microbiota-associated Mice and Diets. All experiments involving 702 
animals complied with all relevant ethical regulations for animal testing and 703 
research and were approved by the University of Michigan, University Committee for 704 
the Use and Care of Animals. Germfree mice were colonized with a synthetic 705 
microbiota composed of 14 fully sequenced human species according to the 706 
methodology previously adopted by Desai et al42. Briefly, seven 6-week-old germfree 707 
male wild-type Swiss Webster mice that had been raised on ad libitum access to a 708 
high fiber chow diet (LabDiet 5013) and autoclaved distilled water were gavaged for 709 
3 consecutive days with 200 µl each day of a mixture of the 14 different species. 710 
Colonized mice were maintained on this high fiber diet for 14 days before being 711 
switched to a series of diet regimes with varying fibers. This feeding sequence 712 
consisted of 7 days of feeding on a gamma-irradiated Fiber-Free (FF) diet 713 
(TD.140343, Harlan Teklad, USA) that does not contain AcGGM or related 714 
molecules.  Mice were then switched for 7 days to a custom version of the same diet 715 
that contained AcGGM at 2.5% w/w, followed by a 7-day washout period on the FF 716 
diet, and finally 7 days of feeding on a version of this diet containing AcGGM at 7.5% 717 
w/w (in both AcGGM diets an equivalent amount of glucose was removed to 718 
accommodate the prebiotic addition). Fecal samples were taken 1 day before and 1 719 
day after each diet transition, effectively allowing us to measure changes in response 720 
to AcGGM supplementation at 1 and 7 days post exposure relative to the FF diet. 721 
The relative abundance of each microbial strain at sampled time points was 722 
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measured by qPCR, using previously validated primer sets, from total DNA extracted 723 
from freshly voided fecal pellets (stored at -20 °C until extraction) exactly as 724 
described previously42. Statistically significant differences were determined using the 725 
unpaired two-tailed Students t-test. 726 
Comparative Genomic Analysis. Identification of similar -mannan catabolic genes 727 
in bacteria belonging to the Clostridium XIVa cluster was performed using the Gene 728 
Ortholog Neighbourhood viewer on the Integrated Microbial Genomes website 729 
(https://img.jgi.doe.gov). This was done using the genes encoding RiGH26 730 
(ROSINTL182_07683, GenBank ABYJ02000124.1:7167-11129) and RiMEP 731 
(ROSINTL182_05476, GenBank ABYJ02000025.1:3200-4429) as the search 732 
homolog and the default threshold e-value of 1e-5. Then, a sequence comparison 733 
was conducted where each R. intestinalis L1-82 RefSeq annotated protein sequence 734 
was subjected to BLASTp searches against other Clostridium XIVa members. 735 
Sequences with coverage <60% and amino acid similarity <45% were excluded. 736 
Data Availability. All data supporting the findings of this study are available within 737 
the article and Supplementary Information, or from the corresponding author upon 738 
request. The transcriptomic data described in this article are submitted under NCBI 739 
BioProject accession number PRJNA516396. The mass spectrometry proteomics 740 
data have been deposited to the ProteomeXchange Consortium via the PRIDE 741 
partner repository with the dataset identifier PXD012448.742 
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FIGURE LEGENDS 968 
Figure 1. General structure of the main classes of -mannan. Linear969 
homopolymeric (upper structure) and linear heteropolymeric (lower three structures) 970 
-mannans are shown. Monosaccharides (D-mannose, green circle; D-glucose, blue971 
circle; D-galactose, yellow circle) and acetylations (2Ac, 2-O-Acetyl; 3Ac, 3-O-Acetyl; 972 
6Ac, 6-O-Acetyl) are represented using the standard Consortium of Functional 973 
Glycomics symbols67. Abbreviations: NR end, non-reducing end; R end, reducing 974 
end. 975 
Figure 2. R. intestinalis upregulates several glycoside hydrolases, two 976 
carbohydrate esterases and an ABC-transporter during -mannan977 
consumption. a, Growth curves of R. intestinalis in YCFA without carbon source 978 
(black) or supplemented with 0.5% of either glucose (Glc, green circles), KGM (blue 979 
circles), CGM (purple circles) or AcGGM (red circles). b, pH measurements during 980 
R. intestinalis growth on Glc and -mannans. In panel a and b, each point on the981 
curves represent the average of three independent experiments. Error bars 982 
represent standard deviations (s.d.). c, RNA expression profile of putative -mannan983 
utilization genes during R. intestinalis L1-82 growth in YCFA supplemented with 984 
0.5% KGM (blue bars) or AcGGM (red bars). The Log2-fold change relative to cells 985 
cultured on YCFA-Glc is shown on the y-axis while the x-axis shows the putative 986 
genes involved in -mannan catabolism. d, Genomic organization of the large and987 
small -mannan utilization loci (MULL and MULS, respectively) from R. intestinalis.988 
Genes with similar predicted functions are coded by the same color. e, Heat map 989 
showing the proteomic detection of relevant proteins with predicted -mannan990 
utilization functions in triplicate samples (1 3) grown on YCFA-Glc and YCFA-991 
AcGGM. Colors represent protein intensity expressed as Log2 of LFQ values; the 992 
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color gradient ranges from 14 (green) to 34 (magenta), with black indicating 24. In 993 
panels c, d and e, locus tag numbers ROSINTL182_XXXXX are abbreviated with the 994 
last numbers after the hyphen. 995 
Figure 3. Cellular location of the endomannanase RiGH26. a, Fluorescent 996 
microscopy images of R. intestinalis cells  cultured on AcGGM or Glc and incubated 997 
with polyclonal antibodies raised against the recombinant endomannanase RiGH26. 998 
Glucose-grown cells exhibit a low intensity fluorescence signal; this is consistent with 999 
the results of the proteomics data showing that, when the organism is cultured on 1000 
glucose, RiGH26 is expressed at basal levels. b, Fluorescent microscopy images of 1001 
R. intestinalis cells grown on WAX (positive control) and incubated with antibodies1002 
raised against the known surface endoxylanase RiXyn10A25. Localization 1003 
microscopy images are representative data from two biological duplicates. 1004 
Figure 4. Cleavage of the -mannans backbone, removal of the side chains and1005 
further depolymerization of the resulting linear manno-oligosaccharides. a, 1006 
HPAEC chromatograms showing the oligosaccharide products after overnight 1007 
digestion of KGM, CGM and AcGGM with RiGH26. Samples were analyzed with the 1008 
following manno-oligosaccharides as external standards: M2, mannobiose; M3, 1009 
mannotriose; M4, mannotetraose; M5, mannopentaose; M6, mannohexaose. b, 1010 
MALDI-TOF analysis of RiGH26-digested AcGGM incubated with either RiCE2, 1011 
RiCEX or both enzymes. Peaks are labeled by DP and number of acetyl groups (Ac). 1012 
c, HPAEC chromatograms showing products generated from CGM pre-digested with 1013 
RiGH26 and subsequently treated with RiGH36. Assignments for peaks not 1014 
occurring in the standard samples are based on comparison with the product profiles 1015 
obtained by MALDI-TOF MS of RiGH26-digested CGM (black spectrum) treated with 1016 
galactose oxidase (GOX; brown spectrum). GOX converts a galactose residue in the 1017 
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oligosaccharides into its corresponding aldehyde, giving a mass-to-charge ratio (m/z) 1018 
of -2. All assigned masses are sodium adducts. Abbreviations: Ox, oxidation; Gal1, 1019 
galactose; Gal1M3, galactosylmannotriose; Gal1M4, galactosylmannotetraose; 1020 
Gal2M4, digalactosylmannotetraose; Gal2M5, digalactosylmannopentaose. d, Product 1021 
profiles from RiGH26-digested CGM degradation experiments with RiGH113 1022 
analyzed by HPAEC-PAD. The release of mannose confirms the exo-activity of 1023 
RiGH113. e, HPAEC-PAD traces showing activity of RiGH3A or RiGH3B towards G51024 
and G4 with the corresponding controls (no enzyme). Product profiles at various time 1025 
points during the reaction are shown in Supplementary Fig. 6. Taken together, the 1026 
data show that RiGH3B is able to hydrolyze completely both tetramers and 1027 
pentamers, producing glucose. RiGH3A shows exo-activity towards both substrates 1028 
that are converted slowly to glucose and a mixture of cello-oligosaccharides. 1029 
Samples were analyzed with the following cello-oligosaccharides as external 1030 
standards: glucose, G1; cellobiose, G2; cellotriose, G3; cellotetraose, G4; 1031 
cellopentaose, G5. f, Chromatograms showing products generated upon incubation 1032 
of RiGH130_2 with M4 and M3. The M1P released (red arrow) was identified by co-1033 
migration with the appropriate standard. In all panels, the data displayed are 1034 
representative of at least three biological triplicates. 1035 
Figure 5. Enzymes for catabolism of mannobiose, mannosylglucose and 1036 
monosaccharides deriving from complex -mannan degradation. a, HPAEC-1037 
PAD traces showing the epimerization of M2 and G2 by RiMep to release M1G1 and 1038 
G1 M1, respectively. b-c, HPAEC-PAD of phosphorolysis reactions of RiGH130_1 1039 
using premixed M1G1 plus M2 from Megazyme. The reaction products were then 1040 
analyzed using an HPAEC method designed for the separation of b, phosphorylated 1041 
manno-oligosaccharides or c, mono- and di-saccharides. M1P, indicated with a red 1042 
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arrow) and G1 peaks in panel b are marked according to the standards d, HPAEC-1043 
PAD analysis of RiPgm-catalyzed conversion of M1P M6P. The M6P released was 1044 
identified by co-migration with the M6P standard. e, Activity of RiGH1_D2 on M6P 1045 
and F6P analyzed by HPAEC-PAD. 1046 
Figure 6. R. intestinalis and B. ovatus co-culture experiments and in vivo 1047 
modulation of a synthetic human gut microbiota via AcGGM. a, c, Growth rates 1048 
of mono- and mixed cultures of R. intestinalis L1-82 (Ri) and B. ovatus ATCC 8483 1049 
(Bo) on either AcGGM or mannose. Growth rate is defined as the maximum increase 1050 
in absorbance at 600 nm (ODmax) divided by the time (Tmax, in hours) to reach the 1051 
maximum growth. b, d, In vitro competition experiment with R. intestinalis L1-82 and1052 
B. ovatus ATCC 8483 on either AcGGM or mannose as sole carbon source. The pH1053 
of the stationary phase cultures after growth on either AcGGM or mannose was 5.8 ± 1054 
0.16 and 5.6 ± 0.11 (two biological triplicates, ± indicates the s.d.), respectively, thus 1055 
showing that the results are not due to differences in acid sensitivity between the two 1056 
strains. The relative abundance of the bacteria for each different phases of growth 1057 
was determined by quantitative PCR of species-specific vs universal primers 1058 
targeting the 16S rRNA genes. In panels a-d, the histogram bars show the mean of 1059 
two biological replicates, with three independent measurements per replicate. Error 1060 
bars represent s.d. Abbreviations: Early exp, early exponential phase; Middle Exp; 1061 
middle exponential phase; Late exp, late exponential phase; Stat, stationary phase. 1062 
e, Relative abundance of bacteria in fecal samples from germfree mice colonized 1063 
with a synthetic human microbiota. Mice were shifted from a fiber-free (FF) diet to 1064 
varying amounts (2.5% and 7.5% w/w) of AcGGM over time. Data are average of 1065 
seven mice. f-i, Relative abundance of individual -mannan-degrading bacteria and1066 
j-m, mucus-degraders. n, Additive relative abundances of three amino acids1067 
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degraders. In panels f-n, histogram bars show the average of seven biological 1068 
replicates while error bars represent s.d. P-values were calculated by two-tailed 1069 
Students t test. An asterisk (*) indicate a statistically significant difference (P < 0.05) 1070 
in the relative abundance of each bacterium compared to that of the specific pre-FF 1071 
diet. ns, not significant (P  0.05). 1072 
Figure 7. Model for the degradation and utilization of complex -mannans in R.1073 
intestinalis. Intracellular degradation of an acetylated galactoglucomanno-  1074 
oligosaccharide is used as an example. Sugars are represented as in Fig. 1. Initial 1075 
depolymerization of acetylated galactoglucomannan (AcGalactoglucomannan) 1076 
occurs at the outer surface of R. intestinalis by the activity of RiGH26 (green). The 1077 
extracellular recruitment of -mannan is facilitated by interactions with CBM27 and1078 
CBM23. Import of products occurs through the ABC transporter 1079 
RiMnBP/RiMPP1/RiMPP2 (orange). Within the cytoplasm, the acetyl and galactosyl 1080 
decorations are removed by the two acetyl esterases RiCE2 and RiCEX (pink) and 1081 
the -galactosidase RiGH36 (yellow). The two -glucosidases RiGH3A and RiGH3B1082 
(blue) release glucose from the non-reducing end of the -manno-oligosaccharide. In1083 
addition, the reducing end mannose-releasing exo-oligomannosidase RiGH113 1084 
(green) can catalyze the removal of mannose units from the decorated manno-1085 
oligosaccharides until it reaches a galactosyl substituent at the subsite -1. Once de-1086 
ornamented, the -manno-oligosaccharides are saccharified by the exo-acting1087 
RiGH130_2 (light green) with accumulation of M2. The M2undergoes subsequent 1088 
epimerization and phosphorolysis by the concerted activity of RiMep - RiGH130_1 1089 
(light green), with release of glucose and M1P. These end products enter the 1090 
glycolytic pathway either directly (for glucose) or after being converted into M6P and 1091 
F6P by the phosphomannose mutase RiPgm (red) and the isomerase RiGH1_D2 1092 
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(turquoise, purple domain). Released mannose is converted to M6P by a hexokinase 1093 
and processed as described above. Galactose enters glycolysis after conversion to 1094 
G1P via the Leloir pathway. The pyruvate generated from glycolysis is converted to1095 
acetyl-CoA and then butyrate. Black arrows show reactions demonstrated in this 1096 
study. Green arrows indicate previously demonstrated steps for the generation of 1097 
butyrate from monosaccharides fermentation68 by R. intestinalis. 1098 
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Table 1.  Binding parameters of RiCBM27 and RiCBM23 to manno- and cello-1099 
oligosaccharidesa. 1100 
Kd (µM)
Ligand RiCBM27 RiCBM23 
M3 1593 ± 30 230 ± 20 
M4 658 ± 20 130 ± 50 
M5 321 ± 20 198 ± 70 
M6 165 ± 10 205 ± 40 
Glc4 No binding No binding 
Glc6 No binding No binding 
aBinding was determined by SPR. Values show the means and standard deviations of at least two 1101 
independent experiments. Kd, dissociation constant. 1102 
1103 
Table 2. Thermodynamic binding parameters of RiMnBP to linear and 1104 
decorated manno-oligosaccharidesa. 1105 
Ligand Kd
(µM)
G 
(kcal 
mol-1) 
H 
(kcal 
mol-1) 
-T S 
(kcal 
mol-1) 
n 
M3 2.62 -7.6 -33.2 25.6 0.7 
M4 3.89 -7.4 -28.6 21.2 0.7 
M5 2.55 -7.7 -21.8 14.1 0.8 
M6 33.75 -6.2 -17.8 11.6 0.5 
M4Ac2 25.65 -6.3 -21.9 15.6 0.9 
M5Ac2 23.53 -6.3 -20.2 13.9 0.8 
aBinding was measured by ITC. Data are means of two independent titrations. Kd, dissociation 1106 
constant; G, Gibbs free energy; H, enthalpy; -T S, entropy; n, binding stoichiometry. 1107 
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Supplementary Information for 
 
The Human Gut Firmicute Roseburia intestinalis is a Primary Degrader of Dietary β-
Mannans 
La Rosa et al. 
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Supplementary Table 1. Upregulation of MULL and MULS genes was not detected when R. 
intestinalis L1-82 grew on galactose.  
Locus tag Log2-folda 
changes ROSINTL182_07683 -0.11 
ROSINTL182_07684 -0.03 
ROSINTL182_07685 0.03 
ROSINTL182_05469 0.43 
ROSINTL182_05470 -0.21 
ROSINTL182_05471 -0.24 
ROSINTL182_05473 -0.27 
ROSINTL182_05474 -0.38 
ROSINTL182_05475 -0.78 
ROSINTL182_05476 -1.01 
ROSINTL182_05477 -0.49 
ROSINTL182_05478 -1.38 
ROSINTL182_05479 -0.63 
ROSINTL182_05480 -0.20 
ROSINTL182_05481 -0.01 
ROSINTL182_05482 -0.11 
ROSINTL182_05483 -0.95 
aLog2-fold changes of the putative β-mannan  
utilization genes (as shown in Fig. 1d) expressed  
by R. intestinalis cells grown on galactose relative 
 to glucose. 
 
 
 
Supplementary Table 2. Sequence similarity between R. intestinalis L1-82’s proteins involved in β-
mannan utilization and other Roseburia strains/species. 
 
R. intestinalis 
M50/1 
R. intestinalis 
XB6B4 
R. faecis 
M72/1 
R. hominis 
A2-183 
R. inulinovorans 
DSM16841 
R. cecicola 
GM 
Locus Tag Function Amino Acids Similarity (%) to R. intestinalis L1-82 
05470/69 GH1 99 99 83 92 90 0 
05471 CEX 99 99 75 76 0 0 
05473 CE2 99 98 76 75 0 0 
05474 GH130_2 99 100 85 95 0 0 
05475 GH130_1 100 100 95 98 0 0 
05476 Mep 99 99 85 89 0 0 
05477 MPP2 99 99 89 90 57 0 
05478 MPP1 100 100 93 89 50 0 
05479 MnBP 99 100 81 75 0 0 
05480 TR 99 98 76 79 48 0 
05481 GH36 99 99 78 82 63 0 
05482 Pgm 99 100 92 94 94 0 
05483 GH113 99 99 76 70 0 0 
07683 GH26 99 99 64 0 0 0 
07684 GH3B 99 99 62 76 76 0 
07685 GH3A 99 99 62 76 76 0 
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Supplementary Table 3. Homologs of RiGH26 (catalytic domain only)a,b.  
Strain Accession Number Coverage Identity Lengthc CBM27 CBM23 
R. intestinalis XB6B4 CBL14297.1 100% 99% 1308 Y Y 
R. intestinalis M50/1 CBL07467.1 100% 99% 1314 Y Y 
R. faecis WP_055067491.1 80% 47% 1374 Y Y 
Roseburia sp. CAG:18_43_25 OLA58885.1 77% 48% 1519 Y Y 
Coprococcus eutactus CAG:665 CCZ93652.1 85% 48% 1555 Y Y 
Coprococcus sp. CAG:131 CDB80322.1 85% 47% 1544 Y Y 
Clostridium butyricum WP_058146428.1 72% 40% 1444 Y Y 
Clostridium disporicum CUO64427.1 72% 38% 1333 Y Y 
Clostridium sp. Marseille-P2414 WP_066889682.1 73% 37% 1147 Y Y 
Clostridium beijerinckii WP_026885856.1 69% 39% 1398 Y Y 
Clostridium saudiense WP_052330667.1 80% 35% 1148 Y Y 
Clostridium puniceum WP_077847551.1 64% 38% 1016 Y Y 
Propionispora vibrioides WP_091746906.1 68% 36% 889 Y Y 
Clostridium sp. DSM 8431 WP_090011638.1 66% 36% 1692 Y Y 
Selenomonas bovis WP_052177425.1 64% 35% 891 Y Y 
Anaerocolumna aminovalerica SFO28893.1 64% 35% 928 Y Y 
aHomologs were identified by BLAST searches against the NCBI non-redundant protein sequence database. bY indicates the presence of a specific CBM in 
the protein sequence. CAmino Acids 
 
 
Supplementary Table 4. Homologs of RiCBM27a.  
Strain Phylum Accession Number E- value Coverage Identity 
R. intestinalis XB6B4 Firmicutes CBL14297.1 2.00E-101 100% 99% 
R. intestinalis M50/1 Firmicutes CBL07467.1 2.00E-100 100% 99% 
Coprococcus eutactus CAG:665 Firmicutes CCZ93652.1 2.00E-23 100% 41% 
Coprococcus sp. CAG:131 Firmicutes CDB80322.1 8.00E-23 100% 40% 
R. faecis Firmicutes WP_055067491.1 2.00E-22 90% 41% 
Roseburia sp. CAG:18_43_25 Firmicutes OLA58885.1 3.00E-22 90% 41% 
Clostridium disporicum Firmicutes CUO64427.1 1.00E-18 98% 34% 
Clostridium butyricum Firmicutes WP_058146428.1 7.00E-18 93% 39% 
Clostridium sp. Marseille-P2414 Firmicutes WP_066889682.1 2.00E-17 98% 33% 
Clostridium puniceum Firmicutes WP_077847551.1 4.00E-17 91% 34% 
Uncultured Clostridium sp. Firmicutes SCJ87681.1 3.00E-15 91% 32% 
Clostridium saudiense Firmicutes WP_052330667.1 4.00E-15 91% 32% 
Clostridium beijerinckii Firmicutes WP_026885856.1 3.00E-11 98% 33% 
Anaerocolumna aminovalerica Firmicutes SFO28893.1 6.00E-11 96% 32% 
Selenomonas bovis Firmicutes WP_052177425.1 9.00E-11 90% 31% 
Clostridium sp. DSM 8431 Firmicutes WP_090011638.1 2.00E-10 98% 30% 
Propionispora vibrioides Firmicutes WP_091746906.1 8.00E-10 91% 32% 
Pelosinus fermentans JBW45 Firmicutes AJQ29746.1 3.00E-09 92% 31% 
aHomologs were identified by BLAST searches against the NCBI non-redundant protein sequence database. 
 
 
Supplementary Table 5. Homologs of RiCBM23a.  
Strain Phylum Accession Number E- value Coverage Identity 
R. intestinalis XB6B4 Firmicutes CBL14297.1 1.00E-123 100% 99% 
R. intestinalis M50/1 Firmicutes CBL07467.1 1.00E-123 100% 99% 
Coprococcus eutactus CAG:665 Firmicutes CCZ93652.1 5.00E-58 93% 58% 
Coprococcus sp. CAG:131 Firmicutes CDB80322.1 2.00E-57 93% 58% 
R. faecis Firmicutes WP_055067491.1 3.00E-44 88% 49% 
Roseburia sp. CAG:18_43_25 Firmicutes OLA58885.1 4.00E-43 88% 49% 
Clostridiales bacterium CHKCI001 Firmicutes CVI73099.1 4.00E-41 93% 44% 
Clostridium beijerinckii Firmicutes WP_026885856.1 9.00E-40 89% 47% 
Clostridium butyricum Firmicutes WP_058146428.1 5.00E-36 94% 42% 
Propionispora vibrioides Firmicutes WP_091746906.1 2.00E-34 99% 43% 
Clostridium puniceum Firmicutes WP_077847551.1 2.00E-35 89% 41% 
Selenomonas bovis Firmicutes WP_052177425.1 2.00E-33 89% 42% 
Clostridium sp. DSM 8431 Firmicutes WP_090011638.1 4.00E-33 93% 40% 
Clostridium disporicum Firmicutes WP_055276275.1 2.00E-30 94% 41% 
Clostridium sp. Marseille-P2414 Firmicutes WP_066889682.1 3.00E-30 91% 40% 
Clostridium saudiense Firmicutes WP_052330667.1 5.00E-30 96% 41% 
Clostridium populeti Firmicutes WP_092560634.1 2.00E-21 92% 33% 
Lachnospiraceae bacterium ND2006 Firmicutes WP_051666040.1 2.00E-21 100% 34% 
Cohnella sp. OV330 Firmicutes WP_090116078.1 1.00E-18 89% 36% 
Anaerocolumna aminovalerica Firmicutes SFO28893.1 3.00E-17 99% 32% 
aHomologs were identified by BLAST searches against the NCBI non-redundant protein sequence database.  
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Supplementary Table 6. Carbohydrates used in this study, listed with supplier and product number. 
Substrate Source Catalogue Number 
Glucose Sigma (G8270) 
Galactose Sigma (G0750) 
Mannose Sigma (M4625) 
Mannobiose Megazyme (O-MBI) 
Mannotriose Megazyme (O-MTR) 
Mannotetraose Megazyme (O-MTE) 
Mannopentaose Megazyme (O-MPE) 
Mannohexaose Megazyme (O-MHE) 
Cellobiose Sigma (C7252) 
Cellotriose Megazyme (O-CTR) 
Cellotetraose Megazyme (O-CTE) 
Cellopentaose Megazyme (O-CPE) 
Cellohexaose Megazyme (O-CHE) 
Mannose-1-phosphate Sigma (M1755) 
Mannose-6-phosphate Sigma (M6876) 
Glucose-1-phosphate Sigma (G7000) 
Glucose-6-phosphate Sigma (G7879) 
Fructose-6-phosphate Sigma (F3627) 
Glucosylmannose plus Mannobiose Megazyme (O-GMMBI) 
61-α-D-Galactosylmannobiose plus Mannotriose Megazyme (OGMM-3) 
61-α-D-Galactosylmannotriose Megazyme (O-GM3) 
63,64-α-D-Galactosylmannopentaose Megazyme (O-GGM5) 
Galactomannan (guar gum) Sigma (G4129) 
Galactomannan (carob) Megazyme (P-GALML) 
Glucomannan (konjac) Megazyme (P-GLCML) 
Acetylated galactoglucomannan (Spruce) This 
 
Birch xylan This 
 
Lichenan (icelandic moss) Megazyme (P-LICHN) 
β-glucan (barley) Megazyme (P-BGBL) 
Curdlan Megazyme (P-CURDL) 
Wheat arabinoxylan Megazyme (P-WAXYL) 
#Produced at the Bioprocess Technology and Biorefining Lab, Faculty of Chemistry, Biotechnology 
 and Food Science, Norwegian University of Life Sciences, according to procedure described in1.  
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Supplementary Table 7. Primers, vector for overexpression in E. coli and protein purification 
techniques used in this studya.  
Gene Primer (5’ - 3’) Vector Purif. Tech.b 
ROSINTL182_07683 
(CBM27/GH26/CBM23) 
F:TTAAGAAGGAGATATACTATGGGGGGATACGAGTATGTCTATGC 
R:AATGGTGGTGATGATGGTGCGCTCCACCTTCTGTCACATTTAAC 
pNIC-CH IMAC/SEC 
ROSINTL182_07683 
(CBM27) 
F:TTAAGAAGGAGATATACTATGGGGGGATACGAGTATGTCTATGC 
R:AATGGTGGTGATGATGGTGCGCGCCCGCTGCATTATACTGG 
pNIC-CH IMAC/SEC 
ROSINTL182_07683 
(CBM23) 
F:TTAAGAAGGAGATATACTATGTCTGTTTTTGCGAATGGAACAAAC 
R:AATGGTGGTGATGATGGTGCGCTCCGGACACGAGTGACTGATC 
pNIC-CH IMAC/SEC 
ROSINTL182_07684 F:TTAAGAAGGAGATATACTATGGGTAACAGTGGAATCGGTGTTC 
R:AATGGTGGTGATGATGGTGCGCCTCTAACTCAATCCAGTCCAACTTC 
pNIC-CH IMAC/SEC 
ROSINTL182_07685 F:TTAAGAAGGAGATATACTATGGAAAAATGGCAAAGATCACTTTATC 
R:AATGGTGGTGATGATGGTGCGCGTCGATTTTCAGTATTAATCCTAAAATAC 
pNIC-CH IMAC/SEC 
ROSINTL182_05469 
(GH1_D2) 
F:TTAAGAAGGAGATATACTATGATACTTAGTATGAATCAGGCAAATAAAG 
R:AATGGTGGTGATGATGGTGCGCTTTTACAGTAGAAACGATCAGACTCATC
 
pNIC-CH IMAC/SEC 
ROSINTL182_05470 
(GH1_D1) 
F: TTAAGAAGGAGATATACTATGTTAGACCCGGTATGTACGCAC 
R: AATGGTGGTGATGATGGTGCGCTCCTCCATTCGTTTCTATTACTTTCTG 
pNIC-CH IMAC/SEC 
ROSINTL182_05471 F:TTAAGAAGGAGATATACTATGGAATATCAAATTAAATACGAAAACGGC 
R:AATGGTGGTGATGATGGTGCGCTTTTTCAGAGGAACCAATGACAGAC 
pNIC-CH IMAC/SEC 
ROSINTL182_05473 F:TTAAGAAGGAGATATACTATGAAACGTGTGATGGAGTGTCCG 
R:AATGGTGGTGATGATGGTGCGCAGATTCCCAGACTGCATCCC 
pNIC-CH IMAC/SEC 
ROSINTL182_05474 F:TTAAGAAGGAGATATACTATGAGCAAATATAAAATGATCAGCCAGC 
R:AATGGTGGTGATGATGGTGCGCGCGTCTTCCGATCTCGGTATC 
pNIC-CH IMAC/SEC 
ROSINTL182_05475 F:TTAAGAAGGAGATATACTATGGAGATTCGACGAATGTTACATGAG 
R:AATGGTGGTGATGATGGTGCGCTTTATCTTCCTTTGCAAGGAACTC 
pNIC-CH IMAC/SEC 
ROSINTL182_05476 F:TTAAGAAGGAGATATACTATGAGTGAGTTAAAAGAACTTGCAGCAG 
R:AATGGTGGTGATGATGGTGCGCGAATCAGTTTTATGCTCCGATTCTG 
pNIC-CH HIC/ 
SEC 
ROSINTL182_05479 F: TTTCAGGGCGCCATGGGCTCAAACAACACAGCAGG 
R: GACGGAGCTCGAATTTTACTCAGTTACTTCAATTCCGTTTG 
pETM-11 IMAC/SEC 
ROSINTL182_05481 F:TTAAGAAGGAGATATACTATGGCAATCACATACTTTGAAAAAGAACGC 
R:AATGGTGGTGATGATGGTGCGCTTTTTCCATTTAATCTTATTTCTTTTCCAC 
pNIC-CH HIC/ 
SEC 
ROSINTL182_05482 F:TTAAGAAGGAGATATACTATGAGCAATTACATGGAAACATACAAACAG 
R:AATGGTGGTGATGATGGTGCGCTTCCTACTGTTATTTCAGCAAGTCTTC 
pNIC-CH HIC/ 
SEC 
ROSINTL182_05483 F:TAAGAAGGAGATATACTATGGAATATATCTGTGGGGTGACTTTTGC 
R:AATGGTGGTGATGATGGTGCGCTTGACCTCAACATCATTTATTAAAAATATC 
pNIC-CH HIC/ 
SEC 
aThe 5’ extension sequences used for molecular cloning are underlined. bPurification techniques employed. 
 
Supplementary Table 8. Primers used for sequencing of the intergenic region between 
ROSINTL182_05470 - 05469. 
Gene Primer (5’ - 3’) Application 
ROSINTL182_05470/ 
ROSINTL182_05469 
F:GGGATTACGCCATATATTACC 
R:GTCTCCGTTTGGATGTGC 
Sequencing of the intergenic region between 
RiGH1_D1 and RiGH1_D2 
 
Supplementary Table 9. Primers used for qPCR. 
Target Primer (5’ - 3’) Supplementary Reference 
R. intestinalis L1-82 F: GCATGACCTGGTGTGAA 
R: TTGGGCCGTGTCTCA Larsen, N. et al
2
 
B. ovatus ATCC 8384 F: GGTGTCGGCTTAAGTGCCAT 
R: CGGAYGTAAGGGCCGTGC Larsen, N. et al
2
 
Universal 16S rRNA F: CCTAYGGGRBGCASCAG 
R: GGACTACNNGGGTATCTAAT Yu, Y. et al
3
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Supplementary Figure 1. R. intestinalis L1-82 AcGGM consumption at zero, middle and later time 
points, determined by HPAEC-PAD. a, Chromatograms showing the oligosaccharides detected in the 
supernatant of R. intestinalis L1-82 while growing on YCFA supplemented with 5 mg ml-1 AcGGM. M2-M6 
standards were 2, mannobiose; 3, mannotriose; 4, mannotetraose; 5, mannopentaose; 6, mannohexaose. b, 
Chromatograms with a gradient adapted to improve the resolution of mono-, di- and shorter oligosaccharides 
present in the same supernatant as in a. The data are representative of three biological replicates. 
Abbreviations: mid exp. phase; middle exponential phase; late exp. phase, late exponential phase.  
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Supplementary Figure 2. Sequence conservation and genomic organization of the β-mannan 
utilization loci among Roseburia species and closely related members of the Clostridium cluster 
XIVa. Common predicted functions are colored according to Fig. 2d. The figure shows that MULL and MULS 
are conserved in all the R. intestinalis strains, R. faecis and R. hominis A2-183; however, the latter genome 
does not include an orthologous GH26 gene. R. inulinovorans lacks most of the genes encoding the β-
mannan utilization apparatus, suggesting a different carbohydrate utilization specialization for this strain. 
Among members of the Clostridium cluster XIVa, several R. gnavus and C. eutactus strains harbor similar 
MULL and MULS genes, although no GH113 was detected. The mannanase GH26 is lacking from the 
genomes of the B. fibrisolvens strains, suggesting that these bacteria are likely unable to hydrolyze 
polymeric β-mannans.  
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Supplementary Figure 3. Schematic of RiGH26 and activity on different glycans. a, Domain 
organization of RiGH26. The protein contains an N-terminal secretion signal peptide (in orange), as detected 
by the SignalP 4.1 server (http://www.cbs.dtu.dk/services/SignalP/), which is predicted to be removed by 
cleavage between Gly29 and Tyr30. The CBMs and catalytic domain are shown in green with the catalytic 
residues in magenta. The red arrow indicates the position of the Proline-Glycine (PG) rich region. The two Ig-
like domains are shown in light blue. Based on these predictions, the gene was cloned and the protein 
expressed without the N-terminal signal, C-terminal PG-rich region and Ig-like sequences. b, Activity of 
RiGH26 on AcGGM. The picture shows the MALDI-TOF spectra of oligosaccharides before (blue) and after 
RiGH26 treatment (red). c,  Summary of the activity of RiGH26 on different glycans under standard assay 
conditions. A green box indicates activity while a red box indicates the absence of detectable products. d, 
Activity of RiGH26 on different concentrations of AcGGM. RiGH26, at 10 nM, was incubated with increasing 
concentration of AcGGM for 1 h in standard assay conditions. The reaction products were diluted to have a 
final concentration of approximately 1 mg ml-1 and subjected to HPAEC-PAD.   
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Supplementary Figure 4. Unrooted maximum likelihood tree of RiGH26 and homologs. Searching for 
RiGH26-like proteins was performed by BLAST against the NCBI non-redundant protein sequence database. 
Sequences with coverage <86% and identity <40% were eliminated. Multiple sequence alignment was 
performed using ClustalW. The phylogenetic tree was generated using the maximum likelihood algorithm in 
Mega 7 (http://megasoftware.net/). Bootstrap values are shown at each node as percentage of 500 
replicates. RiGH26 is indicated by a green-colored diamond. All sequences were identified as members of 
the Firmicutes phylum, with 96% of the sequence belonging to the order Clostridiales. Exceptions were the 
sequence of Selenomonas bovis and Propionospora vibrioides that belong to the class Negativicutes. The 
majority of the sequences were affiliated to the Clostridium Cluster XIVa.   
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Supplementary Figure 5. Binding of RiCBM27 and RiCBM23 to manno-oligosaccharides using SPR 
analysis (related to Table 1). Blank and reference cell corrected (a-b) and raw SPR sensograms (c-j) 
showing the binding of RiCBM27 (blue) and RiCBM23 (green) to manno-oligosaccharides (M3-6). In all 
panels, the results are representative of at least two independent replicates.   
154
11 
 
Supplementary Figure 6. ITC analysis of RiMnBP binding to linear and substituted manno-
oligosaccharides (related to Table 2). Data show RiMnBP binding to manno-oligosaccharides (M3-6), 
diacetylated mannotetraose (M4Ac2) and diacetylated mannopentaose (M5Ac2). The top panel in each pair 
shows the thermograms, whereas the bottom graph depicts the binding isotherms and one set of equivalent 
binding sites model fits to the data (solid lines).   
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Supplementary Figure 7. Activity of RiGH36 on AcGGM. HPAEC-PAD analysis of RiGH26-treated 
AcGGM before and after subsequent incubation with RiGH36. 
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Supplementary Figure 8. Activity of RiGH36 on galactomannan, acetylated manno-oligosaccharides 
and galactomanno-oligosaccharides. a, HPAEC-PAD chromatograms showing the effect of the treatment 
with galactose oxidase (GOX from Dactylium dendroides, Megazyme) on CGM pre-hydrolyzed with RiGH26 
and subsequent incubation with RiGH36. The oligosaccharides (DP4-7) released from CGM by RiGH26 
were oxidized by the GOX; indeed, upon GOX treatment, the galactosylated oligosaccharides at denoted 
DP4-7 disappear and the corresponding oxidized oligosaccharides appear at 20+ minutes. No oxidized 
product could be observed after GOX-treatment of the RiGH26 and RiGH36-treated CGM sample, 
demonstrating that RiGH36 completely removes the galactose residues from the substrates. b, HPAEC-PAD 
analysis of the products released from guar gum galactomannan by RiGH36 alone or when the enzyme is 
combined with the β-mannanase RiGH26. The figure shows that RiGH36 has limited activity on the 
polymeric substrate while it acts synergistically with RiGH26 to degrade the guar gum galactomannan 
completely into mannose, galactose and mannobiose. c, MALDI-TOF spectra of the hydrolysis of a 
preparation containing trisaccharides (DP3), tetrasaccharides (DP4) and pentasaccharides (DP5) with 
different degree of acetylation (Ac), after overnight incubation with RiGH36. d, Increased RiGH36 activity can 
be observed as an increase in DP3 and a corresponding reduction in DP4 and DP5 when the same 
substrate as in panel c was pretreated with RiCE2 and RiCEX to remove the acetyl substitutions. e, HPAEC-
PAD analysis of the reaction products generated after RiGH36 treatment of Gal1M3 (15 mM ). f, Products 
released from Gal2M5 (8.7 mM) by RiGH36 action as analyzed by HPAEC-PAD. In all panels, RiGH36 was 
used at a concentration of 15 nM and incubated with the glycans for 16 h at 37 °C.  
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Supplementary Figure 9. Sequence analysis, activity of RiGH113 towards various manno-
oligosaccharides and time course activity. a, Amino acid sequence alignment of the GH113 protein of R. 
intestinalis L1-82 (RiGH113) and AaManA from Alicyclobacillus acidocaldarius. The protein sequences were 
aligned with JalView (http://www.jalview.org) and conserved amino acids are shown in blue. Red arrows 
indicate the catalytic and substrate interacting residues.  b, Pattern of hydrolysis of manno-oligosaccharides 
by RiGH113.  Enzyme assays were performed overnight. c,  Pattern of hydrolysis of M5 by RiGH113. 
Samples were withdrawn at the indicated time, enzymes were inactivated using 100 mM NaOH and the 
hydrolysates were analyzed by HPAEC-PAD. d, Reaction products of disaccharides catalyzed by RiGH113.  
e, Hydrolysis of Gal1M2 plus M3 and Gal2M5by RiGH113. The reaction products were analyzed by HPAEC-
PAD. Gal1M4, indicates galactosylmannotetraose. In all panels, control reactions without enzyme did not 
yield products.   
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Supplementary Figure 10. Phylogeny and inhibition of RiGH113 activity when blocking the reducing 
end of various manno-oligosaccharides. a, Analysis of RiGH113 activity on native and reduced M5. A 
commercial Cellulomonas fimi GH2 β-mannosidase (CfGH2, Megazyme), which acts from the non-reducing 
end sugar, was used as control. M5 was pretreated with NaBD4 to reduce the reducing (downstream) end 
mannose unit into mannitol. CfGH2 fully hydrolyzes the reduced mannopentamer, whereas RiGH113 is not 
able to hydrolyze it. Note that the reduced oligosaccharide has a considerably shorter retention time than its 
corresponding native oligosaccharide. b, RiGH113 hydrolysis of native and oxidized M4 and c, M5 analyzed 
with HPAEC-PAD. The substrates were pretreated with a Neurospora crassa cellobiose dehydrogenase 
(NcCDH), which oxidizes the reducing end monosaccharide unit into the corresponding lactone/aldonic acid, 
resulting in a considerably longer retention time than its corresponding native oligosaccharide. RiGH113 is 
not able to hydrolyze the oxidized oligosaccharide. d, HPAEC-PAD analysis of the activity of RiGH113 on 
native and reduced Gal2Man5. Gal2Man5 was treated with NaBD4 before addition of RiGH113. e, 
Phylogenetic tree of RiGH113 and homologs identified by a Blast search against the NCBI non-redundant 
protein database. Sequences with coverage ≥86% and identity ≥40% were selected. The resulting 298 
sequences were aligned using Muscle. A phylogenetic tree was generated using the maximum likelihood 
algorithm with 500 bootstrap repetitions in Mega 7 (http://megasoftware.net/). The tree was visualized using 
Figtree (http://tree.bio.ed.ac.uk/software/figtree). RiGH113 and AaManA are indicated with a black arrow. All 
sequences were identified as members of the Firmicutes phylum with the exception of those belonging to 
Microbacterium (Actinobacteria).  
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Supplementary Figure 11. Phylogeny of RiGH3A, RiGH3B and homologs and β-glucosidases 
degradation of different oligosaccharides over time. a, Domain organization of RiGH3A and RiGH3B. 
Similar to other β-glucosidases from Clostridiales4, the N- and C-terminal modules in both RiGH3A and 
RiGH3B are arranged in reverse sequence. b, Phylogenetic tree of RiGH3A, RiGH3B and homologs 
identified by BlastP search against the NCBI non-redundant protein database. Sequences with coverage 
<86% and identity <40% were removed. The resulting 183 sequences were aligned using Muscle. A 
phylogenetic tree was generated using the maximum likelihood algorithm with 500 bootstrap repetitions in 
Mega 7 (http://megasoftware.net/). The tree was visualized using Figtree 
(http://tree.bio.ed.ac.uk/software/figtree). RiGH3A and RiGH3B are indicated with a red arrow. Despite an 
apparent redundancy in structure and biochemical function, the two β-glucosidases appear to have diverged 
significantly, sharing only 40% identity at the amino acid level. Time course analysis of enzymatic reactions 
containing c, RiGH3A and d, RiGH3B. Equal amount of enzymes (10 nM) were used. Aliquots were taken at 
the indicated time points and the enzymes were inactivated by adding NaOH to 100 mM. e,  HPAEC-PAD 
analysis of M5 incubated overnight in the absence or presence of RiGH3A and RiGH3B, showing that neither 
of them are active on this substrate. f, Activity of the β-glucosidases RiGH3A and RiGH3B on disaccharides.   
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Supplementary Figure 12. RiGH3A and RiGH3B activity on glucomannan.  a, HPAEC-PAD analysis of 
RiGH3A or RiGH3B activity on KGM. b, Reaction products of RiGH26-digested KGM catalyzed by RiGH3A 
or RiGH3B.  
 
 
 
 
Supplementary Figure 13. Control reaction to check for the activity of RiGH130_2 on cello-
oligosaccharides. HPAEC-PAD analysis of G5 incubated at standard assay conditions in the absence or 
presence of RiGH130_2. A reaction with the β-glucosidase RiGH3A was used as a control. Only the 
incubation of RiGH3A with G5 released a reaction product.  
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Supplementary Figure 14. HPAEC chromatograms to verify the activity of RiMep on manno-
oligosaccharides. RiMep was incubated with either a, disaccharides or b, M3. RiMep exhibited 
epimerization activity towards G2 and the following manno-oligosaccharides: M1G1, G1M1, M3. 
 
 
 
 
 
Supplementary Figure 15. Control reactions to verify that RiGH130_1 is active only on M1G1. HPAEC-
PAD analysis of M4, M3, a mixture of M2 and either M1G1 or G1M1 incubated under standard assay conditions 
in the absence or presence of RiGH130_1. The reaction products were subjected to HPAEC and identified 
by their co-migration with known standards. In this elution method, M1G1 co-eluted with M2. 
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Supplementary Figure 16. Activity on G1P and domain mapping of RiPgm. a, HPAEC-PAD trace 
showing the activity of RiPgm on G1P. G1P was either untreated (G1P no enzyme) or treated with RiPgm. 
The G6P produced by RiPgm was identified by co-migration with the G6P standard. b, Domain organization 
of RiPgm. As observed for other phosphohexomutases5, the RiPgm protein structure is modular, featuring 
four domains. The catalytic domain spans from residue 43 to 180 and harbors a conserved active site. 
Downstream to the catalytic core domain are three additional domains: domain II (residues 209-314) 
contains a conserved magnesium (Mg) -binding loop; domain III (residues 327-453) contains the sugar-
binding loop that participates in recognizing the two binding orientations of the 1- and 6-phospho-sugars; and 
the C-terminal domain IV (residues 469-570) harbors a phosphate (P) -binding site that is required for 
accommodating the incoming phospho-sugar substrate. 
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Supplementary Figure 17. M. formatexigens β-manno-oligosaccharides utilization cluster, growth 
profile, glycan consumption and competition experiments. a, Schematic presentation of the putative M. 
formatexigens DSM 14469 β-manno-oligosaccharides degradation locus. Genes are indicated by their locus 
tag (BRYFOR_XXXXX is abbreviated with the last numbers after the underscore), assignment to CAZyme 
families and other predicted functions and they are colored according to Fig. 2d. None of the genes has a 
signal peptide as predicted by the SignalP 4.1 server, suggesting an intracellular location. Absence of a 
predicted extracellular endomannanase suggests that M. formatexigens has no hydrolytic capabilities toward 
polymeric mannans. b, M. formatexigens growth on YCFA containing mannose (green), glucose (red), 
AcGGM (blue) or dyalized AcGGM (dAcGGM, dyalized with a Spectra/Por dialysis tubing 1KDa MW, 
Repligen, USA) at 0.5% (w/v). The growth experiment was conducted in 200 µl cultures in 96-well microtiter 
plates incubated at 37 °C in anaerobic conditions. Growth was assessed by measuring the absorbance at 
600 nm (OD600 nm) at 15 min intervals using a Powerwave HT absorbance reader (Biotek Instruments, 
Winooski, VT). HPAEC-PAD traces showing c, mono- and oligo-saccharides and d, polysaccharides 
contained in the YCFA supplemented with AcGGM before (turquoise) and after (pink) fermentation with M. 
formatexigens (Mf). In panel c, MOS indicates manno-oligosaccharides. In panel d, samples were 
chromatographed with the spent supernatant of R. intestinalis (Ri) after overnight growth on YCFA 
supplemented with AcGGM at 0.5% (w/v). The data displayed are examples from three biological replicates. 
The traces show that M. formatexigens can utilize oligosaccharides (in panel c), but not the polymeric 
fraction (in panel d). Relative strain abundance during growth of co-cultures of M. formatexigens (Mf, dark 
red) and either e, R. intestinalis (Ri, turquoise) or f, B. ovatus (Bo, yellow) on AcGGM or mannose . The ratio 
of strains in the co-culture was determined by qPCR using primers described in6. Histogram bars show the 
mean of a biological triplicate. Error bars represent s.d. 
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Supplementary Data 1. List of putative CAZy domain-encoding genes upregulated on AcGGM and KGM. 
RNA-seq results of upregulation under β-mannans induction normalized to a glucose background are shown 
with Log2-fold change values in bold type. Experiments were performed in three biological replicates. Locus tag 
numbers ROSINTL182_XXXXX are abbreviated with the last numbers after the hyphen. The presence of a 
predicted Signal Peptide (SP) was determined with SignalP (v.4.1). Upregulation of CAZyme genes associated 
with the degradation of other polysaccharides such as α-mannan, arabinan, α-rhamnosides and xyloglucan is 
ascribed to the presence of these components in the YCFA medium. 
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      Log2-Fold Change 
Locus 
Tag CAZyme Family Predicted Activity Annotation SP AcGGM KGM 
07683 CBM23,CBM27,GH26 β-Mannanase Fibronectin type III domain protein Yes 5.80 7.25 
05474 GH130 β-1,4-Mannooligosaccharide phosphorylase Hypothetical protein No 5.63 5.42 
05475 GH130 β-1,4-Mannosylglucose phosphorylase Hypothetical protein No 5.47 5.57 
05476 GT4 Epimerase N-acylglucosamine 2-epimerase No 5.41 5.63 
08144 GH94 Cellobiose phosphorylase N,N'-diacetylchitobiose phosphorylase No 4.48 3.58 
09616 GH23, GT61 Peptidoglycan lyase NlpC/P60 family protein No 4.43 2.60 
08143 GH94 Cellobiose phosphorylase N,N'-diacetylchitobiose phosphorylase No 4.31 3.76 
07684 GH3 β-Glucosidase β-Glucosidase No 4.21 4.28 
05473 CE2 Acetyl xylan esterase Hypothetical protein No 4.21 4.10 
07685 GH3 β-Glucosidase β-Glucosidase No 4.13 4.32 
07158 GH23 Peptidoglycan lyase Transglycosylase SLT domain protein No 4.13 2.99 
08193 GH43 α-L-Arabinofuranosidase Arabinofuranosidase No 3.88 3.58 
06992 GH23 Peptidoglycan lyase Putative lipoprotein Yes 3.83 2.18 
08195 CBM35,GH115 Xylan α-1,2-glucuronidase Hypothetical protein No 3.74 3.40 
08196 GH8 Reducing-end-xylose releasing exo-oligoxylanase Glycosyl hydrolase family 8 No 3.69 3.54 
07032 CE1 Esterase Hydrolase, alpha/beta domain protein No 3.69 1.81 
05471 CE2, CE3 Acetyl xylan esterase GDSL-like protein No 3.55 3.47 
06494 CBM22, CBM9,GH10 Endo-1,4-β-xylanase Endo-1,4- β -xylanase  No 3.35 2.48 
08399 GH74 Endoglucanase Candidate Xyloglucanase No 3.34 2.12 
06334 GH27 α-Galactosidase α-Galactosidase No 3.33 2.38 
06340 GH51,GH43 β-Xylosidase/α-L-Arabinofuranosidase Hypothetical protein No 3.27 1.80 
09628 GH3 β-Glucosidase β-Glucosidase No 3.23 1.83 
05034 CBM35 Xylan-binding module ABC Transporter No 3.19 1.87 
06343 CBM6, GH43 α-L-Arabinofuranosidase Arabinofuranosidase No 3.07 1.98 
06338 CBM22, GH10 Endo-1,4-β-xylanase Endo-1,4- β -xylanase  No 3.06 1.44 
08567 GT41 UDP-GlcNAc:peptide Acetylglucosaminyltransferase Tetratricopeptide repeat protein Yes 3.02 4.02 
09626 GH42, GH5 Cellulase/β-galactosidase Hypothetical protein No 3.01 2.02 
08606 CBM50 Peptidoglycan-binding module LysM domain protein No 2.85 2.06 
05969 GT2 Glycosyltransferase, group 2 family  Glycosyltransferase, group 2 family  No 2.82 0.68 
09282 GT83 4-amino-4-deoxy-β-L-Arabinosyltransferase Hypothetical protein No 2.76 0.97 
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     Log2-Fold Change 
Locus 
Tag CAZyme Family Predicted Activity Annotation SP AcGGM KGM 
06337 GH43 β-Xylosidase/α-L-Arabinofuranosidase β-Xylosidase/α-L-Arabinofuranosidase No 2.75 1.54 
06342 CBM48, CE1 Acetyl xylan esterase Putative xylanase No 2.67 1.47 
06341 GH43 α-L-Arabinofuranosidase α-L-Arabinofuranosidase No 2.67 1.88 
07678 CBM61, GH53 endo-β-1,4-galactanase Endo-β-1,4-galactanase No 2.65 1.41 
08358 CE10, CE7 Acetyl xylan esterase/arylesterase  Lysophospholipase No 2.62 1.02 
09560 GH78 α-L-Rhamnosidase α-L-Rhamnosidase No 2.56 1.35 
05470a GH1 β-Mannosidase/β-Glucosidase  Glycosyl hydrolase, family 1 No 2.56 2.09 
06940 CBM37 Xylan-binding module Repeat protein No 2.53 1.17 
06332 GH32, GH43 β-2,1-Fructosidase/α-L-Arabinofuranosidase α-L-Arabinofuranosidase No 2.52 1.41 
08710 GH94 Cellobiose phosphorylase Cellobiose phosphorylase No 2.50 1.42 
05469a GH1 Mannose-6-phosphate isomerase Mannose-6-phosphate isomerase No 2.38 2.15 
06339 GH10 Endo-1,4-β-xylanase Endo-1,4-β-xylanase Yes 2.37 0.51 
05892 GH43 β-Xylosidase/α-L-Arabinofuranosidase β-Xylosidase/α-L-Arabinofuranosidase No 2.32 1.37 
09562 GH94 Cellobiose phosphorylase N,N'-diacetylchitobiose phosphorylase No 2.31 1.17 
08400 GH31 α-Glucosidase α-Glucosidase No 2.27 1.40 
06335 GH43 β-Xylosidase/α-L-Arabinofuranosidase β-Xylosidase/α-L-Arabinofuranosidase No 2.26 0.87 
05893 GH43 β-Xylosidase/α-L-Arabinofuranosidase β-Xylosidase No 2.22 1.36 
05114 GH115 Xylan α-1,2-glucuronidase Hypothetical protein No 2.19 0.85 
08711 GH94 Cellobiose phosphorylase N,N'-diacetylchitobiose phosphorylase No 2.16 0.97 
09559 GH3 β-Glucosidase β-Glucosidase No 2.15 1.32 
06336 GH95 α-L-Fucosidase Hypothetical protein No 2.11 1.00 
09625 GH94 Cellobiose phosphorylase N,N'-diacetylchitobiose phosphorylase No 2.09 0.96 
09492 GH2 β-Galactosidase β-Galactosidase No 2.09 1.03 
09554 GH35 β-Galactosidase β-Galactosidase No 1.99 0.65 
08556 GH5 Endo-β-1,4-glucanase/Cellulase Endoglucanase A No 1.99 2.88 
09556 GH3 β-Glucosidase β-Glucosidase No 1.92 0.97 
05638 GH35 β-Galactosidase Glycosyl hydrolase, family 35 No 1.86 0.86 
08720 GH38 α-Mannosidase α-Mannosidase No 1.84 0.69 
05483 GH113 β-mannanase Hypothetical protein No 1.80 0.68 
05574 GH119 α-Amylase Hypothetical protein No 1.77 0.74 
168
4 
 
     Log2-Fold Change 
Locus 
Tag CAZyme Family Predicted Activity Annotation SP AcGGM KGM 
05891 CE12 Acetyl xylan esterase Hypothetical protein No 1.77 0.73 
08203 GH42 β-Galactosidase/α-L-Arabinopyranosidase  β-Galactosidase No 1.77 0.92 
06331 GH43 β-Xylosidase/α-L-Arabinofuranosidase β-Xylosidase/α-L-Arabinofuranosidase No 1.70 0.84 
09491 GH2 β-Galactosidase β-Galactosidase No 1.70 0.79 
09478 GH73 Endo-β-N-acetylglucosaminidase Hypothetical protein No 1.67 0.54 
05481 GH36 α-Galactosidase α-Galactosidase No 1.64 1.26 
08825 GH13 α-Amylase α-Amylase No 1.64 0.84 
08557 GH32, GH43 Fructan β-2,1-fructosidase/α-L-Arabinofuranosidase Hypothetical protein No 1.63 2.51 
08719 GH2 β-Galactosidase β-Galactosidase No 1.61 0.58 
07340 CE1 Esterase Hydrolase No 1.60 0.78 
09481 GH24 Endo-β-N-acetylglucosaminidase Hypothetical protein No 1.59 0.47 
aLoci ROSINTL182_05469 and ROSINTL182_05470 are annotated as two proteins of 522 and 232 amino acids, respectively. However, we corrected sequence ambiguities at the 3’-end of  
ROSINTL182_05470 and determined the absence of a stop codon in between the two genes. 
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Supplementary Data 2. List of R. intestinalis proteins upregulated when grown on AcGGM versus Glc. 
Proteins are annotated with the UniProt accession numbers and putative function. Locus tag numbers 
ROSINTL182_XXXXX are abbreviated with the last numbers after the hyphen. Values given for the carbon 
sources are Log2 of MaxLFQ intensities, median of three biological replicates. Proteins involved in β-mannan 
catabolism are in bold.  
   
Median Log2 LFQ 
Intensities   
UniProt ID 
Locus 
tag CAZy Family/Predicted function Glc AcGGM Diff.a 
Peptide 
count 
C7GAP5 06975 Pyridine nucleotide-disulfide oxidoreductase 19.14 28.71 9.57 8 
C7G6G5 05478 MPP1, ABC transporter, permease protein 17.82 26.92 9.10 9 
C7GCP5 07683 GH26 / β-mannosidase 20.69 29.25 8.56 85 
C7G6G2 05475 GH130_1 / Mannosyl-glucose phosphorylase 21.76 29.58 7.82 41 
C7G6G4 05477 MPP2, ABC transporter, permease protein 18.47 25.97 7.50 9 
C7G6G3 05476 Mep, Epimerase 16.63 24.02 7.39 31 
C7G9B3 06492 GH1 / Arabinogalactan endo-galactanase 17.49 24.13 6.64 9 
C7G6G1 05474 GH130_2/ Mannoside phosphorylase 23.91 30.17 6.26 28 
C7G6G6 05479 ABC transporter, mannan-binding protein 24.84 30.83 5.98 21 
C7GE35 08187 Hypothetical protein 21.07 27.01 5.95 40 
C7GCP6 07684 GH3B / β -glucosidase 19.37 25.19 5.82 32 
C7GCP7 07685 GH3A / β -glucosidase 20.70 26.45 5.75 48 
C7GE41 08193 GH43 / α-arabinofuranosidase 18.17 23.82 5.65 28 
C7GF65 08570 ABC transporter, solute-binding protein 18.87 24.44 5.56 10 
C7GF66 08571 Hypothetical protein 18.33 23.89 5.56 17 
C7GER5 08417 Maturation rSAM protein, HydE 17.50 22.76 5.26 4 
C7GF51 08556 GH1 / Endoglucanase 18.59 23.57 4.97 5 
C7G6G0 05473 Carbohydrate esterase, CE2 19.06 24.02 4.96 16 
C7GF52 08557 Hypothetical protein 19.32 24.18 4.86 18 
C7GGA9 08977 Sugar-binding domain protein 18.78 23.58 4.80 5 
C7G6F8 05471 Carbohydrate esterase, CEX 21.81 26.53 4.72 29 
C7GE44 08196 GH8 /reducing-end xylose releasing oligoxylanase 18.12 22.83 4.71 12 
C7GE47 08199 ABC transporter, xylan-binding protein 21.72 26.36 4.64 27 
C7GE46 08198 ABC transporter, permease protein 19.22 23.84 4.62 2 
C7GDZ0 08142 Transcriptional regulator, LacI family 19.64 24.12 4.49 12 
C7G8A2 06126 Enolase 13.92 18.33 4.41 30 
C7GB09 07093 Riboflavin biosynthesis protein, RibH 20.58 24.99 4.41 15 
C7GE51 08203 β-galactosidase  20.23 24.63 4.40 23 
C7GCG9 07606 Hypothetical protein 18.15 22.53 4.38 4 
C7G6H0 05483 GH113 19.57 23.93 4.36 13 
C7G9G1 06540 Hypothetical protein 19.35 23.39 4.04 7 
C7GF55 08560 Hypothetical protein 23.21 27.24 4.03 14 
C7GD06 07806 30S ribosomal protein S10 21.10 25.02 3.92 7 
C7GCL0 07648 Membrane protein insertase, YidC/Oxa1 family 16.19 20.07 3.88 14 
C7G9Z7 06727 TRAP transporter solute receptor, DctP family 19.40 23.25 3.85 8 
C7G830 06054 30S ribosomal protein  19.86 23.66 3.80 4 
C7GE73 08224 Endonuclease III 16.77 20.53 3.76 4 
C7GEV7 08459 Signal recognition particle protein 17.84 21.59 3.75 29 
C7GH91 09312 Putative translation elongation factor G 20.71 24.45 3.74 41 
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Median Log2 LFQ 
Intensities   
UniProt ID 
Locus 
tag CAZy Family/Predicted function Glc AcGGM Diff.a 
Peptide 
count 
C7G5M9 05187 IS66 family element, transposase 17.74 21.47 3.73 9 
C7GHZ4 09566 β-lactamase 19.45 23.11 3.66 9 
C7GF62 08567 Tetratricopeptide repeat protein 18.75 22.34 3.59 5 
C7GFK0 08707 Hypothetical protein 21.04 24.62 3.58 7 
C7G9U2 06672 GH38 / α-mannosidase 20.98 24.51 3.54 42 
C7GDY7 08139 Hypothetical protein 21.74 25.27 3.53 9 
C7G7D3 05800 ABC transporter, ATP-binding protein 18.03 21.52 3.49 27 
C7GB06 07090 Riboflavin biosynthesis protein, RibD  17.66 21.12 3.46 8 
C7GD03 07803 50S ribosomal protein L23 21.22 24.67 3.45 8 
C7G702 05669 RelA/SpoT family protein 21.79 25.15 3.35 32 
C7GCZ6 07796 30S ribosomal protein S17 21.65 24.98 3.33 8 
C7GD85 07886 ABC transporter, ATP-binding protein 19.08 22.39 3.32 41 
C7GCG3 07600 ABC transporter, solute-binding protein 20.18 23.44 3.26 16 
C7G7L4 05888 ABC transporter, glycerol-3-phosphate transport system 18.66 21.89 3.24 21 
C7G6G9 05482 Pgm, Phosphomannomutase 21.70 24.84 3.14 62 
C7GDL8 08019 Transketolase, Pentose phosphate pathway 18.99 22.12 3.14 4 
C7GE45 08197 ABC transporter, permease protein 19.66 22.78 3.12 6 
C7GB02 07086 Response regulator receiver domain protein 18.91 21.97 3.06 10 
C7GDY8 08140 Hypothetical protein 22.35 25.39 3.04 3 
C7GDI0 07981 Isoprenoid synthesis protein, IspH 18.51 21.54 3.03 6 
C7GDW1 08113 Hsp20/alpha crystallin family protein 17.12 20.12 3.00 3 
C7GF11 08514 Hypothetical protein 17.75 20.75 3.00 4 
C7G6K9 05523 Polyphosphate:AMP phosphotransferase 20.68 23.66 2.98 17 
C7GBV3 07388 Flagellar basal body protein 21.61 24.58 2.97 22 
C7GCJ0 07628 Pantothenate synthetase 23.69 26.66 2.96 33 
C7GDZ1 08143 Glycosyltransferase family 36 22.95 25.91 2.96 18 
C7G5E4 05102 Aminopeptidase 20.95 23.91 2.95 38 
C7GHF0 09371 GH31 / putative α-xylosidase 21.55 24.50 2.95 21 
C7GCI9 07627 Aspartate 1-decarboxylase 21.25 24.17 2.92 7 
C7G750 05717 Hypothetical protein 18.61 21.51 2.90 6 
C7GDM1 08023 L-arabinose isomerase 18.61 21.51 2.90 13 
C7G674 05384 Putative guanine deaminase 19.64 22.53 2.90 18 
C7G5X1 05280 VanW-like protein 21.63 24.50 2.87 12 
C7GE21 08173 DNA helicase 20.65 23.51 2.86 37 
C7G7T5 05959 Hydrolase 17.63 20.49 2.86 8 
C7G5L1 05169 Malonyl CoA-acyl carrier protein transacylase 19.33 22.19 2.86 26 
C7GFZ7 08854 Translation initiation factor IF-3 22.48 25.25 2.77 11 
C7GCJ1 07629 3-methyl-2-oxobutanoate hydroxymethyltransferase 21.62 24.38 2.77 22 
C7GDL7 08018 Transketolase, Pentose phosphate pathway 21.22 23.98 2.76 5 
C7G9C2 06501 Hypothetical α-amylase 23.76 26.51 2.76 21 
C7GDN0 08031 Hypothetical protein 23.37 26.10 2.73 12 
C7GDZ2 08144 Hypothetical protein 24.69 27.42 2.73 45 
C7G6R3 05578 Hypothetical protein 20.52 23.25 2.72 5 
C7GCL9 07657 ParB-like protein 18.18 20.88 2.71 15 
C7GEV6 08458 30S ribosomal protein S16 20.87 23.58 2.70 5 
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Median Log2 LFQ 
Intensities   
UniProt ID 
Locus 
tag CAZy Family/Predicted function Glc AcGGM Diff.a 
Peptide 
count 
C7G6Y0 05647 Putative catabolite control protein A 17.98 20.68 2.70 3 
C7G6F7 05470 GH1 20.38 23.03 2.65 16 
C7G7Q2 05926 Ribosomal protein S12 methylthiotransferase, RimO 21.85 24.49 2.65 21 
C7GEF2 08304 von Willebrand factor type A domain protein 22.12 24.77 2.65 17 
C7GE38 08190 ABC transporter, solute-binding protein 22.38 25.01 2.63 12 
C7G8L8 06244 Hypothetical phosphoketolase 21.25 23.86 2.60 42 
C7G7C5 05792 ABC transporter, ATP-binding protein 18.52 21.11 2.59 16 
C7GDS7 08079 EDD domain protein, DegV family 22.43 24.99 2.56 13 
C7GCB6 07551 ABC transporter, ATP-binding protein 23.30 25.82 2.53 21 
C7GE37 08189 ABC transporter, permease protein 18.96 21.48 2.52 3 
C7GCF5 07592 Site-determining protein 23.12 25.64 2.52 18 
C7GC93 07528 Phosphopentomutase 19.20 21.71 2.51 20 
C7GE43 08195 GH115 / α-glucuronidase 18.06 20.56 2.50 9 
C7GDL9 08020 Transketolase, thiamine diphosphate binding domain protein 21.69 24.19 2.50 5 
C7GEF1 08303 Hypothetical protein 26.54 29.02 2.48 74 
C7G9L8 06597 Cell shape determining protein, MreB/Mrl family 21.14 23.61 2.48 20 
C7GAG5 06895 Hypothetical protein 20.29 22.74 2.45 10 
C7G8E5 06169 RNA pseudouridine synthase 18.41 20.83 2.42 4 
C7GCX7 07777 30S ribosomal protein S11 22.91 25.31 2.40 12 
C7GDX0 08122 HD domain protein 18.21 20.61 2.40 11 
C7G9H0 06549 Glycerophosphotransferase 18.30 20.69 2.39 41 
C7GGC3 08991 TOBE domain protein 24.99 27.38 2.38 3 
C7G5C9 05087 Hypothetical protein 18.30 20.67 2.38 4 
C7GDQ8 08059 Hypothetical protein 23.67 26.04 2.37 10 
C7GGG3 09031 Signal peptidase I 17.66 20.03 2.37 5 
C7GBY2 07417 ABC transporter, solute-binding protein 21.47 23.82 2.35 12 
C7G9R9 06648 Dipeptidase 16.74 19.09 2.35 16 
C7G7B6 05783 Hypothetical protein 18.06 20.41 2.34 8 
C7GG32 08894 Putative glycogen debranching enzyme 17.64 19.96 2.33 22 
C7GE90 08242 DNA mismatch repair protein, MutS 20.01 22.33 2.32 14 
C7GDQ7 08058 Hypothetical protein 22.86 25.18 2.31 33 
C7GCZ5 07795 50S ribosomal protein L14 24.19 26.49 2.30 13 
C7GA10 06762 Cell Wall Hydrolase 23.34 25.64 2.30 10 
C7GDM0 08021 Putative transaldolase 21.84 24.13 2.29 19 
C7GDH7 07978 Leucine Rich Repeat protein 24.43 26.71 2.29 65 
C7GC36 07471 Siphovirus Gp157 19.46 21.74 2.28 7 
C7GEC8 08280 Hypothetical protein 20.47 22.74 2.27 11 
C7GCF7 07594 Aminotransferase, class I/II 18.27 20.54 2.27 20 
C7G7D2 05799 ABC transporter, ATP-binding protein 19.97 22.21 2.24 37 
C7GD01 07801 30S ribosomal protein S19 25.09 27.32 2.23 16 
C7GE34 08186 Hypothetical protein 19.42 21.64 2.22 4 
C7G7X0 05994 POTRA domain protein, FtsQ-type 17.38 19.61 2.22 2 
C7G8I6 06212 Diguanylate cyclase domain protein 19.56 21.78 2.22 9 
C7GF48 08551 tRNA N6-adenosine threonylcarbamoyltransferase 20.09 22.30 2.22 5 
C7GEE4 08296 Hypothetical protein 21.66 23.87 2.22 4 
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Median Log2 LFQ 
Intensities   
UniProt ID 
Locus 
tag CAZy Family/Predicted function Glc AcGGM Diff.a 
Peptide 
count 
C7GHX4 09545 ATP-dependent metallopeptidase HflB 18.40 20.61 2.21 10 
C7GAT0 07010 Glycerol-3-phosphate responsive antiterminator 20.58 22.77 2.19 12 
C7GDH3 07974 Electron transport complex subunit G 18.83 21.00 2.17 7 
C7GEV1 08453 50S ribosomal protein L19 24.84 27.00 2.16 16 
C7GCE8 07585 Uridine kinase 18.81 20.95 2.14 7 
C7G5B8 05076 Penicillin-binding protein 16.98 19.12 2.14 30 
C7GCZ4 07794 50S ribosomal protein L24 18.24 20.37 2.13 3 
C7G6G7 05480 Transcriptional regulator, LacI family 21.38 23.49 2.11 9 
C7G956 06433 Transcriptional regulator, MarR family 18.39 20.49 2.10 2 
C7GE31 08183 GH53 / Arabinogalactan β-galactanase 21.37 23.46 2.09 7 
C7GE96 08248 Cell shape determining protein, MreB/Mrl family 20.38 22.45 2.07 16 
C7GBN0 07315 ABC transporter, substrate-binding protein, family 5 17.55 19.61 2.06 24 
C7GCY9 07789 50S ribosomal protein L6 25.88 27.92 2.05 19 
C7GCL6 07654 Putative sensor protein, DegS 18.71 20.73 2.02 8 
C7GAP6 06976 FAD dependent oxidoreductase 18.83 20.84 2.01 4 
C7GGY8 09209 Hypothetical protein 28.44 30.44 2.00 10 
C7GED6 08288 Hypothetical protein 20.37 22.36 1.99 13 
C7G9N1 06610 Hypothetical protein 19.55 21.53 1.99 4 
C7GAG4 06894 Hypothetical protein 21.57 23.49 1.92 11 
C7GCL5 07653 Hypothetical protein 20.65 22.54 1.89 22 
C7G890 06114 Hypothetical protein 19.63 21.51 1.88 18 
C7GBN7 07322 Oxidoreductase, aldo/keto reductase family protein 19.49 21.37 1.87 15 
C7GE32 08184 GH2 / β-galactosidase 21.72 23.57 1.85 42 
C7GAY7 07068 Hypothetical protein 22.70 24.52 1.81 2 
C7G6G8 05481 GH36 / α-galactosidase 23.85 25.62 1.77 57 
C7GCF2 07589 Thiamine biosynthesis pathway, ThiH 20.16 21.92 1.77 4 
C7G5Q2 05210 SPFH/Band 7/PHB domain protein 19.95 21.70 1.75 28 
C7GDL6 08017 Rribulose-5-phosphate 4-epimerase 22.71 24.44 1.73 9 
C7G7K2 05876 Sporulation protein YtfJ 19.72 21.39 1.68 8 
C7GDX7 08129 Tetratricopeptide repeat protein 20.78 22.46 1.67 20 
C7GDM3 08024 Carbohydrate kinase 19.94 21.57 1.64 7 
C7G8K4 06230 Cobalt transport protein 17.60 19.23 1.63 9 
C7GDH8 07979 CheR methyltransferase, glutamate biosynthesis 20.36 21.91 1.56 31 
C7GE91 08243 Thymidylate synthase, ThyX 20.78 22.33 1.54 21 
aDifference between AcGGM and Glc Log2-fold values. 
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Discussion and perspectives 
The interest in HGM research has increased tremendously in recent years, and it is 
generally accepted that health benefits from the intake of dietary fibers and prebiotics 
to a large extent can be coupled to changes in HGM composition and catabolic output. 
Focus has been directed towards the SCFAs products of fiber fermentation, due to their 
observed positive effects on immune and metabolic homeostasis and relevance in differ-
ent diseases. However, there is limited insight into how to modify the HGM composition 
and we are lacking knowledge about individual species as well as communities in regards 
to dietary fiber utilization. In this thesis the molecular apparatus for utilization of two 
selected dietary fibers, xylan and mannan, are characterized for the butyrate producing 
R. intestinalis. The studies presented here are the first to describe utilization of these 
two glycans by Firmicutes from the HGM and can thus potentially serve as a model 
system.    
 
Impact of glycan utilization and transport 
 
Modular cell-attached GHs are identified to be responsible for the initial capture of 
complex xylans and mannans by R. intestinalis. GHs from Clostridium cluster XIVa of 
the HGM have a variety of binding modules and substrates, while seemingly performing 
a similar function; capture and hydrolysis of glycans into oligosaccharides at the cell 
surface prior to import facilitated by one or more ABC-transporters[157], [158]. Multi-
plicity and variability of CBMs seem to be a common feature of extracellular enzymes 
from butyrate-producing Firmicutes from the human gut niche[157], [159] and can be 
an advantage in capture and prolonged contact of enzymes with glycans. R. intestinalis 
was shown to be associated to insoluble xylans, including wheat bran, whereas Bacteri-
odes spp. were enriched in solubilized xylan fractions[61], [160], which may be facilitated 
by the multiple CBMs.  
 
In order to understand the selectiveness of the top upregulated ABC-transporters in the 
two studies, binding of oligosaccharides to the SBP components was characterized. The 
specificity of SBPs is typically used as a proxy for the specificity of the ABC transporter 
system. However, TMDs also contribute to the specificity, but lack sufficient affinity, 
[133],. Studies of the maltose uptake system in E. coli, have shown that TMDs possess 
a substrate binding pocket and display specificity for maltose in the absence of the SBP, 
but the apparent Km was significantly increased[161]. This suggests that SBP is crucial 
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for high affinity capture, which defines the specificity of the transporter during substrate 
limiting conditions, e.g. in the human gut. The high conservation of TMD sequences for 
related substrates, compared to high divergence in the sequences of SBP, is consistent 
with the specificity determining role of SBPs. Moreover, the uptake profiles during 
growth of bacteria on oligosaccharides, reflect affinity profiles of the SBP component 
[162]. Generating gene knockouts of transporter genes is powerful in confirming their 
roles, but this is currently not feasible in Roseburia species. 
 
For primary degraders that possess extracellular GHs, the import of oligosaccharides is 
closely coupled to the hydrolysis of glycans at the cell surface. Firmicutes import oligo-
saccharides hydrolyzed from polymers by modular cell-attached GHs and the complete 
depolymerisation is performed by intracellular GHs and accessory CAZymes. In contrast, 
Bacteriodetes (mainly from the Bacteroides genus) rely more on extracellular degrada-
tion by one or several GHs and transport of larger oligosaccharides into the periplasm 
for subsequent degradation into monosaccharides, which are transported over the inner 
membrane via MFS transporters[94], [163]. Instead of having multiple CBMs in extra-
cellular GHs, Bacteriodetes often have fewer or no CBMs in their GHs and rely on 
SGBPs that are a part of the Sus-like system, for capture of substrates. Common to 
both phyla is that only partial degradation of glycans occurs extracellularly. The extent 
of alignment between the degradation products and the preference of uptake systems in 
one organism is likely to govern how selfish or sharing the glycan utilization strategy 
will be. If the degradation products are fully fit to the uptake systems, then very little 
leakage is likely to occur, whereas the generation of a broader set of glycans from ex-
tracellular GHs is likely to enable taxa possessing efficient uptake systems to compete 
for some of the degradation productions.  
 
To facilitate a process where minimum amounts of oligosaccharides are lost to the sur-
rounding environment, the surface GHs must operate at a rate that minimizes accumu-
lation of oligomers at the surface. This form of metabolism is deployed by B. thetaiota-
omicron during the utilization of yeast α-mannans, in which the generated manno-oli-
gosaccharides are rapidly imported into the periplasm, conferring no direct benefits on 
neighboring species[163]. In the growth experiment with R. intestinalis no oligosaccha-
rides were detected in the supernatants, suggesting a similar efficient uptake by the 
respective ABC-transporters[63], [66]. 
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Cross feeding 
 
Cross feeding between HGM is observed on fermentation products, as described for R. 
intestinalis in section 1.3. The dynamics of the HGM community are influenced by this 
type of cross feeding and it has been investigated in a well-defined small representative 
gut microbial community consisting of the three strains B. hydrogenotrophica, F. 
prausnitzii and R. intestinalis[164]. In this study, it was shown that strains grown in 
co-cultures behaved differently than those in monocultures, which was confirmed at the 
transcriptional level. Therefore, studying bacteria in mono-cultures can be insufficient 
to understand the complex competitive environment of our gut. Mono-cultures are, 
however, increasingly carried out to obtain data about individual members of the HGM. 
Such insight, as generated in this thesis, is important, but it is at least as important to 
keep in mind that the individual bacterium may behave different in a community.  
 
An example of changed expression is the study where B. thetaiotaomicron and E. rectale 
were co-colonized in mice[165]. E. rectale adapted to the co-culture by downregulating 
many of its GHs for glycan utilization and instead upregulated oligosaccharide trans-
porters, while B. thetaiotaomicron upregulated polysaccharide utilization loci encoding 
numerous GHs. In our experiments the expression of the GH10 did not appear to be 
downregulated when R. intestinalis was grown in a co-culture with B. ovatus, however, 
caution needs to be taken in inferring general models from single studies. To further 
investigate this, one could do a similar in vivo experiment in mice as described above, 
but with a defined mini-microbiome and examine the transcriptional profile of R. intes-
tinalis in an environment mirroring our gut. 
      
Regulation 
 
Plant derived diets contain more than one type of dietary fibers and the utilization of 
the different glycans requires activation of multiple CAZymes and transporters. Many 
HGM species have the ability to utilize a variety of glycans, but they do typically not 
target all simultaneously. Instead, bacteria have evolved a hierarchical utilization of 
glycans through a phenomenon that resembles catabolite repression[166]. An experiment 
with B. thetaiotaomicron showed that when the bacteria was presented to mucin glycans 
and other carbohydrates, then the degradation of mucin glycans was consistently re-
pressed[167]. In the same study, it was also shown that this metabolic hierarchy is 
species specific, with different species exhibiting variable and sometimes opposite rank 
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orders for some glycans. Structural aspects of glycan substrates have in addition been 
demonstrated to affect prioritization, including linkage profiles, conformation, and mo-
lecular size[166]. This type of metabolic hierarchy has mainly been described for Bacte-
riodetes, however, Firmicutes - with the ability to utilize several glycans - have most 
likely evolved a similar approach for prioritizing. The presence of typically multiple 
transcriptional regulators in glycan utilization gene clusters of Firmicutes is supportive 
of the importance of a complex catabolic regulation.     
 
Operon specific transcriptional regulators enable bacteria to adjust their carbohydrate 
catabolism, to ensure that cellular energy is conserved[168]. Regulatory proteins of the 
LacI-GalR family are often associated with glycan utilization genes in Gram positive 
bacteria, in order to induce or repress the genes in a substrate-specific manner[169]. The 
identified xylan and mannan utilization gene clusters are predicted to encode LacI‐type 
transcriptional regulators. These LacI genes; ROSINTL182_08194 and 
ROSINTL102_05480, are regulated at the transcriptional level by induction of xylan 
and mannan, respectively, suggesting that they are important in transcriptional regula-
tion of specific genes in the presence of these two glycans. We did not pursue LacI genes 
in our work, although further investigation could establish if the two LacI genes directly 
interact with specific operators of the promotor regions and which regulatory signals 
(substrates) act on them. 
 
Discovery of novel CAZy families 
 
Xylan and mannan are, as described in section 1.7-8, usually acetylated at C2 and C3. 
Thus, a molecular machinery that mediates complete breakdown of these glycan requires 
efficient CEs for deacetylation. In this thesis, three CE were characterized. RiCEX, 
RiCE2 and RiAXE. The latter two show 18.6% identity to each other (Appendix 1) 
and share conserved residues with the SGNH lipase esterase superfamily (Pfamcd00229). 
However, both CEs lack functionally characterized homologues, suggesting that they 
belong to new families of CEs. RiAXE is efficient for deacetylation of both C2 and C3 
in xylan, but with a preference for C2 decorations[63]. RiCEX hydrolyzed in concert 
with RiCE2 almost complete deacetylation of mannan, but seems to have a preference 
for oligosaccharides with a degree of acetyl substitution ≥ 2[66]. To pursue the potential 
of RiAXE belonging to a new family, we sought to solve the crystal structure, but we 
did not succeed in obtaining crystals. To get further insight on these two potential new 
CE families, solving the structures of either enzyme would be valuable.  
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CBMs of cell-attached enzymes are important for the recognition of accessible glycans 
in the complex gut environment. The modular cell-attached xylanase RiXyn10A has 
four CBM modules to facilitate binding to xylan. We have characterized one of these 
modules, CBMx, and proposed the assignment into a novel CBM family[63], [170], chap-
ter 4. CBMx lacks functionally described homologues, but related sequences from Fir-
micutes Clostridium XIVa members are available, suggesting this novel family is asso-
ciated or enriched within Clostridiales. Characterization of the binding properties 
showed that it is selective for xylan and with the affinity increasing for oligosaccharides 
from DP4-DP6, with a KD=490 µM for X6, suggesting that CBMx is a low affinity 
binding CBM. The crystal structure and the NMR titration highlight preference to 
arabino-decordated xylan as compared to glucuronodecorated xylan. Further studies are 
needed to evaluate crucial residues in the binding site and the contribution of this CBM 
in the context of the full-length xylanase.  
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Conclusion 
The present Ph.D. thesis summarizes my research on the butyrate producing R. intes-
tinalis from the HGM that focused on bringing new insight to the molecular mechanisms 
for xylan and mannan utilization by Firmicutes. The work has resulted in the identifi-
cation and characterization of key enzymes and transporters. This has together with 
data from the growth experiments provided a detailed view of how R. intestinalis utilize 
complex glycans in a competitive environment with other primary glycan degraders. 
The results have highlighted that the differentiation in glycan capture and uptake pref-
erences might contribute the ability to co-growth on dietary fibers by different taxa - 
future investigations are needed to validate the generality of this finding. The studies 
have also enabled us discover two CEs and one CBM belonging to novel CAZy families, 
with the crystal structure of the CBMx further highlighting the uniqueness of this CBM, 
as compared to its xylan specific counterparts.  
 
Our findings are the first to describe the utilization of xylan and mannan by R. intesti-
nalis and can potentially serve as a model system for utilization of other glycans by this 
taxonomic group of Firmicutes from the HGM. Finally, the findings contribute the 
understanding of the interaction between diet and the HGM. This might be exploited 
to selectively promote key members of the healthy HGM through a prebiotic or synbiotic 
approach, which can serve as a way to enhance local production on butyrate in the 
colon, thereby taken advantage of butyrate’s health promoting effects.  
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Appendix 1 
# Program: needle 
# Aligned_sequences: 2 
# 1: EEU99941.1 ROSINTL182_08194 
# 2: EEV02614.1 ROSINTL182_05471 
# Matrix: EBLOSUM62 
# Gap_penalty: 10.0 
# Extend_penalty: 0.5 
# Length: 614 
# Identity:     114/614 (18.6%) 
# Similarity:   181/614 (29.5%) 
# Gaps:         289/614 (47.1%) 
# Score: 371.5 
#======================================= 
 
EEU99941.1         1 MSGPVAPKDPEKDRSYFYIMKEKETFGSLQTQGEYQGRGVQFIYESDGRL     50 
                                                                        
EEV02614.1         1 --------------------------------------------------      0 
 
EEU99941.1        51 ESSAEVTGEVCDEEILKKLGTVEGFKSLVHSIGISVEMEHSREPVTFVFQ    100 
                                                                        
EEV02614.1         1 --------------------------------------------------      0 
 
EEU99941.1       101 MYGKEDLYGGGTLIETELRGDGAEVRITLDTVKWKTDDDVPGQIRFVFET    150 
                                                                        
EEV02614.1         1 --------------------------------------------------      0 
 
EEU99941.1       151 PEQSARVNVRFFLKDGFFVPKPQEERVVDMESHGYQEMIERSLLSMGDAG    200 
                                                  ||   ||...|..:.:.|... 
EEV02614.1         1 -----------------------------ME---YQIKYENGIANRGCLY     18 
 
EEU99941.1       201 RIRRVVEKARAGEPVTIAYIGGSITQGA-GAVPLHTQCYA---YRFWKAF    246 
                     |:::|:::|:|||.:.||::|||||||: .:.|  ..|||   |.:||   
EEV02614.1        19 RLKKVMDRAKAGEALNIAFLGGSITQGSLSSKP--ELCYAYHVYEWWK--     64 
 
EEU99941.1       247 AGKYGKNNNVKLIKAGVGGTPSELGMIRFERDVLRDGKEKPDLVVVEFAV    296 
                       |.....:...|.||:|||.|:.|:.|.|.|:|   .::||.|::||:| 
EEV02614.1        65 --KTFPQADFTYINAGIGGTTSQFGVARAEADLL---SKEPDFVIIEFSV    109 
 
EEU99941.1       297 NDEGDETKGRCYESLVTKILSMPDAPAVLLLFAVFANDW-NLQERLAPVG    345 
                     ||:..|.....||.||.|:.:....|||||:..||.|:. |.|.....:. 
EEV02614.1       110 NDDSTEHFMETYEGLVRKVYTSKTKPAVLLVHNVFYNNGANAQLMHGRIA    159 
 
EEU99941.1       346 ERYQLPMVSIRDAVTPQFRQTKDRVVSKNQFFYDAFHPTNLGHKIMADCL    395 
                     ..|.||.||::..:.|:....:   :...:...|..||.:.||.::|..: 
EEV02614.1       160 RHYNLPAVSMQSTIYPEVVAGR---IENREITPDDLHPNDAGHALVASVI    206 
 
EEU99941.1       396 MYLIDRA-------VCEPD----ILRRMHEKPVYGDEFAQVKLLDRRDGY    434 
                     .|.:|:.       ..|||    :.:..:||.:            |.... 
EEV02614.1       207 TYFLDKVKTEDATEQSEPDYPAPLTKNTYEKSI------------RHQNS    244 
 
EEU99941.1       435 ERAKICCGAFSGTDQELQCVEMDDSLTPVPEFPYNWQYDGANGRSEDAFQ    484 
                     :...:|.|..:.|..:....:.         |.:.|    ...:..|:.. 
EEV02614.1       245 DENVVCHGFVADTSAQRDITDC---------FKHGW----TASKKGDSIT    281 
 
EEU99941.1       485 MDI--------YCRSLLL------IFKDSGAVDAGRADVFVDDT--KVLT    518 
                     :|:        |.:|:.|      |..|..|..|.|.|...|:|  ..|. 
EEV02614.1       282 LDVEGCNISVQYRKSVKLPAPVAEIIVDGDAEHAVRLDANFDETWGDKLE    331 
 
EEU99941.1       519 ADPHVNGWTHCNPVILLEEKESGWHQVRIQMTP---------------GE    553 
                     .|            .:||..|:..|:|.:::|.               |. 
EEV02614.1       332 LD------------TILEHGENKVHKVEVRLTETHENDAVPFYLVSVIGS    369 
 
EEU99941.1       554 EEKKFTILGFGYVE    567 
                     .||            
EEV02614.1       370 SEK-----------    37 
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